{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T15:13:27Z","timestamp":1789398807983,"version":"build-2803163510"},"reference-count":664,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T00:00:00Z","timestamp":1786320000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100012576","name":"Guangdong Basic and Applied Basic Research Foundation","doi-asserted-by":"publisher","award":["2025B1515020001"],"award-info":[{"award-number":["2025B1515020001"]}],"id":[{"id":"10.13039\/501100012576","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["22477150"],"award-info":[{"award-number":["22477150"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82472137"],"award-info":[{"award-number":["82472137"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["32270815"],"award-info":[{"award-number":["32270815"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100017610","name":"Shenzhen Science and Technology Innovation Program","doi-asserted-by":"publisher","award":["GJHZ20220913142400001"],"award-info":[{"award-number":["GJHZ20220913142400001"]}],"id":[{"id":"10.13039\/501100017610","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100015956","name":"Special Project for Research and Development in Key areas of Guangdong Province","doi-asserted-by":"publisher","award":["2023B1111040002"],"award-info":[{"award-number":["2023B1111040002"]}],"id":[{"id":"10.13039\/501100015956","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2023YFF1501203"],"award-info":[{"award-number":["2023YFF1501203"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100021171","name":"Basic and Applied Basic Research Foundation of Guangdong Province","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100021171","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacological Research"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.phrs.2026.108380","type":"journal-article","created":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T16:24:54Z","timestamp":1786465494000},"page":"108380","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Drug resistance in cancer radiotherapy: From mechanisms to overcoming strategies"],"prefix":"10.1016","volume":"231","author":[{"given":"Yang","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chao-Yun","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-Chen","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zheng","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingming","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhe-Sheng","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leli","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yihang","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.phrs.2026.108380_bib1","first-page":"7","article-title":"Cancer statistics, 2022","volume":"72","author":"Siegel","year":"2022","journal-title":"CA Cancer J. Clin."},{"issue":"3","key":"10.1016\/j.phrs.2026.108380_bib2","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.phrs.2026.108380_bib3","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.662840","article-title":"Radiation Resistance: A Matter of Transcription Factors","volume":"11","author":"Galeaz","year":"2021","journal-title":"Front. Oncol."},{"issue":"7","key":"10.1016\/j.phrs.2026.108380_bib4","doi-asserted-by":"crossref","DOI":"10.3390\/cells9071651","article-title":"CSC Radioresistance: A Therapeutic Challenge to Improve Radiotherapy Effectiveness in Cancer","volume":"9","author":"Olivares-Urbano","year":"2020","journal-title":"Cells"},{"issue":"5","key":"10.1016\/j.phrs.2026.108380_bib5","first-page":"437","article-title":"Radiation therapy-associated toxicity: Etiology, management, and prevention","volume":"71","author":"Wang","year":"2021","journal-title":"CA Cancer J. Clin."},{"issue":"13","key":"10.1016\/j.phrs.2026.108380_bib6","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.2217\/fon-2020-0994","article-title":"The abscopal effect of radiation therapy","volume":"17","author":"Craig","year":"2021","journal-title":"Future Oncol"},{"issue":"4","key":"10.1016\/j.phrs.2026.108380_bib7","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1080\/095530098142176","article-title":"Track structure in radiation biology: theory and applications","volume":"73","author":"Nikjoo","year":"1998","journal-title":"Int. J. Radiat. Biol."},{"issue":"9","key":"10.1016\/j.phrs.2026.108380_bib8","doi-asserted-by":"crossref","first-page":"5057","DOI":"10.1073\/pnas.0830918100","article-title":"Evidence for a lack of DNA double-strand break repair in human cells exposed to very low x-ray doses","volume":"100","author":"Rothkamm","year":"2003","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"11","key":"10.1016\/j.phrs.2026.108380_bib9","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2023.e22090","article-title":"Suppresses of LIM kinase 2 promotes radiosensitivity in radioresistant non-small cell lung cancer cells","volume":"9","author":"Tian","year":"2023","journal-title":"Heliyon"},{"issue":"1-2","key":"10.1016\/j.phrs.2026.108380_bib10","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1615\/CritRevOncog.2018025946","article-title":"Profiles of Radioresistance Mechanisms in Prostate Cancer","volume":"23","author":"Chaiswing","year":"2018","journal-title":"Crit. Rev. Oncog."},{"issue":"2","key":"10.1016\/j.phrs.2026.108380_bib11","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1615\/CritRevOncog.2022044635","article-title":"Improving Radiotherapy Response in the Treatment of Head and Neck Cancer","volume":"27","author":"Wicker","year":"2022","journal-title":"Crit. Rev. Oncog."},{"issue":"3","key":"10.1016\/j.phrs.2026.108380_bib12","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1016\/j.ccell.2019.01.020","article-title":"Inhibition of Nuclear PTEN Tyrosine Phosphorylation Enhances Glioma Radiation Sensitivity through Attenuated DNA Repair","volume":"35","author":"Ma","year":"2019","journal-title":"Cancer Cell"},{"issue":"3","key":"10.1016\/j.phrs.2026.108380_bib13","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.21037\/tlcr-21-152","article-title":"Radiotherapy programs neutrophils to an antitumor phenotype by inducing mesenchymal-epithelial transition","volume":"10","author":"Liu","year":"2021","journal-title":"Transl. Lung Cancer Res."},{"issue":"4","key":"10.1016\/j.phrs.2026.108380_bib14","first-page":"333","article-title":"Metabolomics in cancer research and emerging applications in clinical oncology","volume":"71","author":"Schmidt","year":"2021","journal-title":"CA Cancer J. Clin."},{"issue":"2","key":"10.1016\/j.phrs.2026.108380_bib15","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbcan.2019.188310","article-title":"Mechanisms of acquired tumor drug resistance","volume":"1872","author":"Aleksakhina","year":"2019","journal-title":"Biochim. Biophys. Acta Rev. Cancer"},{"key":"10.1016\/j.phrs.2026.108380_bib16","doi-asserted-by":"crossref","DOI":"10.1016\/j.drup.2025.101229","article-title":"Overcoming cancer therapy resistance: From drug innovation to therapeutics","volume":"81","author":"Wei","year":"2025","journal-title":"Drug Resist. Updat."},{"issue":"2","key":"10.1016\/j.phrs.2026.108380_bib17","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.annonc.2022.10.506","article-title":"Biliary tract cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"34","author":"Vogel","year":"2023","journal-title":"Ann. Oncol."},{"issue":"7","key":"10.1016\/j.phrs.2026.108380_bib18","first-page":"1993","article-title":"Effect of interval between neoadjuvant chemoradiotherapy and surgery on oncological outcomes in poor responders with locally advanced rectal cancer: a retrospective cohort study","volume":"109","author":"Luo","year":"2023","journal-title":"Int. J. Surg."},{"issue":"7","key":"10.1016\/j.phrs.2026.108380_bib19","doi-asserted-by":"crossref","DOI":"10.6004\/jnccn.2024.7023","article-title":"The Impact of Adjuvant Chemotherapy on the Long-Term Prognosis of Breast Malignant Phyllodes Tumors: A Propensity Score-Matched Study","volume":"22","author":"Zhuang","year":"2024","journal-title":"J. Natl. Compr. Canc. Netw."},{"issue":"12","key":"10.1016\/j.phrs.2026.108380_bib20","doi-asserted-by":"crossref","first-page":"2232","DOI":"10.1002\/ijc.35111","article-title":"Phase III randomized trial comparing palliative systemic therapy to best supportive care in advanced esophageal\/GEJ cancer","volume":"155","author":"Noronha","year":"2024","journal-title":"Int. J. Cancer"},{"issue":"5","key":"10.1016\/j.phrs.2026.108380_bib21","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1097\/CAD.0000000000000055","article-title":"Taxanes as radiosensitizers","volume":"25","author":"Golden","year":"2014","journal-title":"Anticancer Drugs"},{"issue":"1","key":"10.1016\/j.phrs.2026.108380_bib22","first-page":"187s","article-title":"Radiation sensitizers: a selective review of molecules targeting DNA and non-DNA targets","volume":"46","author":"Kvols","year":"2005","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.phrs.2026.108380_bib23","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.radonc.2020.06.041","article-title":"Augmenting the therapeutic window of radiotherapy: A perspective on molecularly targeted therapies and nanomaterials","volume":"150","author":"Reda","year":"2020","journal-title":"Radiother. Oncol."},{"issue":"9","key":"10.1016\/j.phrs.2026.108380_bib24","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1038\/nrclinonc.2015.120","article-title":"Opportunities and challenges of radiotherapy for treating cancer","volume":"12","author":"Schaue","year":"2015","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"21","key":"10.1016\/j.phrs.2026.108380_bib25","doi-asserted-by":"crossref","first-page":"8643","DOI":"10.1158\/0008-5472.CAN-07-6611","article-title":"A history of cancer chemotherapy","volume":"68","author":"DeVita","year":"2008","journal-title":"Cancer Res"},{"issue":"7","key":"10.1016\/j.phrs.2026.108380_bib26","doi-asserted-by":"crossref","first-page":"5437","DOI":"10.1021\/acs.jmedchem.3c02008","article-title":"Development of an Imidazopyridazine-Based MNK1\/2 Inhibitor for the Treatment of Lymphoma","volume":"67","author":"Yuan","year":"2024","journal-title":"J. Med. Chem."},{"issue":"17","key":"10.1016\/j.phrs.2026.108380_bib27","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22179451","article-title":"Battling Chemoresistance in Cancer: Root Causes and Strategies to Uproot Them","volume":"22","author":"Ramos","year":"2021","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.phrs.2026.108380_bib28","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s43556-024-00239-2","article-title":"Molecular mechanisms and therapeutic strategies in overcoming chemotherapy resistance in cancer","volume":"6","author":"Gu","year":"2025","journal-title":"Mol. Biomed."},{"issue":"5","key":"10.1016\/j.phrs.2026.108380_bib29","doi-asserted-by":"crossref","first-page":"592","DOI":"10.2174\/1389450116666150825111818","article-title":"Docking Studies for Multi-Target Drugs","volume":"18","author":"Scotti","year":"2017","journal-title":"Curr. Drug Targets"},{"key":"10.1016\/j.phrs.2026.108380_bib30","doi-asserted-by":"crossref","first-page":"263","DOI":"10.3389\/fonc.2019.00263","article-title":"Identification of Genetic Mutations in Cancer: Challenge and Opportunity in the New Era of Targeted Therapy","volume":"9","author":"Jin","year":"2019","journal-title":"Front. Oncol."},{"issue":"7","key":"10.1016\/j.phrs.2026.108380_bib31","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1158\/0008-5472.CAN-14-2305","article-title":"VEGF-A Expression Correlates with TP53 Mutations in Non-Small Cell Lung Cancer: Implications for Antiangiogenesis Therapy","volume":"75","author":"Schwaederl\u00e9","year":"2015","journal-title":"Cancer Res"},{"issue":"1","key":"10.1016\/j.phrs.2026.108380_bib32","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/s40169-015-0075-0","article-title":"KRAS mutant lung cancer: progress thus far on an elusive therapeutic target","volume":"4","author":"Bhattacharya","year":"2015","journal-title":"Clin. Transl. Med."},{"issue":"18","key":"10.1016\/j.phrs.2026.108380_bib33","doi-asserted-by":"crossref","first-page":"26823","DOI":"10.18632\/oncotarget.8662","article-title":"Predictive and prognostic value of preoperative serum tumor markers is EGFR mutation-specific in resectable non-small-cell lung cancer","volume":"7","author":"Jiang","year":"2016","journal-title":"Oncotarget"},{"issue":"6","key":"10.1016\/j.phrs.2026.108380_bib34","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.cancergen.2015.04.001","article-title":"BRAF V600E mutations: a series of case reports in patients with non-small cell lung cancer","volume":"208","author":"Goldman","year":"2015","journal-title":"Cancer Genet"},{"issue":"9839","key":"10.1016\/j.phrs.2026.108380_bib35","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/S0140-6736(12)60868-X","article-title":"Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial","volume":"380","author":"Hauschild","year":"2012","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.phrs.2026.108380_bib36","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1007\/s11912-014-0390-4","article-title":"The efficacy and safety of EGFR inhibitor monotherapy in non-small cell lung cancer: a systematic review","volume":"16","author":"Yang","year":"2014","journal-title":"Curr. Oncol. Rep."},{"issue":"17","key":"10.1016\/j.phrs.2026.108380_bib37","doi-asserted-by":"crossref","first-page":"4478","DOI":"10.1158\/1078-0432.CCR-13-3385","article-title":"Association of EGFR expression level and cetuximab activity in patient-derived xenograft models of human non-small cell lung cancer","volume":"20","author":"Amendt","year":"2014","journal-title":"Clin. Cancer Res."},{"issue":"13","key":"10.1016\/j.phrs.2026.108380_bib38","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1016\/S1470-2045(13)70498-4","article-title":"Cetuximab and non-small-cell lung cancer: end of the story?","volume":"14","author":"Rossi","year":"2013","journal-title":"Lancet Oncol"},{"issue":"5","key":"10.1016\/j.phrs.2026.108380_bib39","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1159\/000443368","article-title":"Drug Resistance to EGFR Inhibitors in Lung Cancer","volume":"61","author":"Tetsu","year":"2016","journal-title":"Chemotherapy"},{"key":"10.1016\/j.phrs.2026.108380_bib40","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.semcancer.2016.11.002","article-title":"New strategies for targeting drug combinations to overcome mutation-driven drug resistance","volume":"42","author":"Wang","year":"2017","journal-title":"Semin. Cancer Biol."},{"issue":"31","key":"10.1016\/j.phrs.2026.108380_bib41","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.1203530109","article-title":"Lung cancers with acquired resistance to EGFR inhibitors occasionally harbor BRAF gene mutations but lack mutations in KRAS, NRAS, or MEK1","volume":"109","author":"Ohashi","year":"2012","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"4","key":"10.1016\/j.phrs.2026.108380_bib42","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1038\/nm.2713","article-title":"A common BIM deletion polymorphism mediates intrinsic resistance and inferior responses to tyrosine kinase inhibitors in cancer","volume":"18","author":"Ng","year":"2012","journal-title":"Nat. Med."},{"issue":"2","key":"10.1016\/j.phrs.2026.108380_bib43","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1007\/s10555-015-9570-4","article-title":"Targeting roles of inflammatory microenvironment in lung cancer and metastasis","volume":"34","author":"Shi","year":"2015","journal-title":"Cancer Metastasis Rev"},{"issue":"7538","key":"10.1016\/j.phrs.2026.108380_bib44","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1038\/nature13948","article-title":"Convergent loss of PTEN leads to clinical resistance to a PI(3)K\u03b1 inhibitor","volume":"518","author":"Juric","year":"2015","journal-title":"Nature"},{"issue":"13","key":"10.1016\/j.phrs.2026.108380_bib45","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1080\/15384101.2014.1003008","article-title":"Combinatorial Action of MicroRNAs let-7 and miR-34 Effectively Synergizes with Erlotinib to Suppress Non-small Cell Lung Cancer Cell Proliferation","volume":"14","author":"Stahlhut","year":"2015","journal-title":"Cell Cycle"},{"issue":"6","key":"10.1016\/j.phrs.2026.108380_bib46","doi-asserted-by":"crossref","first-page":"e40","DOI":"10.1097\/JTO.0000000000000503","article-title":"Spatial Tumor Heterogeneity in Lung Cancer with Acquired Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor Resistance: Targeting High-Level MET-Amplification and EGFR T790M Mutation Occurring at Different Sites in the Same Patient","volume":"10","author":"Scheffler","year":"2015","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.phrs.2026.108380_bib47","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.critrevonc.2015.08.004","article-title":"Dominant mechanisms of primary resistance differ from dominant mechanisms of secondary resistance to targeted therapies","volume":"97","author":"Asi\u0107","year":"2016","journal-title":"Crit. Rev. Oncol. Hematol."},{"issue":"5","key":"10.1016\/j.phrs.2026.108380_bib48","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2019.2535","article-title":"Estimation of the Percentage of US Patients With Cancer Who Are Eligible for and Respond to Checkpoint Inhibitor Immunotherapy Drugs","volume":"2","author":"Haslam","year":"2019","journal-title":"JAMA Netw. Open"},{"issue":"7528","key":"10.1016\/j.phrs.2026.108380_bib49","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/nature14011","article-title":"Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients","volume":"515","author":"Herbst","year":"2014","journal-title":"Nature"},{"issue":"7528","key":"10.1016\/j.phrs.2026.108380_bib50","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1038\/nature13954","article-title":"PD-1 blockade induces responses by inhibiting adaptive immune resistance","volume":"515","author":"Tumeh","year":"2014","journal-title":"Nature"},{"issue":"7","key":"10.1016\/j.phrs.2026.108380_bib51","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1038\/s41591-018-0057-z","article-title":"A transcriptionally and functionally distinct PD-1(+) CD8(+) T cell pool with predictive potential in non-small-cell lung cancer treated with PD-1 blockade,","volume":"24","author":"Thommen","year":"2018","journal-title":"Nat. Med."},{"issue":"6230","key":"10.1016\/j.phrs.2026.108380_bib52","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1126\/science.aaa1348","article-title":"Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer","volume":"348","author":"Rizvi","year":"2015","journal-title":"Science"},{"issue":"5","key":"10.1016\/j.phrs.2026.108380_bib53","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1016\/j.ccell.2018.03.018","article-title":"Genomic Features of Response to Combination Immunotherapy in Patients with Advanced Non-Small-Cell Lung Cancer","volume":"33","author":"Hellmann","year":"2018","journal-title":"Cancer Cell"},{"issue":"26","key":"10.1016\/j.phrs.2026.108380_bib54","doi-asserted-by":"crossref","first-page":"2509","DOI":"10.1056\/NEJMoa1500596","article-title":"PD-1 Blockade in Tumors with Mismatch-Repair Deficiency","volume":"372","author":"Le","year":"2015","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.phrs.2026.108380_bib55","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1038\/s41591-019-0734-6","article-title":"Peripheral CD8(+) T cell characteristics associated with durable responses to immune checkpoint blockade in patients with metastatic melanoma,","volume":"26","author":"Fairfax","year":"2020","journal-title":"Nat. Med."},{"issue":"7652","key":"10.1016\/j.phrs.2026.108380_bib56","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1038\/nature22079","article-title":"T-cell invigoration to tumour burden ratio associated with anti-PD-1 response","volume":"545","author":"Huang","year":"2017","journal-title":"Nature"},{"issue":"2","key":"10.1016\/j.phrs.2026.108380_bib57","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.ccell.2022.01.001","article-title":"Lactic acid promotes PD-1 expression in regulatory T cells in highly glycolytic tumor microenvironments","volume":"40","author":"Kumagai","year":"2022","journal-title":"Cancer Cell"},{"issue":"11","key":"10.1016\/j.phrs.2026.108380_bib58","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1038\/s41590-020-0769-3","article-title":"The PD-1 expression balance between effector and regulatory T cells predicts the clinical efficacy of PD-1 blockade therapies","volume":"21","author":"Kumagai","year":"2020","journal-title":"Nat. Immunol."},{"issue":"1","key":"10.1016\/j.phrs.2026.108380_bib59","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1038\/s41416-018-0333-1","article-title":"Immunosuppression mediated by myeloid-derived suppressor cells (MDSCs) during tumour progression","volume":"120","author":"Groth","year":"2019","journal-title":"Br. J. Cancer"},{"issue":"3","key":"10.1016\/j.phrs.2026.108380_bib60","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2021.109844","article-title":"Targeting TREM2 on tumor-associated macrophages enhances immunotherapy","volume":"37","author":"Binnewies","year":"2021","journal-title":"Cell Rep"},{"issue":"389","key":"10.1016\/j.phrs.2026.108380_bib61","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aal3604","article-title":"vivo imaging reveals a tumor-associated macrophage-mediated resistance pathway in anti-PD-1 therapy","volume":"9","author":"Arlauckas","year":"2017","journal-title":"Sci. Transl. Med."},{"issue":"8","key":"10.1016\/j.phrs.2026.108380_bib62","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1158\/0008-5472.CAN-14-3016","article-title":"IL10 and PD-1 Cooperate to Limit the Activity of Tumor-Specific CD8+ T Cells","volume":"75","author":"Sun","year":"2015","journal-title":"Cancer Res"},{"issue":"7693","key":"10.1016\/j.phrs.2026.108380_bib63","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1038\/nature25501","article-title":"TGF\u03b2 attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells","volume":"554","author":"Mariathasan","year":"2018","journal-title":"Nature"},{"issue":"6","key":"10.1016\/j.phrs.2026.108380_bib64","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1038\/nm.3541","article-title":"Tumor endothelium FasL establishes a selective immune barrier promoting tolerance in tumors","volume":"20","author":"Motz","year":"2014","journal-title":"Nat. Med."},{"key":"10.1016\/j.phrs.2026.108380_bib65","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.coi.2015.01.011","article-title":"Targeting the tumor vasculature to enhance T cell activity","volume":"33","author":"Lanitis","year":"2015","journal-title":"Curr. Opin. Immunol."},{"issue":"1160","key":"10.1016\/j.phrs.2026.108380_bib66","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1093\/bjr\/tqae100","article-title":"Strategies for overcoming tumour resistance to immunotherapy: harnessing the power of radiation therapy","volume":"97","author":"Passelli","year":"2024","journal-title":"Br. J. Radiol."},{"issue":"1-2","key":"10.1016\/j.phrs.2026.108380_bib67","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.canlet.2011.12.012","article-title":"Ionizing radiation-induced metabolic oxidative stress and prolonged cell injury","volume":"327","author":"Azzam","year":"2012","journal-title":"Cancer Lett"},{"issue":"9","key":"10.1016\/j.phrs.2026.108380_bib68","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1093\/abbs\/gmz076","article-title":"Pathways and assays for DNA double-strand break repair by homologous recombination","volume":"51","author":"Li","year":"2019","journal-title":"Acta Biochim. Biophys. Sin."},{"issue":"1","key":"10.1016\/j.phrs.2026.108380_bib69","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1038\/nrc.2015.2","article-title":"DNA damage and the balance between survival and death in cancer biology","volume":"16","author":"Roos","year":"2016","journal-title":"Nat. Rev. Cancer"},{"issue":"1","key":"10.1016\/j.phrs.2026.108380_bib70","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1038\/cr.2008.1","article-title":"Homologous recombination in DNA repair and DNA damage tolerance","volume":"18","author":"Li","year":"2008","journal-title":"Cell Res"},{"key":"10.1016\/j.phrs.2026.108380_bib71","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.pharmthera.2016.02.003","article-title":"DNA repair targeted therapy: The past or future of cancer treatment?","volume":"160","author":"Gavande","year":"2016","journal-title":"Pharmacol. Ther."},{"issue":"1","key":"10.1016\/j.phrs.2026.108380_bib72","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1186\/s12943-023-01801-2","article-title":"Molecular mechanisms of tumor resistance to radiotherapy","volume":"22","author":"Wu","year":"2023","journal-title":"Mol. Cancer"},{"issue":"3","key":"10.1016\/j.phrs.2026.108380_bib73","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1038\/85798","article-title":"DNA double-strand breaks: signaling, repair and the cancer connection","volume":"27","author":"Khanna","year":"2001","journal-title":"Nat. Genet."},{"issue":"6","key":"10.1016\/j.phrs.2026.108380_bib74","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1016\/j.molcel.2017.05.015","article-title":"and DNA-PK: The Trinity at the Heart of the DNA Damage Response","volume":"66","author":"Blackford","year":"2017","journal-title":"Mol. Cell"},{"issue":"6367","key":"10.1016\/j.phrs.2026.108380_bib75","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1126\/science.aan8414","article-title":"3.9 \u00c5 structure of the yeast Mec1-Ddc2 complex, a homolog of human ATR-ATRIP","volume":"358","author":"Wang","year":"2017","journal-title":"Science"},{"issue":"7904","key":"10.1016\/j.phrs.2026.108380_bib76","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1038\/s41586-022-04530-6","article-title":"Crucial role and mechanism of transcription-coupled DNA repair in bacteria","volume":"604","author":"Bharati","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.phrs.2026.108380_bib77","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.trac.2015.11.018","article-title":"Recent progress in electrochemical sensors and assays for DNA damage and repair","volume":"79","author":"Fojta","year":"2016","journal-title":"Trends Analyt. Chem."},{"issue":"1","key":"10.1016\/j.phrs.2026.108380_bib78","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1186\/s12885-018-4776-9","article-title":"Overexpression of the MRE11-RAD50-NBS1 (MRN) complex in rectal cancer correlates with poor response to neoadjuvant radiotherapy and prognosis","volume":"18","author":"Ho","year":"2018","journal-title":"BMC Cancer"},{"issue":"2","key":"10.1016\/j.phrs.2026.108380_bib79","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/j.ijrobp.2016.10.018","article-title":"Ku70, Ku80, and sClusterin: A Cluster of Predicting Factors for Response to Neoadjuvant Chemoradiation Therapy in Patients With Locally Advanced Rectal Cancer","volume":"97","author":"Pucci","year":"2017","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"issue":"6","key":"10.1016\/j.phrs.2026.108380_bib80","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1007\/s00109-019-01760-6","article-title":"Rab5C enhances resistance to ionizing radiation in rectal cancer","volume":"97","author":"Baptistella","year":"2019","journal-title":"J. Mol. Med. (Berl.)"},{"issue":"3","key":"10.1016\/j.phrs.2026.108380_bib81","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/j.molcel.2015.12.010","article-title":"FBXW7 Facilitates Nonhomologous End-Joining via K63-Linked Polyubiquitylation of XRCC4","volume":"61","author":"Zhang","year":"2016","journal-title":"Mol. Cell"},{"issue":"1","key":"10.1016\/j.phrs.2026.108380_bib82","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1186\/s13045-017-0443-x","article-title":"The cell cycle checkpoint inhibitors in the treatment of leukemias","volume":"10","author":"Ghelli Luserna di Rora","year":"2017","journal-title":"J. Hematol. Oncol."},{"issue":"10","key":"10.1016\/j.phrs.2026.108380_bib83","doi-asserted-by":"crossref","first-page":"5725","DOI":"10.7314\/APJCP.2013.14.10.5725","article-title":"Involvement of cdc25c in cell cycle alteration of a radioresistant lung cancer cell line established with fractionated ionizing radiation","volume":"14","author":"Li","year":"2013","journal-title":"Asian Pac. J. Cancer Prev."},{"issue":"5868","key":"10.1016\/j.phrs.2026.108380_bib84","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1126\/science.1140735","article-title":"An oncogene-induced DNA damage model for cancer development","volume":"319","author":"Halazonetis","year":"2008","journal-title":"Science"},{"issue":"6592","key":"10.1016\/j.phrs.2026.108380_bib85","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1126\/science.abi6378","article-title":"Cancer cells use self-inflicted DNA breaks to evade growth limits imposed by genotoxic stress","volume":"376","author":"Larsen","year":"2022","journal-title":"Science"},{"issue":"1","key":"10.1016\/j.phrs.2026.108380_bib86","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1093\/mutage\/gei063","article-title":"DNA damage checkpoints in mammals","volume":"21","author":"Niida","year":"2006","journal-title":"Mutagenesis"},{"issue":"3","key":"10.1016\/j.phrs.2026.108380_bib87","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1038\/35043058","article-title":"The many substrates and functions of ATM","volume":"1","author":"Kastan","year":"2000","journal-title":"Nat. Rev. Mol. Cell Biol."},{"issue":"4","key":"10.1016\/j.phrs.2026.108380_bib88","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1038\/nrm3546","article-title":"The ATM protein kinase: regulating the cellular response to genotoxic stress, and more","volume":"14","author":"Shiloh","year":"2013","journal-title":"Nat. Rev. Mol. Cell Biol."},{"issue":"11","key":"10.1016\/j.phrs.2026.108380_bib89","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1038\/sj.cdd.4400874","article-title":"ATM, a central controller of cellular responses to DNA damage","volume":"8","author":"Khanna","year":"2001","journal-title":"Cell Death Differ"},{"key":"10.1016\/j.phrs.2026.108380_bib90","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.pharmthera.2014.12.001","article-title":"ATM and ATR as therapeutic targets in cancer","volume":"149","author":"Weber","year":"2015","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.phrs.2026.108380_bib91","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1186\/s13046-015-0221-y","article-title":"Metabolic reprogramming: the emerging concept and associated therapeutic strategies","volume":"34","author":"Yoshida","year":"2015","journal-title":"J. Exp. Clin. Cancer Res."},{"issue":"4","key":"10.1016\/j.phrs.2026.108380_bib92","doi-asserted-by":"crossref","first-page":"547","DOI":"10.3727\/096504017X15016337254605","article-title":"miR-449a Suppresses LDHA-Mediated Glycolysis to Enhance the Sensitivity of Non-Small Cell Lung Cancer Cells to Ionizing Radiation","volume":"26","author":"Li","year":"2018","journal-title":"Oncol. Res."},{"issue":"2","key":"10.1016\/j.phrs.2026.108380_bib93","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1007\/s00018-015-2070-4","article-title":"Reprogramming of glucose, fatty acid and amino acid metabolism for cancer progression","volume":"73","author":"Li","year":"2016","journal-title":"Cell. Mol. Life Sci."},{"issue":"2","key":"10.1016\/j.phrs.2026.108380_bib94","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/j.radonc.2014.07.015","article-title":"AKT-mediated enhanced aerobic glycolysis causes acquired radioresistance by human tumor cells","volume":"112","author":"Shimura","year":"2014","journal-title":"Radiother. Oncol."},{"issue":"2 Pt A","key":"10.1016\/j.phrs.2026.108380_bib95","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.canlet.2014.04.001","article-title":"The Warburg effect in tumor progression: mitochondrial oxidative metabolism as an anti-metastasis mechanism","volume":"356","author":"Lu","year":"2015","journal-title":"Cancer Lett"},{"issue":"11","key":"10.1016\/j.phrs.2026.108380_bib96","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1158\/2326-6066.CIR-20-0111","article-title":"Lactate-Modulated Immunosuppression of Myeloid-Derived Suppressor Cells Contributes to the Radioresistance of Pancreatic Cancer","volume":"8","author":"Yang","year":"2020","journal-title":"Cancer Immunol. Res."},{"issue":"6","key":"10.1016\/j.phrs.2026.108380_bib97","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1002\/hep.32177","article-title":"Integration of glucose and cardiolipin anabolism confers radiation resistance of HCC","volume":"75","author":"Fang","year":"2022","journal-title":"Hepatology"},{"issue":"3","key":"10.1016\/j.phrs.2026.108380_bib98","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.trecan.2020.10.004","article-title":"Fat and Furious: Lipid Metabolism in Antitumoral Therapy Response and Resistance","volume":"7","author":"Bacci","year":"2021","journal-title":"Trends Cancer"},{"issue":"1","key":"10.1016\/j.phrs.2026.108380_bib99","doi-asserted-by":"crossref","DOI":"10.3390\/cancers10010003","article-title":"Lipid Metabolism and Lipid Droplets in Pancreatic Cancer and Stellate Cells","volume":"10","author":"Sunami","year":"2017","journal-title":"Cancers (Basel)"},{"issue":"1","key":"10.1016\/j.phrs.2026.108380_bib100","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1038\/s41467-022-29137-3","article-title":"Fatty acid oxidation fuels glioblastoma radioresistance with CD47-mediated immune evasion","volume":"13","author":"Jiang","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.phrs.2026.108380_bib101","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.3389\/fonc.2019.01201","article-title":"CPT1A\/2-Mediated FAO Enhancement-A Metabolic Target in Radioresistant Breast Cancer","volume":"9","author":"Han","year":"2019","journal-title":"Front. Oncol."},{"issue":"6","key":"10.1016\/j.phrs.2026.108380_bib102","doi-asserted-by":"crossref","first-page":"2050","DOI":"10.1111\/cas.14011","article-title":"PGC1\u03b1\/CEBPB\/CPT1A axis promotes radiation resistance of nasopharyngeal carcinoma through activating fatty acid oxidation","volume":"110","author":"Du","year":"2019","journal-title":"Cancer Sci"},{"issue":"5","key":"10.1016\/j.phrs.2026.108380_bib103","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1016\/j.celrep.2019.07.002","article-title":"Glutamine Synthetase Promotes Radiation Resistance via Facilitating Nucleotide Metabolism and Subsequent DNA Damage Repair","volume":"28","author":"Fu","year":"2019","journal-title":"Cell Rep"},{"issue":"1","key":"10.1016\/j.phrs.2026.108380_bib104","doi-asserted-by":"crossref","first-page":"3811","DOI":"10.1038\/s41467-020-17512-x","article-title":"Purine metabolism regulates DNA repair and therapy resistance in glioblastoma","volume":"11","author":"Zhou","year":"2020","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.phrs.2026.108380_bib105","doi-asserted-by":"crossref","DOI":"10.3390\/cancers11010112","article-title":"Hypoxic Radioresistance: Can ROS Be the Key to Overcome It?","volume":"11","author":"Wang","year":"2019","journal-title":"Cancers (Basel)"},{"issue":"3","key":"10.1016\/j.phrs.2026.108380_bib106","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1016\/j.critrevonc.2013.09.001","article-title":"Nrf2 is a potential therapeutic target in radioresistance in human cancer","volume":"88","author":"Zhou","year":"2013","journal-title":"Crit. Rev. Oncol. Hematol"},{"issue":"1","key":"10.1016\/j.phrs.2026.108380_bib107","doi-asserted-by":"crossref","DOI":"10.3390\/cells10010083","article-title":"Keap1-Nrf2 Pathway Regulates ALDH and Contributes to Radioresistance in Breast Cancer Stem Cells","volume":"10","author":"Kamble","year":"2021","journal-title":"Cells"},{"issue":"21","key":"10.1016\/j.phrs.2026.108380_bib108","doi-asserted-by":"crossref","first-page":"3939","DOI":"10.7150\/jca.26041","article-title":"Overexpression of Peroxiredoxin 6 (PRDX6) Promotes the Aggressive Phenotypes of Esophageal Squamous Cell Carcinoma","volume":"9","author":"He","year":"2018","journal-title":"J. Cancer"},{"key":"10.1016\/j.phrs.2026.108380_bib109","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.radonc.2021.03.012","article-title":"Deciphering the epigenetic network in cancer radioresistance","volume":"159","author":"Cabrera-Licona","year":"2021","journal-title":"Radiother. Oncol."},{"issue":"8","key":"10.1016\/j.phrs.2026.108380_bib110","doi-asserted-by":"crossref","first-page":"3812","DOI":"10.1002\/cam4.1614","article-title":"The pivotal role of DNA methylation in the radio-sensitivity of tumor radiotherapy","volume":"7","author":"Zhu","year":"2018","journal-title":"Cancer Med"},{"issue":"4","key":"10.1016\/j.phrs.2026.108380_bib111","doi-asserted-by":"crossref","first-page":"646","DOI":"10.7150\/jca.15652","article-title":"mRNA and methylation profiling of radioresistant esophageal cancer cells: The involvement of Sall2 in acquired aggressive phenotypes","volume":"8","author":"Luo","year":"2017","journal-title":"J. Cancer"},{"issue":"8","key":"10.1016\/j.phrs.2026.108380_bib112","doi-asserted-by":"crossref","first-page":"839","DOI":"10.4161\/epi.25498","article-title":"Radiation-induced epigenetic DNA methylation modification of radiation-response pathways","volume":"8","author":"Antwih","year":"2013","journal-title":"Epigenetics"},{"key":"10.1016\/j.phrs.2026.108380_bib113","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.omto.2020.04.007","article-title":"Radiation-Induced DNMT3B Promotes Radioresistance in Nasopharyngeal Carcinoma through Methylation of p53 and p21","volume":"17","author":"Wu","year":"2020","journal-title":"Mol. Ther. Oncolytics"},{"issue":"12","key":"10.1016\/j.phrs.2026.108380_bib114","doi-asserted-by":"crossref","first-page":"4174","DOI":"10.1158\/1078-0432.CCR-08-2929","article-title":"Methylation of RASSF1A, RASSF2A, and HIN-1 is associated with poor outcome after radiotherapy, but not surgery, in oral squamous cell carcinoma","volume":"15","author":"Huang","year":"2009","journal-title":"Clin. Cancer Res."},{"issue":"40","key":"10.1016\/j.phrs.2026.108380_bib115","doi-asserted-by":"crossref","first-page":"5927","DOI":"10.1038\/sj.onc.1210403","article-title":"Frequent silencing of RUNX3 in esophageal squamous cell carcinomas is associated with radioresistance and poor prognosis","volume":"26","author":"Sakakura","year":"2007","journal-title":"Oncogene"},{"key":"10.1016\/j.phrs.2026.108380_bib116","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.canlet.2017.03.028","article-title":"HDAC4 and HDAC6 sustain DNA double strand break repair and stem-like phenotype by promoting radioresistance in glioblastoma cells","volume":"397","author":"Marampon","year":"2017","journal-title":"Cancer Lett"},{"issue":"32","key":"10.1016\/j.phrs.2026.108380_bib117","doi-asserted-by":"crossref","first-page":"52823","DOI":"10.18632\/oncotarget.17275","article-title":"Chromatin remodeling modulates radiosensitivity of the daughter cells derived from cell population exposed to low- And high-LET irradiation","volume":"8","author":"Wang","year":"2017","journal-title":"Oncotarget"},{"issue":"1","key":"10.1016\/j.phrs.2026.108380_bib118","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/s13148-019-0800-4","article-title":"Elevated HDAC activity and altered histone phospho-acetylation confer acquired radio-resistant phenotype to breast cancer cells","volume":"12","author":"Sharda","year":"2020","journal-title":"Clin. Epigenetics"},{"issue":"7","key":"10.1016\/j.phrs.2026.108380_bib119","doi-asserted-by":"crossref","first-page":"773","DOI":"10.18632\/oncotarget.26616","article-title":"ALT cancer cells are specifically sensitive to lysine acetyl transferase inhibition","volume":"10","author":"Bakhos-Douaihy","year":"2019","journal-title":"Oncotarget"},{"issue":"12","key":"10.1016\/j.phrs.2026.108380_bib120","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1093\/neuonc\/noaa128","article-title":"Inhibition of SETMAR-H3K36me2-NHEJ repair axis in residual disease cells prevents glioblastoma recurrence","volume":"22","author":"Kaur","year":"2020","journal-title":"Neuro Oncol"},{"issue":"5","key":"10.1016\/j.phrs.2026.108380_bib121","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1080\/09553002.2017.1270472","article-title":"Epigenetic silencing and activation of transcription: influence on the radiation sensitivity of glioma cell lines","volume":"93","author":"Sak","year":"2017","journal-title":"Int. J. Radiat. Biol."},{"issue":"9","key":"10.1016\/j.phrs.2026.108380_bib122","doi-asserted-by":"crossref","first-page":"2637","DOI":"10.1158\/0008-5472.CAN-15-2116","article-title":"An epigenetic reprogramming strategy to resensitize radioresistant prostate cancer cells","volume":"76","author":"Peitzsch","year":"2016","journal-title":"Cancer Res"},{"issue":"5","key":"10.1016\/j.phrs.2026.108380_bib123","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1093\/jrr\/rraa052","article-title":"hTERT promoter methylation promotes small cell lung cancer progression and radiotherapy resistance","volume":"61","author":"Zhai","year":"2020","journal-title":"J. Radiat. Res."},{"issue":"9","key":"10.1016\/j.phrs.2026.108380_bib124","doi-asserted-by":"crossref","first-page":"4677","DOI":"10.21873\/anticanres.11020","article-title":"Strong kdm4b and kdm4d expression associates with radioresistance and aggressive phenotype in classical hodgkin lymphoma","volume":"36","author":"Bur","year":"2016","journal-title":"Anticancer Res"},{"issue":"1","key":"10.1016\/j.phrs.2026.108380_bib125","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.canlet.2015.07.003","article-title":"Silencing JARID1B suppresses oncogenicity, stemness and increases radiation sensitivity in human oral carcinoma","volume":"368","author":"Lin","year":"2015","journal-title":"Cancer Lett"},{"issue":"12","key":"10.1016\/j.phrs.2026.108380_bib126","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1038\/s41419-020-03279-y","article-title":"JmjC-KDMs KDM3A and KDM6B modulate radioresistance under hypoxic conditions in esophageal squamous cell carcinoma","volume":"11","author":"Macedo-Silva","year":"2020","journal-title":"Cell Death Dis"},{"issue":"5","key":"10.1016\/j.phrs.2026.108380_bib127","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1158\/1535-7163.MCT-17-1053","article-title":"Inhibition of the histone h3k27 demethylase utx enhances tumor cell radiosensitivity","volume":"17","author":"Rath","year":"2018","journal-title":"Mol. Cancer Ther."},{"issue":"6","key":"10.1016\/j.phrs.2026.108380_bib128","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/cancers12061662","article-title":"Non-coding RNAs in cancer radiosensitivity: MicroRNAs and lncrnas as regulators of radiation-induced signaling pathways","volume":"12","author":"Podralska","year":"2020","journal-title":"Cancers (Basel)"},{"issue":"12","key":"10.1016\/j.phrs.2026.108380_bib129","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines11123240","article-title":"The Mechanism of Ubiquitination or Deubiquitination Modifications in Regulating Solid Tumor Radiosensitivity","volume":"11","author":"Zhang","year":"2023","journal-title":"Biomedicines"},{"issue":"1","key":"10.1016\/j.phrs.2026.108380_bib130","doi-asserted-by":"crossref","first-page":"341","DOI":"10.3892\/or.2015.3958","article-title":"RNF8 plays an important role in the radioresistance of human nasopharyngeal cancer cells in vitro","volume":"34","author":"Wang","year":"2015","journal-title":"Oncol. Rep."},{"issue":"9","key":"10.1016\/j.phrs.2026.108380_bib131","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.3727\/096504018X15154085345907","article-title":"Silencing of E3 Ubiquitin Ligase RNF8 Enhances Ionizing Radiation Sensitivity of Medulloblastoma Cells by Promoting the Deubiquitination of PCNA","volume":"26","author":"Li","year":"2018","journal-title":"Oncol. Res."},{"issue":"1","key":"10.1016\/j.phrs.2026.108380_bib132","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1186\/s12967-022-03516-2","article-title":"LINC00665 knockdown confers sensitivity in irradiated non-small cell lung cancer cells through the miR-582-5p\/UCHL3\/AhR axis","volume":"20","author":"Xu","year":"2022","journal-title":"J. Transl. Med."},{"issue":"10","key":"10.1016\/j.phrs.2026.108380_bib133","first-page":"14277","article-title":"Silencing UCHL3 enhances radio-sensitivity of non-small cell lung cancer cells by inhibiting DNA repair","volume":"13","author":"Liu","year":"2021","journal-title":"Aging (Albany N. Y.)"},{"issue":"23","key":"10.1016\/j.phrs.2026.108380_bib134","doi-asserted-by":"crossref","first-page":"2581","DOI":"10.1101\/gad.289439.116","article-title":"A phosphorylation-deubiquitination cascade regulates the BRCA2-RAD51 axis in homologous recombination","volume":"30","author":"Luo","year":"2016","journal-title":"Genes Dev"},{"issue":"7","key":"10.1016\/j.phrs.2026.108380_bib135","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.1038\/s41418-021-00740-z","article-title":"USP9X-mediated KDM4C deubiquitination promotes lung cancer radioresistance by epigenetically inducing TGF-\u03b22 transcription","volume":"28","author":"Jie","year":"2021","journal-title":"Cell Death Differ"},{"issue":"19","key":"10.1016\/j.phrs.2026.108380_bib136","doi-asserted-by":"crossref","first-page":"9339","DOI":"10.1158\/0008-5472.CAN-06-3126","article-title":"Cancer stem cells--perspectives on current status and future directions: AACR Workshop on cancer stem cells","volume":"66","author":"Clarke","year":"2006","journal-title":"Cancer Res"},{"issue":"10","key":"10.1016\/j.phrs.2026.108380_bib137","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.2217\/fon.10.121","article-title":"Are cancer stem cells radioresistant?","volume":"6","author":"Hittelman","year":"2010","journal-title":"Future Oncol"},{"issue":"1 1","key":"10.1016\/j.phrs.2026.108380_bib138","article-title":"Cancer stem cells: Role in tumor growth, recurrence, metastasis, and treatment resistance","volume":"95","author":"Chang","year":"2016","journal-title":"Medicine (Baltimore)"},{"issue":"9","key":"10.1016\/j.phrs.2026.108380_bib139","doi-asserted-by":"crossref","DOI":"10.1002\/ctm2.545","article-title":"A methyltransferase-like 14\/miR-99a-5p\/tribble 2 positive feedback circuit promotes cancer stem cell persistence and radioresistance via histone deacetylase 2-mediated epigenetic modulation in esophageal squamous cell carcinoma","volume":"11","author":"Liu","year":"2021","journal-title":"Clin. Transl. Med."},{"key":"10.1016\/j.phrs.2026.108380_bib140","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.canlet.2017.02.012","article-title":"Targeting autophagy in cancer stem cells as an anticancer therapy","volume":"393","author":"Lei","year":"2017","journal-title":"Cancer Lett"},{"issue":"1","key":"10.1016\/j.phrs.2026.108380_bib141","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.canlet.2012.11.019","article-title":"Cancer stem cells, the epithelial to mesenchymal transition (EMT) and radioresistance: potential role of hypoxia","volume":"341","author":"Marie-Egyptienne","year":"2013","journal-title":"Cancer Lett"},{"key":"10.1016\/j.phrs.2026.108380_bib142","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.semcancer.2014.06.002","article-title":"Crosstalk between DNA repair and cancer stem cell (CSC) associated intracellular pathways","volume":"31","author":"Skvortsov","year":"2015","journal-title":"Semin. Cancer Biol."},{"key":"10.1016\/j.phrs.2026.108380_bib143","doi-asserted-by":"crossref","DOI":"10.1155\/2015\/425708","article-title":"Antioxidant Mechanisms and ROS-Related MicroRNAs in Cancer Stem Cells","volume":"2015","author":"Dando","year":"2015","journal-title":"Oxid. Med. Cell. Longev."},{"key":"10.1016\/j.phrs.2026.108380_bib144","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1186\/s12885-016-2647-9","article-title":"A radiosensitizing effect of RAD51 inhibition in glioblastoma stem-like cells","volume":"16","author":"Balbous","year":"2016","journal-title":"BMC Cancer"},{"issue":"7120","key":"10.1016\/j.phrs.2026.108380_bib145","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1038\/nature05236","article-title":"Glioma stem cells promote radioresistance by preferential activation of the DNA damage response","volume":"444","author":"Bao","year":"2006","journal-title":"Nature"},{"issue":"6","key":"10.1016\/j.phrs.2026.108380_bib146","doi-asserted-by":"crossref","DOI":"10.3390\/cancers11060862","article-title":"Cancer Stem Cells and Radioresistance: DNA Repair and Beyond","volume":"11","author":"Schulz","year":"2019","journal-title":"Cancers (Basel)"},{"issue":"7412","key":"10.1016\/j.phrs.2026.108380_bib147","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1038\/nature11344","article-title":"Defining the mode of tumour growth by clonal analysis","volume":"488","author":"Driessens","year":"2012","journal-title":"Nature"},{"issue":"3","key":"10.1016\/j.phrs.2026.108380_bib148","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1016\/j.radonc.2013.10.040","article-title":"CD133+ cells contribute to radioresistance via altered regulation of DNA repair genes in human lung cancer cells","volume":"110","author":"Desai","year":"2014","journal-title":"Radiother. Oncol."},{"issue":"9","key":"10.1016\/j.phrs.2026.108380_bib149","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1038\/ncb3013","article-title":"ATM-mediated stabilization of ZEB1 promotes DNA damage response and radioresistance through CHK1","volume":"16","author":"Zhang","year":"2014","journal-title":"Nat. Cell Biol."},{"issue":"6","key":"10.1016\/j.phrs.2026.108380_bib150","doi-asserted-by":"crossref","first-page":"2247","DOI":"10.3892\/or.2012.2068","article-title":"Chk1 knockdown confers radiosensitization in prostate cancer stem cells","volume":"28","author":"Wang","year":"2012","journal-title":"Oncol. Rep."},{"issue":"1","key":"10.1016\/j.phrs.2026.108380_bib151","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.molonc.2014.08.003","article-title":"Abrogation of radioresistance in glioblastoma stem-like cells by inhibition of ATM kinase","volume":"9","author":"Carruthers","year":"2015","journal-title":"Mol. Oncol."},{"issue":"7239","key":"10.1016\/j.phrs.2026.108380_bib152","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1038\/nature07733","article-title":"Association of reactive oxygen species levels and radioresistance in cancer stem cells","volume":"458","author":"Diehn","year":"2009","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.phrs.2026.108380_bib153","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3109\/09553002.2014.934929","article-title":"Ionizing radiation-induced oxidative stress, epigenetic changes and genomic instability: the pivotal role of mitochondria","volume":"91","author":"Szumiel","year":"2015","journal-title":"Int. J. Radiat. Biol."},{"issue":"12","key":"10.1016\/j.phrs.2026.108380_bib154","doi-asserted-by":"crossref","first-page":"3643","DOI":"10.1002\/jcb.24228","article-title":"Quiescence and attenuated DNA damage response promote survival of esophageal cancer stem cells","volume":"113","author":"Chen","year":"2012","journal-title":"J. Cell. Biochem."},{"issue":"1","key":"10.1016\/j.phrs.2026.108380_bib155","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.devcel.2017.02.016","article-title":"Cleaning House: Selective Autophagy of Organelles","volume":"41","author":"Anding","year":"2017","journal-title":"Dev. Cell"},{"issue":"7182","key":"10.1016\/j.phrs.2026.108380_bib156","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1038\/nature06639","article-title":"Autophagy fights disease through cellular self-digestion","volume":"451","author":"Mizushima","year":"2008","journal-title":"Nature"},{"issue":"3","key":"10.1016\/j.phrs.2026.108380_bib157","doi-asserted-by":"crossref","DOI":"10.3390\/ijms20030461","article-title":"Current Outlook on Autophagy in Human Leukemia: Foe in Cancer Stem Cells and Drug Resistance, Friend in New Therapeutic Interventions","volume":"20","author":"Rothe","year":"2019","journal-title":"Int. J. Mol. Sci."},{"issue":"7584","key":"10.1016\/j.phrs.2026.108380_bib158","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1038\/nature16187","article-title":"Autophagy maintains stemness by preventing senescence","volume":"529","author":"Garc\u00eda-Prat","year":"2016","journal-title":"Nature"},{"issue":"10","key":"10.1016\/j.phrs.2026.108380_bib159","doi-asserted-by":"crossref","DOI":"10.1038\/cddis.2013.338","article-title":"Autophagy prevents irradiation injury and maintains stemness through decreasing ROS generation in mesenchymal stem cells","volume":"4","author":"Hou","year":"2013","journal-title":"Cell Death Dis"},{"issue":"3","key":"10.1016\/j.phrs.2026.108380_bib160","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1038\/cdd.2014.150","article-title":"Oxidative stress and autophagy: the clash between damage and metabolic needs","volume":"22","author":"Filomeni","year":"2015","journal-title":"Cell Death Differ"},{"issue":"2","key":"10.1016\/j.phrs.2026.108380_bib161","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.stem.2010.07.007","article-title":"Oxygen in stem cell biology: a critical component of the stem cell niche","volume":"7","author":"Mohyeldin","year":"2010","journal-title":"Cell Stem Cell"},{"issue":"8","key":"10.1016\/j.phrs.2026.108380_bib162","doi-asserted-by":"crossref","first-page":"636","DOI":"10.3109\/09553002.2014.916841","article-title":"Hypoxia as a biomarker for radioresistant cancer stem cells","volume":"90","author":"Peitzsch","year":"2014","journal-title":"Int. J. Radiat. Biol."},{"issue":"2","key":"10.1016\/j.phrs.2026.108380_bib163","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1111\/1440-1681.12693","article-title":"Drug resistance and cancer stem cells: the shared but distinct roles of hypoxia-inducible factors HIF1\u03b1 and HIF2\u03b1","volume":"44","author":"Sch\u00f6ning","year":"2017","journal-title":"Clin. Exp. Pharmacol. Physiol."},{"issue":"1","key":"10.1016\/j.phrs.2026.108380_bib164","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1038\/s41392-020-0110-5","article-title":"Targeting cancer stem cell pathways for cancer therapy","volume":"5","author":"Yang","year":"2020","journal-title":"Signal Transduct. Target. Ther."},{"issue":"1","key":"10.1016\/j.phrs.2026.108380_bib165","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/s12015-016-9691-3","article-title":"Eliminating Cancer Stem Cells by Targeting Embryonic Signaling Pathways","volume":"13","author":"Oren","year":"2017","journal-title":"Stem Cell Rev. Rep."},{"issue":"2","key":"10.1016\/j.phrs.2026.108380_bib166","doi-asserted-by":"crossref","first-page":"109","DOI":"10.20892\/j.issn.2095-3941.2016.0032","article-title":"Developmental pathways associated with cancer metastasis: Notch, Wnt, and Hedgehog","volume":"14","author":"Nwabo Kamdje","year":"2017","journal-title":"Cancer Biol. Med."},{"key":"10.1016\/j.phrs.2026.108380_bib167","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.phrs.2019.02.027","article-title":"Targeting the crosstalks of Wnt pathway with Hedgehog and Notch for cancer therapy","volume":"142","author":"Chatterjee","year":"2019","journal-title":"Pharmacol. Res."},{"issue":"7","key":"10.1016\/j.phrs.2026.108380_bib168","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.1158\/0008-5472.CAN-14-1924","article-title":"Aldehyde Dehydrogenase Is Regulated by \u03b2-Catenin\/TCF and Promotes Radioresistance in Prostate Cancer Progenitor Cells","volume":"75","author":"Cojoc","year":"2015","journal-title":"Cancer Res"},{"issue":"7","key":"10.1016\/j.phrs.2026.108380_bib169","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1093\/neuonc\/now258","article-title":"Hypoxia in the glioblastoma microenvironment: shaping the phenotype of cancer stem-like cells","volume":"19","author":"Colwell","year":"2017","journal-title":"Neuro Oncol"},{"issue":"1","key":"10.1016\/j.phrs.2026.108380_bib170","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/s13045-016-0373-z","article-title":"Natural compounds targeting major cell signaling pathways: a novel paradigm for osteosarcoma therapy","volume":"10","author":"Angulo","year":"2017","journal-title":"J. Hematol. Oncol."},{"issue":"8","key":"10.1016\/j.phrs.2026.108380_bib171","doi-asserted-by":"crossref","DOI":"10.3390\/cancers11081191","article-title":"Reactive Oxygen Species in the Tumor Microenvironment: An Overview","volume":"11","author":"Weinberg","year":"2019","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.phrs.2026.108380_bib172","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.775238","article-title":"Targeting Epithelial-to-Mesenchymal Transition in Radioresistance: Crosslinked Mechanisms and Strategies","volume":"12","author":"Qiao","year":"2022","journal-title":"Front. Oncol."},{"issue":"1","key":"10.1016\/j.phrs.2026.108380_bib173","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/s12929-020-00632-3","article-title":"Epigenetic regulation of epithelial-mesenchymal transition: focusing on hypoxia and TGF-\u03b2 signaling","volume":"27","author":"Lin","year":"2020","journal-title":"J. Biomed. Sci."},{"issue":"1","key":"10.1016\/j.phrs.2026.108380_bib174","first-page":"14","article-title":"Cancer-associated fibroblasts and their role in tumor progression","volume":"26","author":"Ermakov","year":"2022","journal-title":"Vavilovskii Zhurnal Genet Selektsii"},{"issue":"1","key":"10.1016\/j.phrs.2026.108380_bib175","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1111\/cas.15560","article-title":"CDCA7 promotes TGF-\u03b2-induced epithelial-mesenchymal transition via transcriptionally regulating Smad4\/Smad7 in ESCC","volume":"114","author":"Li","year":"2023","journal-title":"Cancer Sci"},{"issue":"2","key":"10.1016\/j.phrs.2026.108380_bib176","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.advms.2021.03.004","article-title":"A new gene panel as a marker for ESCC poor prognosis; INPP5A, TWIST1, MMP2, and EGFR","volume":"66","author":"Fardi Golyan","year":"2021","journal-title":"Adv. Med. Sci."},{"issue":"6","key":"10.1016\/j.phrs.2026.108380_bib177","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1038\/onc.2017.370","article-title":"SPSB3 targets SNAIL for degradation in GSK-3\u03b2 phosphorylation-dependent manner and regulates metastasis","volume":"37","author":"Liu","year":"2018","journal-title":"Oncogene"},{"issue":"8","key":"10.1016\/j.phrs.2026.108380_bib178","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1111\/1759-7714.14366","article-title":"Epiplakin1 promotes the progression of esophageal squamous cell carcinoma by activating the PI3K-AKT signaling pathway","volume":"13","author":"Qiao","year":"2022","journal-title":"Thorac. Cancer"},{"issue":"1","key":"10.1016\/j.phrs.2026.108380_bib179","doi-asserted-by":"crossref","first-page":"259","DOI":"10.7150\/ijbs.53795","article-title":"NETO2 promotes esophageal cancer progression by inducing proliferation and metastasis via PI3K\/AKT and ERK pathway","volume":"17","author":"Xu","year":"2021","journal-title":"Int. J. Biol. Sci."},{"issue":"1","key":"10.1016\/j.phrs.2026.108380_bib180","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1158\/2159-8290.CD-21-1059","article-title":"Hallmarks of Cancer: New Dimensions","volume":"12","author":"Hanahan","year":"2022","journal-title":"Cancer Discov"},{"issue":"24","key":"10.1016\/j.phrs.2026.108380_bib181","doi-asserted-by":"crossref","first-page":"14453","DOI":"10.1073\/pnas.95.24.14453","article-title":"The intrinsic radioresistance of glioblastoma-derived cell lines is associated with a failure of p53 to induce p21(BAX) expression","volume":"95","author":"Shu","year":"1998","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"2","key":"10.1016\/j.phrs.2026.108380_bib182","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1002\/med.21379","article-title":"Direct Activation of Bax Protein for Cancer Therapy","volume":"36","author":"Liu","year":"2016","journal-title":"Med. Res. Rev."},{"issue":"1","key":"10.1016\/j.phrs.2026.108380_bib183","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1023\/A:1014448721327","article-title":"BCL-2 family proteins modulate radiosensitivity in human malignant glioma cells","volume":"56","author":"Streffer","year":"2002","journal-title":"J. Neurooncol."},{"issue":"9","key":"10.1016\/j.phrs.2026.108380_bib184","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1016\/S0959-8049(99)00134-3","article-title":"Role of Bcl-2 family proteins (Bax, Bcl-2 and Bcl-X) on cellular susceptibility to radiation in pancreatic cancer cells","volume":"35","author":"Lee","year":"1999","journal-title":"Eur. J. Cancer"},{"issue":"4","key":"10.1016\/j.phrs.2026.108380_bib185","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1002\/ijc.10503","article-title":"Overexpression of Bcl-2 in squamous cell carcinoma of the larynx: a marker of radioresistance","volume":"100","author":"Condon","year":"2002","journal-title":"Int. J. Cancer"},{"issue":"4","key":"10.1016\/j.phrs.2026.108380_bib186","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1016\/j.ijrobp.2019.11.029","article-title":"Mesothelioma Cells Depend on the Antiapoptotic Protein Bcl-xL for Survival and Are Sensitized to Ionizing Radiation by BH3-Mimetics","volume":"106","author":"Jackson","year":"2020","journal-title":"Int. J. Radiat. Oncol. Biol. Phys"},{"issue":"12","key":"10.1016\/j.phrs.2026.108380_bib187","first-page":"4130","article-title":"RNA binding motif protein 3 (RBM3) drives radioresistance in nasopharyngeal carcinoma by reducing apoptosis via the PI3K\/AKT\/Bcl-2 signaling pathway","volume":"10","author":"Ma","year":"2018","journal-title":"Am. J. Transl. Res."},{"issue":"9","key":"10.1016\/j.phrs.2026.108380_bib188","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1007\/s00432-018-2696-3","article-title":"Disruption of MEK\/ERK\/c-Myc signaling radiosensitizes prostate cancer cells in vitro and in vivo","volume":"144","author":"Ciccarelli","year":"2018","journal-title":"J. Cancer Res. Clin. Oncol."},{"issue":"9","key":"10.1016\/j.phrs.2026.108380_bib189","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1038\/sj.cdd.4401050","article-title":"MEK\/ERK pathway protects ionizing radiation-induced loss of mitochondrial membrane potential and cell death in lymphocytic leukemia cells","volume":"9","author":"Shonai","year":"2002","journal-title":"Cell Death Differ"},{"issue":"1","key":"10.1016\/j.phrs.2026.108380_bib190","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1186\/s13046-019-1419-1","article-title":"Apatinib potentiates irradiation effect via suppressing PI3K\/AKT signaling pathway in hepatocellular carcinoma","volume":"38","author":"Liao","year":"2019","journal-title":"J. Exp. Clin. Cancer Res."},{"issue":"11","key":"10.1016\/j.phrs.2026.108380_bib191","doi-asserted-by":"crossref","first-page":"4881","DOI":"10.1158\/0008-5472.CAN-04-3028","article-title":"Survivin as a radioresistance factor, and prognostic and therapeutic target for radiotherapy in rectal cancer","volume":"65","author":"R\u00f6del","year":"2005","journal-title":"Cancer Res"},{"issue":"8","key":"10.1016\/j.phrs.2026.108380_bib192","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1038\/s41435-019-0078-8","article-title":"Inhibitor of apoptosis proteins in human health and disease","volume":"20","author":"Hrdinka","year":"2019","journal-title":"Genes Immun"},{"issue":"7","key":"10.1016\/j.phrs.2026.108380_bib193","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1038\/s41568-022-00459-0","article-title":"Targeting ferroptosis as a vulnerability in cancer","volume":"22","author":"Lei","year":"2022","journal-title":"Nat. Rev. Cancer"},{"issue":"4","key":"10.1016\/j.phrs.2026.108380_bib194","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1016\/j.bbrc.2019.08.117","article-title":"MiR-7-5p is a key factor that controls radioresistance via intracellular Fe(2+) content in clinically relevant radioresistant cells,","volume":"518","author":"Tomita","year":"2019","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"2","key":"10.1016\/j.phrs.2026.108380_bib195","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1038\/s41422-019-0263-3","article-title":"The role of ferroptosis in ionizing radiation-induced cell death and tumor suppression","volume":"30","author":"Lei","year":"2020","journal-title":"Cell Res"},{"issue":"1","key":"10.1016\/j.phrs.2026.108380_bib196","doi-asserted-by":"crossref","first-page":"2206","DOI":"10.1038\/s41467-022-29905-1","article-title":"A targetable CoQ-FSP1 axis drives ferroptosis- and radiation-resistance in KEAP1 inactive lung cancers","volume":"13","author":"Koppula","year":"2022","journal-title":"Nat. Commun."},{"issue":"8","key":"10.1016\/j.phrs.2026.108380_bib197","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1038\/nrc.2017.51","article-title":"Microenvironmental regulation of tumour angiogenesis","volume":"17","author":"De Palma","year":"2017","journal-title":"Nat. Rev. Cancer"},{"issue":"10","key":"10.1016\/j.phrs.2026.108380_bib198","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1038\/nrc.2017.78","article-title":"Exercise-dependent regulation of the tumour microenvironment","volume":"17","author":"Koelwyn","year":"2017","journal-title":"Nat. Rev. Cancer"},{"issue":"1","key":"10.1016\/j.phrs.2026.108380_bib199","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1002\/mco2.6","article-title":"Metabolism in tumor microenvironment: Implications for cancer immunotherapy","volume":"1","author":"Shi","year":"2020","journal-title":"MedComm"},{"issue":"1","key":"10.1016\/j.phrs.2026.108380_bib200","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.radmp.2020.01.006","article-title":"HIF-1 signaling: A key orchestrator of cancer radioresistance","volume":"1","author":"Huang","year":"2020","journal-title":"Radiat. Med. Prot."},{"key":"10.1016\/j.phrs.2026.108380_bib201","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.molmet.2018.11.013","article-title":"6-Phosphofructo-2-kinase\/fructose-2,6-biphosphatase 3 and 4: A pair of valves for fine-tuning of glucose metabolism in human cancer","volume":"20","author":"Yi","year":"2019","journal-title":"Mol. Metab."},{"key":"10.1016\/j.phrs.2026.108380_bib202","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2020.102961","article-title":"The role of epithelial-mesenchymal transition in regulating radioresistance","volume":"150","author":"Zhou","year":"2020","journal-title":"Crit. Rev. Oncol. Hematol"},{"issue":"2","key":"10.1016\/j.phrs.2026.108380_bib203","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.jbo.2016.03.001","article-title":"Hypoxia-induced autophagy as an additional mechanism in human osteosarcoma radioresistance","volume":"5","author":"Feng","year":"2016","journal-title":"J. Bone Oncol."},{"issue":"10","key":"10.1016\/j.phrs.2026.108380_bib204","doi-asserted-by":"crossref","first-page":"1760","DOI":"10.1038\/s41416-022-01956-7","article-title":"Exosomal protein angiopoietin-like 4 mediated radioresistance of lung cancer by inhibiting ferroptosis under hypoxic microenvironment","volume":"127","author":"Zhang","year":"2022","journal-title":"Br. J. Cancer"},{"issue":"3","key":"10.1016\/j.phrs.2026.108380_bib205","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1007\/s00441-016-2467-x","article-title":"Fibroblast activation in cancer: when seed fertilizes soil","volume":"365","author":"Kuzet","year":"2016","journal-title":"Cell Tissue Res"},{"issue":"1","key":"10.1016\/j.phrs.2026.108380_bib206","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1152\/physrev.00048.2019","article-title":"Diversity and Biology of Cancer-Associated Fibroblasts","volume":"101","author":"Biffi","year":"2021","journal-title":"Physiol. Rev."},{"issue":"2","key":"10.1016\/j.phrs.2026.108380_bib207","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1038\/s41573-018-0004-1","article-title":"Turning foes to friends: targeting cancer-associated fibroblasts","volume":"18","author":"Chen","year":"2019","journal-title":"Nat. Rev. Drug Discov."},{"issue":"8","key":"10.1016\/j.phrs.2026.108380_bib208","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1038\/s41575-020-0300-1","article-title":"Pancreatic cancer stroma: an update on therapeutic targeting strategies","volume":"17","author":"Hosein","year":"2020","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"issue":"1","key":"10.1016\/j.phrs.2026.108380_bib209","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1186\/s12885-019-5353-6","article-title":"Cancer-associated fibroblasts induce epithelial-mesenchymal transition of bladder cancer cells through paracrine IL-6 signalling","volume":"19","author":"Goulet","year":"2019","journal-title":"BMC Cancer"},{"issue":"1","key":"10.1016\/j.phrs.2026.108380_bib210","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1186\/s12943-019-0994-2","article-title":"Cancer-associated fibroblasts as abettors of tumor progression at the crossroads of EMT and therapy resistance","volume":"18","author":"Fiori","year":"2019","journal-title":"Mol. Cancer"},{"issue":"1","key":"10.1016\/j.phrs.2026.108380_bib211","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1038\/s41420-021-00506-z","article-title":"Carcinoma-associated fibroblasts derived exosomes modulate breast cancer cell stemness through exonic circHIF1A by miR-580-5p in hypoxic stress","volume":"7","author":"Zhan","year":"2021","journal-title":"Cell Death Discov"},{"issue":"14","key":"10.1016\/j.phrs.2026.108380_bib212","doi-asserted-by":"crossref","first-page":"3932","DOI":"10.7150\/thno.25541","article-title":"Carcinoma-associated fibroblasts promote the stemness and chemoresistance of colorectal cancer by transferring exosomal lncRNA H19","volume":"8","author":"Ren","year":"2018","journal-title":"Theranostics"},{"issue":"5","key":"10.1016\/j.phrs.2026.108380_bib213","doi-asserted-by":"crossref","DOI":"10.1038\/cddis.2017.180","article-title":"CAF-secreted CXCL1 conferred radioresistance by regulating DNA damage response in a ROS-dependent manner in esophageal squamous cell carcinoma","volume":"8","author":"Zhang","year":"2017","journal-title":"Cell Death Dis"},{"issue":"6","key":"10.1016\/j.phrs.2026.108380_bib214","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.1158\/1078-0432.CCR-18-0773","article-title":"Cancer-associated Fibroblast-promoted LncRNA DNM3OS Confers Radioresistance by Regulating DNA Damage Response in Esophageal Squamous Cell Carcinoma","volume":"25","author":"Zhang","year":"2019","journal-title":"Clin. Cancer Res."},{"issue":"1","key":"10.1016\/j.phrs.2026.108380_bib215","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1186\/s12943-021-01428-1","article-title":"Crosstalk between cancer-associated fibroblasts and immune cells in the tumor microenvironment: new findings and future perspectives","volume":"20","author":"Mao","year":"2021","journal-title":"Mol. Cancer"},{"issue":"9","key":"10.1016\/j.phrs.2026.108380_bib216","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2015.1034918","article-title":"Cancer associated fibroblasts have phenotypic and functional characteristics similar to the fibrocytes that represent a novel MDSC subset","volume":"4","author":"Gunaydin","year":"2015","journal-title":"Oncoimmunology"},{"issue":"4","key":"10.1016\/j.phrs.2026.108380_bib217","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1038\/s41419-019-1435-2","article-title":"Cancer-associated fibroblasts enhance tumor-associated macrophages enrichment and suppress NK cells function in colorectal cancer","volume":"10","author":"Zhang","year":"2019","journal-title":"Cell Death Dis"},{"issue":"23","key":"10.1016\/j.phrs.2026.108380_bib218","doi-asserted-by":"crossref","first-page":"3984","DOI":"10.4161\/cc.8.23.10238","article-title":"The reverse Warburg effect: aerobic glycolysis in cancer associated fibroblasts and the tumor stroma","volume":"8","author":"Pavlides","year":"2009","journal-title":"Cell Cycle"},{"issue":"5","key":"10.1016\/j.phrs.2026.108380_bib219","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1016\/j.cmet.2016.08.011","article-title":"LDHA-Associated Lactic Acid Production Blunts Tumor Immunosurveillance by T and NK Cells","volume":"24","author":"Brand","year":"2016","journal-title":"Cell Metab"},{"key":"10.1016\/j.phrs.2026.108380_bib220","doi-asserted-by":"crossref","DOI":"10.1038\/s41588-025-02253-8","article-title":"Single-cell and spatial transcriptomics reveal mechanisms of radioresistance and immune escape in recurrent nasopharyngeal carcinoma","author":"You","year":"2025","journal-title":"Nat. Genet."},{"issue":"1","key":"10.1016\/j.phrs.2026.108380_bib221","doi-asserted-by":"crossref","DOI":"10.1016\/j.cell.2018.03.015","article-title":"SnapShot: CGAS-STING Signaling","volume":"173","author":"Galluzzi","year":"2018","journal-title":"Cell"},{"issue":"7","key":"10.1016\/j.phrs.2026.108380_bib222","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1016\/S1470-2045(15)00054-6","article-title":"Local radiotherapy and granulocyte-macrophage colony-stimulating factor to generate abscopal responses in patients with metastatic solid tumours: a proof-of-principle trial","volume":"16","author":"Golden","year":"2015","journal-title":"Lancet Oncol"},{"issue":"10","key":"10.1016\/j.phrs.2026.108380_bib223","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1056\/NEJMoa1112824","article-title":"Immunologic correlates of the abscopal effect in a patient with melanoma","volume":"366","author":"Postow","year":"2012","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.phrs.2026.108380_bib224","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1038\/s41467-020-20243-8","article-title":"Nanoscale coordination polymers induce immunogenic cell death by amplifying radiation therapy mediated oxidative stress","volume":"12","author":"Huang","year":"2021","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.phrs.2026.108380_bib225","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1038\/s41467-017-01566-5","article-title":"Host STING-dependent MDSC mobilization drives extrinsic radiation resistance","volume":"8","author":"Liang","year":"2017","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.phrs.2026.108380_bib226","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1038\/s41467-023-36523-y","article-title":"TRIM21 inhibits irradiation-induced mitochondrial DNA release and impairs antitumour immunity in nasopharyngeal carcinoma tumour models","volume":"14","author":"Li","year":"2023","journal-title":"Nat. Commun."},{"issue":"5","key":"10.1016\/j.phrs.2026.108380_bib227","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1016\/j.ijrobp.2021.12.162","article-title":"Radiation Therapy Promotes Hepatocellular Carcinoma Immune Cloaking via PD-L1 Upregulation Induced by cGAS-STING Activation","volume":"112","author":"Du","year":"2022","journal-title":"Int. J. Radiat. Oncol. Biol. Phys"},{"issue":"5","key":"10.1016\/j.phrs.2026.108380_bib228","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1007\/s00066-016-0948-1","article-title":"Adenosine can thwart antitumor immune responses elicited by radiotherapy: Therapeutic strategies alleviating protumor ADO activities","volume":"192","author":"Vaupel","year":"2016","journal-title":"Strahlenther. Onkol."},{"issue":"1","key":"10.1016\/j.phrs.2026.108380_bib229","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1158\/1078-0432.CCR-16-0870","article-title":"Tumor-Derived CCL2 Mediates Resistance to Radiotherapy in Pancreatic Ductal Adenocarcinoma","volume":"23","author":"Kalbasi","year":"2017","journal-title":"Clin. Cancer Res."},{"issue":"1","key":"10.1016\/j.phrs.2026.108380_bib230","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1158\/2326-6066.CIR-19-0305","article-title":"Activin A Promotes Regulatory T-cell-Mediated Immunosuppression in Irradiated Breast Cancer","volume":"9","author":"De Martino","year":"2021","journal-title":"Cancer Immunol. Res."},{"issue":"10","key":"10.1016\/j.phrs.2026.108380_bib231","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1038\/nm1001-1118","article-title":"Immune-mediated eradication of tumors through the blockade of transforming growth factor-beta signaling in T cells,","volume":"7","author":"Gorelik","year":"2001","journal-title":"Nat. Med."},{"issue":"5","key":"10.1016\/j.phrs.2026.108380_bib232","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.ccr.2005.10.012","article-title":"TGF-beta directly targets cytotoxic T cell functions during tumor evasion of immune surveillance,","volume":"8","author":"Thomas","year":"2005","journal-title":"Cancer Cell"},{"issue":"1","key":"10.1016\/j.phrs.2026.108380_bib233","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1158\/2159-8290.CD-21-0003","article-title":"Low-Dose Radiotherapy Reverses Tumor Immune Desertification and Resistance to Immunotherapy","volume":"12","author":"Herrera","year":"2022","journal-title":"Cancer Discov"},{"issue":"2","key":"10.1016\/j.phrs.2026.108380_bib234","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1002\/hep.29328","article-title":"Targeting histone deacetylase 4\/ubiquitin-conjugating enzyme 9 impairs DNA repair for radiosensitization of hepatocellular carcinoma cells in mice","volume":"67","author":"Tsai","year":"2018","journal-title":"Hepatology"},{"issue":"31","key":"10.1016\/j.phrs.2026.108380_bib235","doi-asserted-by":"crossref","DOI":"10.1002\/adhm.202402474","article-title":"Glutathione-Depleted Photodynamic Nanoadjuvant for Triggering Nonferrous Ferroptosis to Amplify Radiotherapy of Breast Cancer","volume":"13","author":"Shi","year":"2024","journal-title":"Adv. Healthc. Mater."},{"issue":"3","key":"10.1016\/j.phrs.2026.108380_bib236","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1007\/s10637-016-0326-y","article-title":"RRx-001, A novel dinitroazetidine radiosensitizer","volume":"34","author":"Oronsky","year":"2016","journal-title":"Invest. New Drugs"},{"issue":"5","key":"10.1016\/j.phrs.2026.108380_bib237","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1016\/j.ijrobp.2017.03.024","article-title":"Clinical Advances of Hypoxia-Activated Prodrugs in Combination With Radiation Therapy","volume":"98","author":"Mistry","year":"2017","journal-title":"Int. J. Radiat. Oncol. Biol. Phys"},{"issue":"10","key":"10.1016\/j.phrs.2026.108380_bib238","doi-asserted-by":"crossref","first-page":"2649","DOI":"10.1021\/acs.jpcb.5b11432","article-title":"Mechanisms Responsible for High Energy Radiation Induced Damage to Single-Stranded DNA Modified by Radiosensitizing 5-Halogenated Deoxyuridines","volume":"120","author":"Wang","year":"2016","journal-title":"J. Phys. Chem. B"},{"issue":"2","key":"10.1016\/j.phrs.2026.108380_bib239","doi-asserted-by":"crossref","first-page":"250","DOI":"10.2174\/1871520616666161013145853","article-title":"Enzyme-driven chemo-and radiation-therapy with 12 pyrimidine nucleoside analogs not yet in the clinic","volume":"17","author":"Greer","year":"2017","journal-title":"Anticancer Agents Med. Chem."},{"issue":"20","key":"10.1016\/j.phrs.2026.108380_bib240","doi-asserted-by":"crossref","first-page":"6044","DOI":"10.1158\/1078-0432.CCR-17-0969","article-title":"Radiosensitization of adenoid cystic carcinoma with MDM2 inhibition","volume":"23","author":"Prabakaran","year":"2017","journal-title":"Clin. Cancer Res."},{"issue":"2","key":"10.1016\/j.phrs.2026.108380_bib241","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/j.radonc.2015.12.007","article-title":"Growth inhibition and chemo-radiosensitization of head and neck squamous cell carcinoma (HNSCC) by survivin-siRNA lentivirus","volume":"118","author":"Khan","year":"2016","journal-title":"Radiother. Oncol."},{"issue":"8_ement","key":"10.1016\/j.phrs.2026.108380_bib242","article-title":"Abstract 1027: EGFR targeting antibody SYM004 causes radiosensitization in tumor cells expressing wild-type K-Ras via modulation of MAPK signaling","volume":"73","author":"Saker","year":"2013","journal-title":"Cancer Res"},{"issue":"7","key":"10.1016\/j.phrs.2026.108380_bib243","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1158\/1535-7163.MCT-16-0740","article-title":"Nanoformulation of olaparib amplifies PARP inhibition and sensitizes PTEN\/TP53-deficient prostate cancer to radiation","volume":"16","author":"Van De Ven","year":"2017","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.phrs.2026.108380_bib244","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.msec.2016.05.093","article-title":"Improved efficacy of cisplatin in combination with a nano-formulation of pentacyclic triterpenediol","volume":"68","author":"Alam","year":"2016","journal-title":"Mater. Sci. Eng. C Mater. Biol. Appl."},{"issue":"2","key":"10.1016\/j.phrs.2026.108380_bib245","article-title":"Radiosensitization in prostate cancer: Mechanisms and targets","volume":"96","author":"Baldwin","year":"2016","journal-title":"Int. J. Radiat. Oncol. Biol. Phys"},{"issue":"33","key":"10.1016\/j.phrs.2026.108380_bib246","doi-asserted-by":"crossref","first-page":"7143","DOI":"10.1002\/adma.201602111","article-title":"Catalase-loaded taox nanoshells as bio-nanoreactors combining high-z element and enzyme delivery for enhancing radiotherapy","volume":"28","author":"Song","year":"2016","journal-title":"Adv. Mater."},{"key":"10.1016\/j.phrs.2026.108380_bib247","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.biomaterials.2017.01.001","article-title":"Development of a hypoxia-triggered and hypoxic radiosensitized liposome as a doxorubicin carrier to promote synergetic chemo-\/radio-therapy for glioma","volume":"121","author":"Liu","year":"2017","journal-title":"Biomaterials"},{"issue":"1","key":"10.1016\/j.phrs.2026.108380_bib248","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1080\/10717544.2017.1378939","article-title":"Enhancement of radiotherapy efficacy by pleiotropic liposomes encapsulated paclitaxel and perfluorotributylamine","volume":"24","author":"Jiang","year":"2017","journal-title":"Drug Deliv"},{"issue":"9","key":"10.1016\/j.phrs.2026.108380_bib249","doi-asserted-by":"crossref","first-page":"8992","DOI":"10.1021\/nn502146r","article-title":"Enhancing radiotherapy by lipid nanocapsule-mediated delivery of amphiphilic gold nanoparticles to intracellular membranes","volume":"8","author":"Yang","year":"2014","journal-title":"ACS Nano"},{"issue":"21","key":"10.1016\/j.phrs.2026.108380_bib250","doi-asserted-by":"crossref","first-page":"19217","DOI":"10.1021\/am505246w","article-title":"Rational design of cancer-targeted BSA protein nanoparticles as radiosensitizer to overcome cancer radioresistance","volume":"6","author":"Huang","year":"2014","journal-title":"ACS Appl. Mater. Interfaces"},{"issue":"9","key":"10.1016\/j.phrs.2026.108380_bib251","doi-asserted-by":"crossref","first-page":"8976","DOI":"10.1021\/acsnano.5b02913","article-title":"Improving Cancer Chemoradiotherapy Treatment by Dual Controlled Release of Wortmannin and Docetaxel in Polymeric Nanoparticles","volume":"9","author":"Au","year":"2015","journal-title":"ACS Nano"},{"issue":"14","key":"10.1016\/j.phrs.2026.108380_bib252","doi-asserted-by":"crossref","first-page":"2716","DOI":"10.1002\/adma.201504617","article-title":"Perfluorocarbon-Loaded Hollow Bi2Se3 Nanoparticles for Timely Supply of Oxygen under Near-Infrared Light to Enhance the Radiotherapy of Cancer","volume":"28","author":"Song","year":"2016","journal-title":"Adv. Mater."},{"key":"10.1016\/j.phrs.2026.108380_bib253","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.biomaterials.2017.06.036","article-title":"Anti-RhoJ antibody functionalized Au@I nanoparticles as CT-guided tumor vessel-targeting radiosensitizers in patient-derived tumor xenograft model","volume":"141","author":"Liu","year":"2017","journal-title":"Biomaterials"},{"issue":"7","key":"10.1016\/j.phrs.2026.108380_bib254","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1158\/0008-5472.CAN-14-1931","article-title":"Tumor radiosensitization by monomethyl auristatin E: Mechanism of action and targeted delivery","volume":"75","author":"Buckel","year":"2015","journal-title":"Cancer Res"},{"issue":"1","key":"10.1016\/j.phrs.2026.108380_bib255","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.tips.2017.11.003","article-title":"Cancer Radiosensitizers","volume":"39","author":"Wang","year":"2018","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.phrs.2026.108380_bib256","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.addr.2015.12.012","article-title":"Gold nanoparticles for applications in cancer radiotherapy: Mechanisms and recent advancements","volume":"109","author":"Her","year":"2017","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"7","key":"10.1016\/j.phrs.2026.108380_bib257","doi-asserted-by":"crossref","first-page":"7164","DOI":"10.1021\/acsnano.7b03037","article-title":"Polyoxometalate-Based Radiosensitization Platform for Treating Hypoxic Tumors by Attenuating Radioresistance and Enhancing Radiation Response","volume":"11","author":"Yong","year":"2017","journal-title":"ACS Nano"},{"issue":"23","key":"10.1016\/j.phrs.2026.108380_bib258","doi-asserted-by":"crossref","first-page":"24170","DOI":"10.1021\/acsnano.3c09424","article-title":"Camouflaged Nanoreactors Mediated Radiotherapy-Adjuvant Chemodynamic Synergistic Therapy","volume":"17","author":"Lu","year":"2023","journal-title":"ACS Nano"},{"issue":"20","key":"10.1016\/j.phrs.2026.108380_bib259","doi-asserted-by":"crossref","first-page":"20445","DOI":"10.1021\/acsnano.3c06967","article-title":"A Multifunctional Covalent Organic Framework Nanozyme for Promoting Ferroptotic Radiotherapy against Esophageal Cancer","volume":"17","author":"Zhou","year":"2023","journal-title":"ACS Nano"},{"key":"10.1016\/j.phrs.2026.108380_bib260","doi-asserted-by":"crossref","DOI":"10.1016\/j.cej.2024.153595","article-title":"Albumin tailoring molecular rotation and electrophilicity of a GSH-depleting radiosensitizer for potentiating ferroptosis-mediated radioimmunotherapy","volume":"495","author":"Gao","year":"2024","journal-title":"Chem. Eng. J."},{"issue":"10","key":"10.1016\/j.phrs.2026.108380_bib261","doi-asserted-by":"crossref","DOI":"10.1002\/adma.202105783","article-title":"Engineering Radiosensitizer-Based Metal-Phenolic Networks Potentiate STING Pathway Activation for Advanced Radiotherapy","volume":"34","author":"Yan","year":"2022","journal-title":"Adv. Mater."},{"issue":"5","key":"10.1016\/j.phrs.2026.108380_bib262","doi-asserted-by":"crossref","first-page":"4189","DOI":"10.1021\/acsnano.3c09293","article-title":"An Immunocompetent Hafnium Oxide-Based STING Nanoagonist for Cancer Radio-immunotherapy","volume":"18","author":"Cao","year":"2024","journal-title":"ACS Nano"},{"issue":"5","key":"10.1016\/j.phrs.2026.108380_bib263","doi-asserted-by":"crossref","first-page":"4495","DOI":"10.1021\/acsnano.2c10352","article-title":"Biomineralized MnO2 Nanoplatforms Mediated Delivery of Immune Checkpoint Inhibitors with STING Pathway Activation to Potentiate Cancer Radio-Immunotherapy","volume":"17","author":"Deng","year":"2023","journal-title":"ACS Nano"},{"issue":"51","key":"10.1016\/j.phrs.2026.108380_bib264","doi-asserted-by":"crossref","DOI":"10.1002\/adfm.202306930","article-title":"Personalized Carbon Monoxide-Loaded Biomimetic Single-Atom Nanozyme for Ferroptosis-Enhanced FLASH Radioimmunotherapy","volume":"33","author":"Lyu","year":"2023","journal-title":"Adv. Funct. Mater."},{"issue":"23","key":"10.1016\/j.phrs.2026.108380_bib265","doi-asserted-by":"crossref","DOI":"10.1002\/anie.202302525","article-title":"X-Ray-triggered Carbon Monoxide and Manganese Dioxide Generation based on Scintillating Nanoparticles for Cascade Cancer Radiosensitization","volume":"62","author":"Du","year":"2023","journal-title":"Angew. Chem. Int. Ed. Engl"},{"key":"10.1016\/j.phrs.2026.108380_bib266","first-page":"560","article-title":"Tellurium-driven maple leaf-shaped manganese nanotherapeutics reshape tumor microenvironment via chemical transition in situ to achieve highly efficient radioimmunotherapy of triple negative breast cancer","volume":"27","author":"Huang","year":"2023","journal-title":"Bioact. Mater."},{"issue":"4","key":"10.1016\/j.phrs.2026.108380_bib267","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1039\/C9CC07878A","article-title":"A cancer cell membrane-camouflaged nanoreactor for enhanced radiotherapy against cancer metastasis","volume":"56","author":"Pan","year":"2020","journal-title":"Chem. Commun. (Camb.)"},{"issue":"1","key":"10.1016\/j.phrs.2026.108380_bib268","article-title":"Biodegradable copper-iodide clusters modulate mitochondrial function and suppress tumor growth under ultralow-dose X-ray irradiation","volume":"15","author":"Ma","year":"2024","journal-title":"Nat. Commun."},{"issue":"23","key":"10.1016\/j.phrs.2026.108380_bib269","doi-asserted-by":"crossref","first-page":"23998","DOI":"10.1021\/acsnano.3c08875","article-title":"A Polymeric Hydrogel to Eliminate Programmed Death-Ligand 1 for Enhanced Tumor Radio-Immunotherapy","volume":"17","author":"Shen","year":"2023","journal-title":"ACS Nano"},{"issue":"12","key":"10.1016\/j.phrs.2026.108380_bib270","doi-asserted-by":"crossref","first-page":"1892","DOI":"10.1038\/s41565-024-01784-1","article-title":"A cuproptosis nanocapsule for cancer radiotherapy","volume":"19","author":"Liao","year":"2024","journal-title":"Nat. Nanotechnol."},{"issue":"12","key":"10.1016\/j.phrs.2026.108380_bib271","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1038\/s41565-022-01225-x","article-title":"Zinc cyclic di-AMP nanoparticles target and suppress tumours via endothelial STING activation and tumour-associated macrophage reinvigoration","volume":"17","author":"Yang","year":"2022","journal-title":"Nat. Nanotechnol."},{"issue":"29","key":"10.1016\/j.phrs.2026.108380_bib272","doi-asserted-by":"crossref","DOI":"10.1002\/adma.202401222","article-title":"A Dual-Channel Ca2+ Nanomodulator Induces Intracellular Ca2+ Disorders via Endogenous Ca2+ Redistribution for Tumor Radiosensitization","volume":"36","author":"Wang","year":"2024","journal-title":"Adv. Mater."},{"issue":"34","key":"10.1016\/j.phrs.2026.108380_bib273","doi-asserted-by":"crossref","DOI":"10.1002\/advs.202309569","article-title":"Abraxane-Like\u201d Radiosensitizer for In Situ Oral Cancer Therapy","volume":"11","author":"Gong","year":"2024","journal-title":"Adv. Sci."},{"issue":"2","key":"10.1016\/j.phrs.2026.108380_bib274","doi-asserted-by":"crossref","first-page":"2602","DOI":"10.1021\/acsami.2c17691","article-title":"Remodeling the Tumor Microenvironment with Core\u2212Shell Nanosensitizer Featuring Dual-Modal Imaging and Multimodal Therapy for Breast Cancer","volume":"15","author":"Hou","year":"2023","journal-title":"ACS Appl. Mater. Interfaces"},{"issue":"10","key":"10.1016\/j.phrs.2026.108380_bib275","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2024.110533","article-title":"Magnetic-vortex nanodonuts enhance ferroptosis effect of tumor ablation through an imaging-guided hyperthermia\/radiosensitization strategy","volume":"27","author":"Guo","year":"2024","journal-title":"iScience"},{"issue":"34","key":"10.1016\/j.phrs.2026.108380_bib276","doi-asserted-by":"crossref","first-page":"5170","DOI":"10.1039\/C9TB00991D","article-title":"Intelligent protein-coated bismuth sulfide and manganese oxide nanocomposites obtained by biomineralization for multimodal imaging-guided enhanced tumor therapy","volume":"7","author":"Zhang","year":"2019","journal-title":"J. Mater. Chem. B"},{"issue":"51","key":"10.1016\/j.phrs.2026.108380_bib277","doi-asserted-by":"crossref","DOI":"10.1002\/adfm.202409966","article-title":"Reshaping Immunosuppressive Tumor Microenvironment Using Ferroptosis\/Cuproptosis Nanosensitizers for Enhanced Radioimmunotherapy","volume":"34","author":"He","year":"2024","journal-title":"Adv. Funct. Mater."},{"issue":"7","key":"10.1016\/j.phrs.2026.108380_bib278","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1038\/nrc3958","article-title":"The tumour microenvironment after radiotherapy: mechanisms of resistance and recurrence","volume":"15","author":"Barker","year":"2015","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.phrs.2026.108380_bib279","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1146\/annurev-med-081313-121208","article-title":"The DNA damage response: implications for tumor responses to radiation and chemotherapy","volume":"66","author":"Goldstein","year":"2015","journal-title":"Annu. Rev. Med."},{"issue":"14","key":"10.1016\/j.phrs.2026.108380_bib280","doi-asserted-by":"crossref","first-page":"4542","DOI":"10.1158\/1078-0432.CCR-18-3004","article-title":"Downregulation of Human DAB2IP Gene Expression in Renal Cell Carcinoma Results in Resistance to Ionizing Radiation","volume":"25","author":"Yun","year":"2019","journal-title":"Clin. Cancer Res."},{"issue":"13","key":"10.1016\/j.phrs.2026.108380_bib281","doi-asserted-by":"crossref","first-page":"6770","DOI":"10.1093\/nar\/gkad505","article-title":"ATM phosphorylates the FATC domain of DNA-PKcs at threonine 4102 to promote non-homologous end joining","volume":"51","author":"Lu","year":"2023","journal-title":"Nucleic Acids Res"},{"issue":"7","key":"10.1016\/j.phrs.2026.108380_bib282","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1158\/1078-0432.CCR-19-1515","article-title":"Smoothened Promotes Glioblastoma Radiation Resistance Via Activating USP3-Mediated Claspin Deubiquitination","volume":"26","author":"Tu","year":"2020","journal-title":"Clin. Cancer Res."},{"issue":"14","key":"10.1016\/j.phrs.2026.108380_bib283","doi-asserted-by":"crossref","first-page":"2752","DOI":"10.1093\/nar\/28.14.2752","article-title":"K. Meek, Both V(D)J recombination and radioresistance require DNA-PK kinase activity, though minimal levels suffice for V(D)J recombination","volume":"28","author":"Kienker","year":"2000","journal-title":"Nucleic Acids Res"},{"issue":"4","key":"10.1016\/j.phrs.2026.108380_bib284","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1038\/sj.cr.7290230","article-title":"The modulation of radiation-induced cell death by genistein in K562 cells: activation of thymidine kinase 1","volume":"14","author":"Jeong","year":"2004","journal-title":"Cell Res"},{"issue":"13","key":"10.1016\/j.phrs.2026.108380_bib285","doi-asserted-by":"crossref","first-page":"4200","DOI":"10.1158\/1078-0432.CCR-10-2537","article-title":"WEE1 kinase targeting combined with DNA-damaging cancer therapy catalyzes mitotic catastrophe","volume":"17","author":"De Witt Hamer","year":"2011","journal-title":"Clin. Cancer Res."},{"issue":"6","key":"10.1016\/j.phrs.2026.108380_bib286","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1038\/sj.cr.7290253","article-title":"Downregulation of wild-type p53 protein by HER-2\/neu mediated PI3K pathway activation in human breast cancer cells: its effect on cell proliferation and implication for therapy","volume":"14","author":"Zheng","year":"2004","journal-title":"Cell Res"},{"issue":"10","key":"10.1016\/j.phrs.2026.108380_bib287","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1038\/nm1096-1140","article-title":"Selective radiosensitization of p53-deficient cells by caffeine-mediated activation of p34cdc2 kinase","volume":"2","author":"Yao","year":"1996","journal-title":"Nat. Med."},{"key":"10.1016\/j.phrs.2026.108380_bib288","article-title":"HDAC2-Mediated METTL3 Delactylation Promotes DNA Damage Repair and Chemotherapy Resistance in Triple-Negative Breast Cancer","author":"He","year":"2025","journal-title":"Adv. Sci."},{"issue":"10","key":"10.1016\/j.phrs.2026.108380_bib289","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1158\/2159-8290.CD-14-0157","article-title":"ATM regulates 3-methylpurine-DNA glycosylase and promotes therapeutic resistance to alkylating agents","volume":"4","author":"Agnihotri","year":"2014","journal-title":"Cancer Discov"},{"issue":"1","key":"10.1016\/j.phrs.2026.108380_bib290","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1038\/s41467-018-07729-2","article-title":"ATM orchestrates the DNA-damage response to counter toxic non-homologous end-joining at broken replication forks","volume":"10","author":"Balmus","year":"2019","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.phrs.2026.108380_bib291","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.ctrv.2006.09.006","article-title":"Molecular mechanisms of resistance and toxicity associated with platinating agents","volume":"33","author":"Rabik","year":"2007","journal-title":"Cancer Treat. Rev."},{"issue":"1","key":"10.1016\/j.phrs.2026.108380_bib292","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.taap.2008.01.001","article-title":"Apoptotic death induced by the cyclophosphamide analogue mafosfamide in human lymphoblastoid cells: contribution of DNA replication, transcription inhibition and Chk\/p53 signaling","volume":"229","author":"Goldstein","year":"2008","journal-title":"Toxicol. Appl. Pharmacol."},{"issue":"3","key":"10.1016\/j.phrs.2026.108380_bib293","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1021\/bi00324a025","article-title":"Adducts of the antitumor drug cis-diamminedichloroplatinum(II) with DNA: formation, identification, and quantitation","volume":"24","author":"Fichtinger-Schepman","year":"1985","journal-title":"Biochemistry"},{"issue":"10","key":"10.1016\/j.phrs.2026.108380_bib294","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1056\/NEJMoa060570","article-title":"DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy","volume":"355","author":"Olaussen","year":"2006","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/j.phrs.2026.108380_bib295","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1200\/JCO.2016.68.1841","article-title":"Randomized Prospective Biomarker Trial of ERCC1 for Comparing Platinum and Nonplatinum Therapy in Advanced Non-Small-Cell Lung Cancer: ERCC1 Trial (ET)","volume":"35","author":"Lee","year":"2017","journal-title":"J. Clin. Oncol."},{"issue":"28","key":"10.1016\/j.phrs.2026.108380_bib296","doi-asserted-by":"crossref","first-page":"14174","DOI":"10.1073\/pnas.1821194116","article-title":"The VEGF receptor neuropilin 2 promotes homologous recombination by stimulating YAP\/TAZ-mediated Rad51 expression","volume":"116","author":"Elaimy","year":"2019","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"19","key":"10.1016\/j.phrs.2026.108380_bib297","doi-asserted-by":"crossref","first-page":"10764","DOI":"10.1073\/pnas.96.19.10764","article-title":"Role of DNA mismatch repair and p53 in signaling induction of apoptosis by alkylating agents","volume":"96","author":"Hickman","year":"1999","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"2","key":"10.1016\/j.phrs.2026.108380_bib298","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1038\/sj.onc.1207080","article-title":"Apoptosis triggered by DNA damage O6-methylguanine in human lymphocytes requires DNA replication and is mediated by p53 and Fas\/CD95\/Apo-1","volume":"23","author":"Roos","year":"2004","journal-title":"Oncogene"},{"issue":"2-3","key":"10.1016\/j.phrs.2026.108380_bib299","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/0921-8777(90)90010-3","article-title":"Mismatch binding proteins and tolerance to alkylating agents in human cells","volume":"236","author":"Karran","year":"1990","journal-title":"Mutat. Res."},{"issue":"15","key":"10.1016\/j.phrs.2026.108380_bib300","doi-asserted-by":"crossref","first-page":"9781","DOI":"10.1093\/nar\/gku659","article-title":"Repair of O6-methylguanine adducts in human telomeric G-quadruplex DNA by O6-alkylguanine-DNA alkyltransferase","volume":"42","author":"Hellman","year":"2014","journal-title":"Nucleic Acids Res"},{"issue":"19","key":"10.1016\/j.phrs.2026.108380_bib301","first-page":"6119","article-title":"Mammalian O6-alkylguanine-DNA alkyltransferase: regulation and importance in response to alkylating carcinogenic and therapeutic agents","volume":"50","author":"Pegg","year":"1990","journal-title":"Cancer Res"},{"issue":"9","key":"10.1016\/j.phrs.2026.108380_bib302","doi-asserted-by":"crossref","first-page":"2388","DOI":"10.1200\/JCO.2002.06.110","article-title":"Clinical relevance of MGMT in the treatment of cancer","volume":"20","author":"Gerson","year":"2002","journal-title":"J. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.phrs.2026.108380_bib303","first-page":"577","article-title":"Quantitative immunohistochemical estimates of O6-alkylguanine-DNA alkyltransferase expression in normal and malignant human colon","volume":"2","author":"Zaidi","year":"1996","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.phrs.2026.108380_bib304","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2023.216078","article-title":"RBBP4 regulates the expression of the Mre11-Rad50-NBS1 (MRN) complex and promotes DNA double-strand break repair to mediate glioblastoma chemoradiotherapy resistance","volume":"557","author":"Li","year":"2023","journal-title":"Cancer Lett"},{"issue":"7150","key":"10.1016\/j.phrs.2026.108380_bib305","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1038\/nature05938","article-title":"Antitumour drugs impede DNA uncoiling by topoisomerase I","volume":"448","author":"Koster","year":"2007","journal-title":"Nature"},{"issue":"4","key":"10.1016\/j.phrs.2026.108380_bib306","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/S1470-2045(02)00715-5","article-title":"Culprit and victim -- DNA topoisomerase II","volume":"3","author":"Kellner","year":"2002","journal-title":"Lancet Oncol"},{"issue":"10","key":"10.1016\/j.phrs.2026.108380_bib307","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1016\/S1568-7864(03)00116-2","article-title":"Association of XRCC1 and tyrosyl DNA phosphodiesterase (Tdp1) for the repair of topoisomerase I-mediated DNA lesions","volume":"2","author":"Plo","year":"2003","journal-title":"DNA Repair"},{"issue":"6","key":"10.1016\/j.phrs.2026.108380_bib308","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1016\/S1097-2765(01)00419-1","article-title":"Recombination at double-strand breaks and DNA ends: conserved mechanisms from phage to humans","volume":"8","author":"Cromie","year":"2001","journal-title":"Mol. Cell"},{"issue":"3","key":"10.1016\/j.phrs.2026.108380_bib309","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1007\/s10637-010-9626-9","article-title":"Irinotecan and DNA-PKcs inhibitors synergize in killing of colon cancer cells","volume":"30","author":"Davidson","year":"2012","journal-title":"Invest. New Drugs"},{"issue":"12","key":"10.1016\/j.phrs.2026.108380_bib310","doi-asserted-by":"crossref","first-page":"4659","DOI":"10.1182\/blood-2003-07-2527","article-title":"A novel DNA-dependent protein kinase inhibitor, NU7026, potentiates the cytotoxicity of topoisomerase II poisons used in the treatment of leukemia","volume":"103","author":"Willmore","year":"2004","journal-title":"Blood"},{"issue":"24","key":"10.1016\/j.phrs.2026.108380_bib311","doi-asserted-by":"crossref","first-page":"9152","DOI":"10.1158\/0008-5472.CAN-04-2727","article-title":"Identification and characterization of a novel and specific inhibitor of the ataxia-telangiectasia mutated kinase ATM","volume":"64","author":"Hickson","year":"2004","journal-title":"Cancer Res"},{"issue":"5","key":"10.1016\/j.phrs.2026.108380_bib312","first-page":"1169","article-title":"The effect of loss of Brca1 on the sensitivity to anticancer agents in p53-deficient cells","volume":"22","author":"Fedier","year":"2003","journal-title":"Int. J. Oncol."},{"issue":"2","key":"10.1016\/j.phrs.2026.108380_bib313","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.molcel.2010.09.019","article-title":"The DNA damage response: making it safe to play with knives","volume":"40","author":"Ciccia","year":"2010","journal-title":"Mol. Cell"},{"issue":"7015","key":"10.1016\/j.phrs.2026.108380_bib314","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1038\/nature03097","article-title":"Cell-cycle checkpoints and cancer","volume":"432","author":"Kastan","year":"2004","journal-title":"Nature"},{"issue":"5","key":"10.1016\/j.phrs.2026.108380_bib315","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1016\/j.molcel.2019.12.023","article-title":"Cancer Cells Employ Nuclear Caspase-8 to Overcome the p53-Dependent G2\/M Checkpoint through Cleavage of USP28","volume":"77","author":"M\u00fcller","year":"2020","journal-title":"Mol. Cell"},{"issue":"12","key":"10.1016\/j.phrs.2026.108380_bib316","article-title":"Reactive oxygen species: Janus-faced molecules in the era of modern cancer therapy","volume":"12","author":"O'Reilly","year":"2024","journal-title":"J. Immunother. Cancer"},{"issue":"8","key":"10.1016\/j.phrs.2026.108380_bib317","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1038\/s41573-024-00979-4","article-title":"Targeting ROS in cancer: rationale and strategies","volume":"23","author":"Glorieux","year":"2024","journal-title":"Nat. Rev. Drug Discov."},{"issue":"1","key":"10.1016\/j.phrs.2026.108380_bib318","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.molcel.2023.11.001","article-title":"Regulation of antioxidants in cancer","volume":"84","author":"Hecht","year":"2024","journal-title":"Mol. Cell"},{"issue":"3","key":"10.1016\/j.phrs.2026.108380_bib319","doi-asserted-by":"crossref","first-page":"133","DOI":"10.14348\/molcells.2023.0028","article-title":"Molecular Basis of the KEAP1-NRF2 Signaling Pathway","volume":"46","author":"Suzuki","year":"2023","journal-title":"Mol. Cells"},{"issue":"8","key":"10.1016\/j.phrs.2026.108380_bib320","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1089\/ars.2010.3534","article-title":"Basic principles and emerging concepts in the redox control of transcription factors","volume":"15","author":"Brigelius-Floh\u00e9","year":"2011","journal-title":"Antioxid. Redox Signal."},{"issue":"7354","key":"10.1016\/j.phrs.2026.108380_bib321","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1038\/nature10189","article-title":"Oncogene-induced Nrf2 transcription promotes ROS detoxification and tumorigenesis","volume":"475","author":"DeNicola","year":"2011","journal-title":"Nature"},{"issue":"36","key":"10.1016\/j.phrs.2026.108380_bib322","doi-asserted-by":"crossref","first-page":"13568","DOI":"10.1073\/pnas.0806268105","article-title":"Cancer related mutations in NRF2 impair its recognition by Keap1-Cul3 E3 ligase and promote malignancy","volume":"105","author":"Shibata","year":"2008","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"14","key":"10.1016\/j.phrs.2026.108380_bib323","doi-asserted-by":"crossref","first-page":"3743","DOI":"10.1158\/1078-0432.CCR-09-3352","article-title":"Nrf2 and Keap1 abnormalities in non-small cell lung carcinoma and association with clinicopathologic features","volume":"16","author":"Solis","year":"2010","journal-title":"Clin. Cancer Res."},{"issue":"1","key":"10.1016\/j.phrs.2026.108380_bib324","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.ccr.2012.05.016","article-title":"Nrf2 redirects glucose and glutamine into anabolic pathways in metabolic reprogramming","volume":"22","author":"Mitsuishi","year":"2012","journal-title":"Cancer Cell"},{"issue":"1","key":"10.1016\/j.phrs.2026.108380_bib325","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.cmet.2020.10.002","article-title":"Upregulation of Antioxidant Capacity and Nucleotide Precursor Availability Suffices for Oncogenic Transformation","volume":"33","author":"Zhang","year":"2021","journal-title":"Cell Metab"},{"issue":"4","key":"10.1016\/j.phrs.2026.108380_bib326","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1038\/s42255-023-00781-3","article-title":"The GAPDH redox switch safeguards reductive capacity and enables survival of stressed tumour cells","volume":"5","author":"Talwar","year":"2023","journal-title":"Nat. Metab."},{"issue":"1","key":"10.1016\/j.phrs.2026.108380_bib327","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.cell.2006.05.036","article-title":"TIGAR, a p53-inducible regulator of glycolysis and apoptosis","volume":"126","author":"Bensaad","year":"2006","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.phrs.2026.108380_bib328","doi-asserted-by":"crossref","first-page":"4860","DOI":"10.1038\/s41467-021-24859-2","article-title":"GOT1 inhibition promotes pancreatic cancer cell death by ferroptosis","volume":"12","author":"Kremer","year":"2021","journal-title":"Nat. Commun."},{"issue":"7639","key":"10.1016\/j.phrs.2026.108380_bib329","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1038\/nature21052","article-title":"Genomic deletion of malic enzyme 2 confers collateral lethality in pancreatic cancer","volume":"542","author":"Dey","year":"2017","journal-title":"Nature"},{"issue":"2","key":"10.1016\/j.phrs.2026.108380_bib330","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.ccell.2019.12.012","article-title":"Dynamic ROS Control by TIGAR Regulates the Initiation and Progression of Pancreatic Cancer","volume":"37","author":"Cheung","year":"2020","journal-title":"Cancer Cell"},{"issue":"6","key":"10.1016\/j.phrs.2026.108380_bib331","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1016\/j.ccell.2018.05.001","article-title":"Cancer Cells Co-opt the Neuronal Redox-Sensing Channel TRPA1 to Promote Oxidative-Stress Tolerance","volume":"33","author":"Takahashi","year":"2018","journal-title":"Cancer Cell"},{"issue":"14","key":"10.1016\/j.phrs.2026.108380_bib332","doi-asserted-by":"crossref","DOI":"10.1002\/advs.202204438","article-title":"DDRGK1 Enhances Osteosarcoma Chemoresistance via Inhibiting KEAP1-Mediated NRF2 Ubiquitination","volume":"10","author":"Wang","year":"2023","journal-title":"Adv. Sci."},{"issue":"6","key":"10.1016\/j.phrs.2026.108380_bib333","doi-asserted-by":"crossref","first-page":"1820","DOI":"10.1002\/hep.25549","article-title":"Amplified in breast cancer 1 enhances human cholangiocarcinoma growth and chemoresistance by simultaneous activation of Akt and Nrf2 pathways","volume":"55","author":"Chen","year":"2012","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.phrs.2026.108380_bib334","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.bbrc.2007.09.115","article-title":"X-linked inhibitor of apoptosis protein increases mitochondrial antioxidants through NF-kappaB activation,","volume":"364","author":"Kairisalo","year":"2007","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"1-2","key":"10.1016\/j.phrs.2026.108380_bib335","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.febslet.2004.10.082","article-title":"NF-kappaB activation prevents apoptotic oxidative stress via an increase of both thioredoxin and MnSOD levels in TNFalpha-treated Ewing sarcoma cells,","volume":"578","author":"Djavaheri-Mergny","year":"2004","journal-title":"FEBS Lett"},{"issue":"1","key":"10.1016\/j.phrs.2026.108380_bib336","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1038\/cr.2010.178","article-title":"Crosstalk of reactive oxygen species and NF-\u03baB signaling","volume":"21","author":"Morgan","year":"2011","journal-title":"Cell Res"},{"issue":"9","key":"10.1016\/j.phrs.2026.108380_bib337","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1158\/2326-6066.CIR-14-0112","article-title":"NF-\u03baB, an active player in human cancers","volume":"2","author":"Xia","year":"2014","journal-title":"Cancer Immunol. Res."},{"issue":"2","key":"10.1016\/j.phrs.2026.108380_bib338","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1038\/sj.cdd.4400784","article-title":"Protective role of nuclear factor kappa B against nitric oxide-induced apoptosis in J774 macrophages","volume":"8","author":"D'Acquisto","year":"2001","journal-title":"Cell Death Differ"},{"issue":"4","key":"10.1016\/j.phrs.2026.108380_bib339","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1038\/nrc780","article-title":"NF-kappaB in cancer: from innocent bystander to major culprit","volume":"2","author":"Karin","year":"2002","journal-title":"Nat. Rev. Cancer"},{"issue":"3","key":"10.1016\/j.phrs.2026.108380_bib340","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.ccr.2004.09.003","article-title":"Nuclear factor-kappaB: the enemy within","volume":"6","author":"Aggarwal","year":"2004","journal-title":"Cancer Cell"},{"issue":"19","key":"10.1016\/j.phrs.2026.108380_bib341","first-page":"5334","article-title":"Blockade of nuclear factor-kappaB signaling inhibits angiogenesis and tumorigenicity of human ovarian cancer cells by suppressing expression of vascular endothelial growth factor and interleukin 8","volume":"60","author":"Huang","year":"2000","journal-title":"Cancer Res"},{"issue":"5","key":"10.1016\/j.phrs.2026.108380_bib342","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.1002\/med.21674","article-title":"Targeting telomerase for its advent in cancer therapeutics","volume":"40","author":"Bajaj","year":"2020","journal-title":"Med. Res. Rev."},{"issue":"11","key":"10.1016\/j.phrs.2026.108380_bib343","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1038\/s41388-024-02938-0","article-title":"Tumor-derived interleukin 35 mediates the dissemination of gemcitabine resistance in pancreatic adenocarcinoma","volume":"43","author":"Sun","year":"2024","journal-title":"Oncogene"},{"issue":"4","key":"10.1016\/j.phrs.2026.108380_bib344","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1172\/JCI36551","article-title":"Triggering of TLR7 and TLR8 expressed by human lung cancer cells induces cell survival and chemoresistance","volume":"120","author":"Cherfils-Vicini","year":"2010","journal-title":"J. Clin. Invest."},{"issue":"6","key":"10.1016\/j.phrs.2026.108380_bib345","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1016\/j.molcel.2012.01.008","article-title":"The mitochondrial ATPase inhibitory factor 1 triggers a ROS-mediated retrograde prosurvival and proliferative response","volume":"45","author":"Formentini","year":"2012","journal-title":"Mol. Cell"},{"issue":"2 Pt B","key":"10.1016\/j.phrs.2026.108380_bib346","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1016\/j.canlet.2014.11.016","article-title":"Targeting pyruvate kinase M2 contributes to radiosensitivity of non-small cell lung cancer cells in vitro and in vivo","volume":"356","author":"Meng","year":"2015","journal-title":"Cancer Lett"},{"issue":"1","key":"10.1016\/j.phrs.2026.108380_bib347","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.radonc.2009.11.007","article-title":"Glycolytic metabolism and tumour response to fractionated irradiation","volume":"94","author":"Sattler","year":"2010","journal-title":"Radiother. Oncol."},{"issue":"3","key":"10.1016\/j.phrs.2026.108380_bib348","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.drup.2011.03.001","article-title":"Hypoxia-mediated drug resistance: novel insights on the functional interaction of HIFs and cell death pathways","volume":"14","author":"Rohwer","year":"2011","journal-title":"Drug Resist. Updat."},{"issue":"9","key":"10.1016\/j.phrs.2026.108380_bib349","doi-asserted-by":"crossref","first-page":"3664","DOI":"10.1172\/JCI67230","article-title":"HIF-1 mediates metabolic responses to intratumoral hypoxia and oncogenic mutations","volume":"123","author":"Semenza","year":"2013","journal-title":"J. Clin. Invest."},{"issue":"4","key":"10.1016\/j.phrs.2026.108380_bib350","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1007\/s11033-015-3858-x","article-title":"Cancer metabolism and the Warburg effect: the role of HIF-1 and PI3K","volume":"42","author":"Courtnay","year":"2015","journal-title":"Mol. Biol. Rep."},{"issue":"1","key":"10.1016\/j.phrs.2026.108380_bib351","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1186\/s13046-020-01629-4","article-title":"Emerging roles and the regulation of aerobic glycolysis in hepatocellular carcinoma","volume":"39","author":"Feng","year":"2020","journal-title":"J. Exp. Clin. Cancer Res."},{"issue":"5","key":"10.1016\/j.phrs.2026.108380_bib352","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1016\/j.cell.2008.08.021","article-title":"Cancer cell metabolism: Warburg and beyond","volume":"134","author":"Hsu","year":"2008","journal-title":"Cell"},{"issue":"4","key":"10.1016\/j.phrs.2026.108380_bib353","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1053\/j.gastro.2021.12.249","article-title":"BZW1 Facilitates Glycolysis and Promotes Tumor Growth in Pancreatic Ductal Adenocarcinoma Through Potentiating eIF2\u03b1 Phosphorylation","volume":"162","author":"Li","year":"2022","journal-title":"Gastroenterology"},{"issue":"3","key":"10.1016\/j.phrs.2026.108380_bib354","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1016\/j.ccell.2018.01.010","article-title":"Transcriptional Regulation of the Warburg Effect in Cancer by SIX1","volume":"33","author":"Li","year":"2018","journal-title":"Cancer Cell"},{"issue":"14","key":"10.1016\/j.phrs.2026.108380_bib355","first-page":"3847","article-title":"The glycolytic phenotype in carcinogenesis and tumor invasion: insights through mathematical models","volume":"63","author":"Gatenby","year":"2003","journal-title":"Cancer Res"},{"issue":"1","key":"10.1016\/j.phrs.2026.108380_bib356","first-page":"216","article-title":"The metabolic cooperation between cells in solid cancer tumors","volume":"1846","author":"Icard","year":"2014","journal-title":"Biochim. Biophys. Acta"},{"issue":"8021","key":"10.1016\/j.phrs.2026.108380_bib357","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1038\/s41586-024-07620-9","article-title":"NBS1 lactylation is required for efficient DNA repair and chemotherapy resistance","volume":"631","author":"Chen","year":"2024","journal-title":"Nature"},{"issue":"7","key":"10.1016\/j.phrs.2026.108380_bib358","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1080\/15548627.2019.1580105","article-title":"The HGF-MET axis coordinates liver cancer metabolism and autophagy for chemotherapeutic resistance","volume":"15","author":"Huang","year":"2019","journal-title":"Autophagy"},{"key":"10.1016\/j.phrs.2026.108380_bib359","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/S0076-6879(05)00024-8","article-title":"The genetics of ATP-binding cassette transporters","volume":"400","author":"Dean","year":"2005","journal-title":"Methods Enzymol"},{"issue":"9","key":"10.1016\/j.phrs.2026.108380_bib360","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1080\/1061186X.2022.2091578","article-title":"ABC transporters in breast cancer: their roles in multidrug resistance and beyond","volume":"30","author":"Modi","year":"2022","journal-title":"J. Drug Target."},{"key":"10.1016\/j.phrs.2026.108380_bib361","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.ejmech.2017.07.062","article-title":"Overcoming ABC transporter-mediated multidrug resistance: The dual role of tyrosine kinase inhibitors as multitargeting agents","volume":"142","author":"Beretta","year":"2017","journal-title":"Eur. J. Med. Chem."},{"issue":"2","key":"10.1016\/j.phrs.2026.108380_bib362","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1038\/nrc2789","article-title":"ABC transporters in cancer: more than just drug efflux pumps","volume":"10","author":"Fletcher","year":"2010","journal-title":"Nat. Rev. Cancer"},{"issue":"18","key":"10.1016\/j.phrs.2026.108380_bib363","doi-asserted-by":"crossref","first-page":"3226","DOI":"10.1111\/j.1742-4658.2011.08235.x","article-title":"Multidrug resistance proteins (MRPs\/ABCCs) in cancer chemotherapy and genetic diseases","volume":"278","author":"Chen","year":"2011","journal-title":"FEBS J"},{"issue":"2","key":"10.1016\/j.phrs.2026.108380_bib364","doi-asserted-by":"crossref","first-page":"51","DOI":"10.5732\/cjc.011.10466","article-title":"Role of ABC transporters in cancer chemotherapy","volume":"31","author":"Sun","year":"2012","journal-title":"Chin. J. Cancer"},{"key":"10.1016\/j.phrs.2026.108380_bib365","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.drup.2016.03.001","article-title":"ABC transporters as mediators of drug resistance and contributors to cancer cell biology","volume":"26","author":"Fletcher","year":"2016","journal-title":"Drug Resist. Updat."},{"issue":"5","key":"10.1016\/j.phrs.2026.108380_bib366","doi-asserted-by":"crossref","DOI":"10.3892\/ijmm.2025.5521","article-title":"ABCG8\u2011mediated sterol efflux increases cancer cell progression via the LRP6\/Wnt\/\u03b2\u2011catenin signaling pathway in radiotherapy\u2011resistant MDA\u2011MB\u2011231 triple\u2011negative breast cancer cells","volume":"55","author":"Ko","year":"2025","journal-title":"Int. J. Mol. Med."},{"issue":"5","key":"10.1016\/j.phrs.2026.108380_bib367","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1136\/thx.51.5.526","article-title":"Detection of the multidrug resistance marker P-glycoprotein by immunohistochemistry in malignant lung tumours","volume":"51","author":"Beer","year":"1996","journal-title":"Thorax"},{"issue":"7","key":"10.1016\/j.phrs.2026.108380_bib368","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1038\/s41568-018-0005-8","article-title":"Revisiting the role of ABC transporters in multidrug-resistant cancer","volume":"18","author":"Robey","year":"2018","journal-title":"Nat. Rev. Cancer"},{"issue":"2","key":"10.1016\/j.phrs.2026.108380_bib369","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/0360-3016(82)90517-X","article-title":"Changes in early and late radiation responses with altered dose fractionation: implications for dose-survival relationships","volume":"8","author":"Thames","year":"1982","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"issue":"2","key":"10.1016\/j.phrs.2026.108380_bib370","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/S0360-3016(01)01686-8","article-title":"Repopulation of FaDu human squamous cell carcinoma during fractionated radiotherapy correlates with reoxygenation","volume":"51","author":"Petersen","year":"2001","journal-title":"Int. J. Radiat. Oncol. Biol. Phys"},{"issue":"1","key":"10.1016\/j.phrs.2026.108380_bib371","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/0360-3016(85)90366-9","article-title":"A review of alpha\/beta ratios for experimental tumors: implications for clinical studies of altered fractionation","volume":"11","author":"Williams","year":"1985","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"issue":"3","key":"10.1016\/j.phrs.2026.108380_bib372","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.radonc.2004.10.009","article-title":"Recovery from sublethal damage during fractionated irradiation of human FaDu SCC","volume":"74","author":"Petersen","year":"2005","journal-title":"Radiother. Oncol."},{"issue":"1","key":"10.1016\/j.phrs.2026.108380_bib373","doi-asserted-by":"crossref","first-page":"57","DOI":"10.3109\/02841869109091814","article-title":"F. W\u00fcrschmidt, Influence of treatment time on the response of rat rhabdomyosarcoma R1H to fractionated irradiation","volume":"30","author":"Beck-Bornholdt","year":"1991","journal-title":"Acta Oncol"},{"issue":"2","key":"10.1016\/j.phrs.2026.108380_bib374","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/0360-3016(89)90353-2","article-title":"The proportion of stem cells in murine tumors","volume":"16","author":"Hill","year":"1989","journal-title":"Int. J. Radiat. Oncol. Biol. Phys"},{"issue":"13","key":"10.1016\/j.phrs.2026.108380_bib375","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1038\/s41388-024-03264-1","article-title":"PRMT5-regulated splicing of DNA repair genes drives chemoresistance in breast cancer stem cells","volume":"44","author":"Gillespie","year":"2025","journal-title":"Oncogene"},{"issue":"11","key":"10.1016\/j.phrs.2026.108380_bib376","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1038\/nbt1350","article-title":"Chemotherapy-resistant human AML stem cells home to and engraft within the bone-marrow endosteal region","volume":"25","author":"Ishikawa","year":"2007","journal-title":"Nat. Biotechnol."},{"issue":"22","key":"10.1016\/j.phrs.2026.108380_bib377","doi-asserted-by":"crossref","first-page":"7856","DOI":"10.1039\/D0CS00379D","article-title":"Cancer stem cell-targeted bio-imaging and chemotherapeutic perspective","volume":"49","author":"Han","year":"2020","journal-title":"Chem. Soc. Rev."},{"issue":"9","key":"10.1016\/j.phrs.2026.108380_bib378","doi-asserted-by":"crossref","first-page":"2193","DOI":"10.1016\/j.celrep.2016.02.016","article-title":"P-Rex1 Promotes Resistance to VEGF\/VEGFR-Targeted Therapy in Prostate Cancer","volume":"14","author":"Goel","year":"2016","journal-title":"Cell Rep"},{"issue":"6501","key":"10.1016\/j.phrs.2026.108380_bib379","doi-asserted-by":"crossref","DOI":"10.1126\/science.aay1813","article-title":"Tumor-initiating cells establish an IL-33-TGF-\u03b2 niche signaling loop to promote cancer progression","volume":"369","author":"Taniguchi","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.phrs.2026.108380_bib380","article-title":"Adenylate kinase hCINAP determines self-renewal of colorectal cancer stem cells by facilitating LDHA phosphorylation","volume":"8","author":"Ji","year":"2017","journal-title":"Nat. Commun."},{"key":"10.1016\/j.phrs.2026.108380_bib381","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.humpath.2017.03.012","article-title":"Expression of MRP1 and ABCG2 is associated with adverse clinical outcomes of papillary thyroid carcinoma with a solid component","volume":"67","author":"Ohashi","year":"2017","journal-title":"Hum. Pathol."},{"issue":"35","key":"10.1016\/j.phrs.2026.108380_bib382","doi-asserted-by":"crossref","first-page":"59165","DOI":"10.18632\/oncotarget.19467","article-title":"Prostate Tumor Overexpressed-1 (PTOV1) promotes docetaxel-resistance and survival of castration resistant prostate cancer cells","volume":"8","author":"C\u00e1novas","year":"2017","journal-title":"Oncotarget"},{"issue":"28","key":"10.1016\/j.phrs.2026.108380_bib383","doi-asserted-by":"crossref","first-page":"11166","DOI":"10.1074\/jbc.RA118.003187","article-title":"ATP-binding cassette member B5 (ABCB5) promotes tumor cell invasiveness in human colorectal cancer","volume":"293","author":"Guo","year":"2018","journal-title":"J. Biol. Chem."},{"issue":"15","key":"10.1016\/j.phrs.2026.108380_bib384","doi-asserted-by":"crossref","first-page":"4196","DOI":"10.1158\/0008-5472.CAN-14-0582","article-title":"ABCB5 maintains melanoma-initiating cells through a proinflammatory cytokine signaling circuit","volume":"74","author":"Wilson","year":"2014","journal-title":"Cancer Res"},{"issue":"2","key":"10.1016\/j.phrs.2026.108380_bib385","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1002\/hep.23692","article-title":"Octamer 4 (Oct4) mediates chemotherapeutic drug resistance in liver cancer cells through a potential Oct4-AKT-ATP-binding cassette G2 pathway","volume":"52","author":"Wang","year":"2010","journal-title":"Hepatology"},{"issue":"12","key":"10.1016\/j.phrs.2026.108380_bib386","doi-asserted-by":"crossref","first-page":"3255","DOI":"10.1158\/0008-5472.CAN-20-3892","article-title":"Induction of ADAM10 by Radiation Therapy Drives Fibrosis, Resistance, and Epithelial-to-Mesenchyal Transition in Pancreatic Cancer","volume":"81","author":"Mueller","year":"2021","journal-title":"Cancer Res"},{"issue":"9","key":"10.1016\/j.phrs.2026.108380_bib387","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1164\/rccm.201109-1706OC","article-title":"Hypoxia-inducible factor 1 mediates nasal polypogenesis by inducing epithelial-to-mesenchymal transition","volume":"185","author":"Shin","year":"2012","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"4-5","key":"10.1016\/j.phrs.2026.108380_bib388","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.drup.2008.07.001","article-title":"Molecular signature and therapeutic perspective of the epithelial-to-mesenchymal transitions in epithelial cancers","volume":"11","author":"Sabbah","year":"2008","journal-title":"Drug Resist. Updat."},{"issue":"6","key":"10.1016\/j.phrs.2026.108380_bib389","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1038\/nrc2131","article-title":"Snail, Zeb and bHLH factors in tumour progression: an alliance against the epithelial phenotype?","volume":"7","author":"Peinado","year":"2007","journal-title":"Nat. Rev. Cancer"},{"issue":"5","key":"10.1016\/j.phrs.2026.108380_bib390","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.molmed.2008.03.004","article-title":"Epithelial-mesenchymal transition and the invasive potential of tumors","volume":"14","author":"Gavert","year":"2008","journal-title":"Trends Mol. Med."},{"issue":"7955","key":"10.1016\/j.phrs.2026.108380_bib391","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1038\/s41586-023-05838-7","article-title":"RHOJ controls EMT-associated resistance to chemotherapy","volume":"616","author":"Debaugnies","year":"2023","journal-title":"Nature"},{"issue":"7579","key":"10.1016\/j.phrs.2026.108380_bib392","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1038\/nature15748","article-title":"Epithelial-to-mesenchymal transition is not required for lung metastasis but contributes to chemoresistance","volume":"527","author":"Fischer","year":"2015","journal-title":"Nature"},{"issue":"7579","key":"10.1016\/j.phrs.2026.108380_bib393","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1038\/nature16064","article-title":"Epithelial-to-mesenchymal transition is dispensable for metastasis but induces chemoresistance in pancreatic cancer","volume":"527","author":"Zheng","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.phrs.2026.108380_bib394","doi-asserted-by":"crossref","DOI":"10.1016\/j.drup.2025.101227","article-title":"TGF\u03b2-activated Asporin interacts with STMN1 to promote prostate cancer docetaxel chemoresistance and metastasis by upregulating the Wnt\/\u03b2-catenin signaling pathway","volume":"81","author":"Ge","year":"2025","journal-title":"Drug Resist. Updat."},{"issue":"8","key":"10.1016\/j.phrs.2026.108380_bib395","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1158\/0008-5472.CAN-23-0438","article-title":"ASCL1 Drives Tolerance to Osimertinib in EGFR Mutant Lung Cancer in Permissive Cellular Contexts","volume":"84","author":"Hu","year":"2024","journal-title":"Cancer Res"},{"issue":"3","key":"10.1016\/j.phrs.2026.108380_bib396","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1038\/s41401-020-0457-8","article-title":"TGF\u03b22-mediated epithelial-mesenchymal transition and NF-\u03baB pathway activation contribute to osimertinib resistance","volume":"42","author":"Jiang","year":"2021","journal-title":"Acta Pharmacol. Sin."},{"issue":"9","key":"10.1016\/j.phrs.2026.108380_bib397","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1038\/s41419-024-07039-0","article-title":"PIM1 kinase promotes EMT-associated osimertinib resistance via regulating GSK3\u03b2 signaling pathway in EGFR-mutant non-small cell lung cancer","volume":"15","author":"Zhou","year":"2024","journal-title":"Cell Death Dis"},{"issue":"5","key":"10.1016\/j.phrs.2026.108380_bib398","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1038\/s41388-024-03220-z","article-title":"RBM15 facilitates osimertinib resistance of lung adenocarcinoma through m6A-dependent epigenetic silencing of SPOCK1","volume":"44","author":"Li","year":"2025","journal-title":"Oncogene"},{"issue":"21","key":"10.1016\/j.phrs.2026.108380_bib399","doi-asserted-by":"crossref","DOI":"10.1002\/adma.202206370","article-title":"Nanoparticle-Mediated Radiotherapy Remodels the Tumor Microenvironment to Enhance Antitumor Efficacy","volume":"35","author":"Zhen","year":"2023","journal-title":"Adv. Mater."},{"issue":"8","key":"10.1016\/j.phrs.2026.108380_bib400","doi-asserted-by":"crossref","first-page":"2784","DOI":"10.1073\/pnas.1018866109","article-title":"Antiangiogenic agents increase breast cancer stem cells via the generation of tumor hypoxia","volume":"109","author":"Conley","year":"2012","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"12","key":"10.1016\/j.phrs.2026.108380_bib401","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1042\/CS20150451","article-title":"Regulation of the breast cancer stem cell phenotype by hypoxia-inducible factors","volume":"129","author":"Semenza","year":"2015","journal-title":"Clin. Sci. (Lond.)"},{"issue":"3","key":"10.1016\/j.phrs.2026.108380_bib402","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1159\/000088478","article-title":"VEGF as a key mediator of angiogenesis in cancer","volume":"69","author":"Carmeliet","year":"2005","journal-title":"Oncology"},{"issue":"2","key":"10.1016\/j.phrs.2026.108380_bib403","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1007\/s10555-007-9066-y","article-title":"Hypoxia: a key regulator of angiogenesis in cancer","volume":"26","author":"Liao","year":"2007","journal-title":"Cancer Metastasis Rev"},{"key":"10.1016\/j.phrs.2026.108380_bib404","first-page":"71","article-title":"Oxygen sensing: a common crossroad in cancer and neurodegeneration","volume":"345","author":"Quaegebeur","year":"2010","journal-title":"Curr. Top. Microbiol. Immunol."},{"key":"10.1016\/j.phrs.2026.108380_bib405","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.semcancer.2017.01.007","article-title":"Targeting pH regulating proteins for cancer therapy-Progress and limitations","volume":"43","author":"Parks","year":"2017","journal-title":"Semin. Cancer Biol."},{"issue":"6","key":"10.1016\/j.phrs.2026.108380_bib406","first-page":"453","article-title":"Lactic Acid: No Longer an Inert and End-Product of Glycolysis","volume":"32","author":"Sun","year":"2017","journal-title":"Physiology (Bethesda)"},{"issue":"9","key":"10.1016\/j.phrs.2026.108380_bib407","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1038\/nrc.2016.73","article-title":"The biology and function of fibroblasts in cancer","volume":"16","author":"Kalluri","year":"2016","journal-title":"Nat. Rev. Cancer"},{"issue":"1","key":"10.1016\/j.phrs.2026.108380_bib408","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1038\/nm.1908","article-title":"A stroma-related gene signature predicts resistance to neoadjuvant chemotherapy in breast cancer","volume":"15","author":"Farmer","year":"2009","journal-title":"Nat. Med."},{"key":"10.1016\/j.phrs.2026.108380_bib409","doi-asserted-by":"crossref","DOI":"10.1016\/j.drup.2025.101273","article-title":"The multifaceted contributions of cancer-associated fibroblasts to drug resistance in primary and metastatic tumors","volume":"82","author":"Zhang","year":"2025","journal-title":"Drug Resist. Updat."},{"issue":"5","key":"10.1016\/j.phrs.2026.108380_bib410","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1016\/j.cmet.2016.10.010","article-title":"Tumor-Induced IL-6 Reprograms Host Metabolism to Suppress Anti-tumor Immunity","volume":"24","author":"Flint","year":"2016","journal-title":"Cell Metab"},{"issue":"1","key":"10.1016\/j.phrs.2026.108380_bib411","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.immuni.2018.06.006","article-title":"Tumor Cell-Intrinsic Factors Underlie Heterogeneity of Immune Cell Infiltration and Response to Immunotherapy","volume":"49","author":"Li","year":"2018","journal-title":"Immunity"},{"issue":"3","key":"10.1016\/j.phrs.2026.108380_bib412","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.cell.2005.02.034","article-title":"Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1\/CXCL12 secretion","volume":"121","author":"Orimo","year":"2005","journal-title":"Cell"},{"issue":"9","key":"10.1016\/j.phrs.2026.108380_bib413","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1158\/2326-6066.CIR-16-0311","article-title":"Development of Aggressive Pancreatic Ductal Adenocarcinomas Depends on Granulocyte Colony Stimulating Factor Secretion in Carcinoma Cells","volume":"5","author":"Pickup","year":"2017","journal-title":"Cancer Immunol. Res."},{"issue":"8","key":"10.1016\/j.phrs.2026.108380_bib414","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1038\/nri2808","article-title":"The polarization of immune cells in the tumour environment by TGFb","volume":"10","author":"Flavell","year":"2010","journal-title":"eta, Nat. Rev. Immunol."},{"issue":"50","key":"10.1016\/j.phrs.2026.108380_bib415","doi-asserted-by":"crossref","first-page":"20212","DOI":"10.1073\/pnas.1320318110","article-title":"Targeting CXCL12 from FAP-expressing carcinoma-associated fibroblasts synergizes with anti-PD-L1 immunotherapy in pancreatic cancer","volume":"110","author":"Feig","year":"2013","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"1","key":"10.1016\/j.phrs.2026.108380_bib416","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1038\/s41467-018-03347-0","article-title":"Cancer-associated fibroblasts induce antigen-specific deletion of CD8 (+) T Cells to protect tumour cells","volume":"9","author":"Lakins","year":"2018","journal-title":"Nat. Commun."},{"issue":"9","key":"10.1016\/j.phrs.2026.108380_bib417","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1158\/1078-0432.CCR-23-3206","article-title":"Radiotherapy Enhances Metastasis Through Immune Suppression by Inducing PD-L1 and MDSC in Distal Sites","volume":"30","author":"Hou","year":"2024","journal-title":"Clin. Cancer Res."},{"issue":"12","key":"10.1016\/j.phrs.2026.108380_bib418","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1093\/jnci\/djz036","article-title":"STAT3 Modulation of Regulatory T Cells in Response to Radiation Therapy in Head and Neck Cancer","volume":"111","author":"Oweida","year":"2019","journal-title":"J. Natl. Cancer Inst."},{"issue":"10","key":"10.1016\/j.phrs.2026.108380_bib419","doi-asserted-by":"crossref","first-page":"1694","DOI":"10.1016\/j.cell.2022.03.033","article-title":"Quiescent cancer cells resist T cell attack by forming an immunosuppressive niche","volume":"185","author":"Baldominos","year":"2022","journal-title":"Cell"},{"issue":"22","key":"10.1016\/j.phrs.2026.108380_bib420","article-title":"Cuproptosis Induced by ROS Responsive Nanoparticles with Elesclomol and Copper Combined with \u03b1PD-L1 for Enhanced Cancer Immunotherapy","volume":"35","author":"Guo","year":"2023","journal-title":"Adv. Mater."},{"issue":"3","key":"10.1016\/j.phrs.2026.108380_bib421","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1016\/j.chembiol.2013.12.014","article-title":"A small molecule screen identifies an inhibitor of DNA repair inducing the degradation of TFIIH and the chemosensitization of tumor cells to platinum","volume":"21","author":"Alekseev","year":"2014","journal-title":"Chem. Biol."},{"issue":"24","key":"10.1016\/j.phrs.2026.108380_bib422","doi-asserted-by":"crossref","first-page":"7432","DOI":"10.1158\/1078-0432.CCR-07-1768","article-title":"Tumors established with cell lines selected for oxaliplatin resistance respond to oxaliplatin if combined with cetuximab","volume":"13","author":"Prewett","year":"2007","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.phrs.2026.108380_bib423","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1186\/1471-2407-14-151","article-title":"Pharmacological inhibition of poly(ADP-ribose) polymerase-1 modulates resistance of human glioblastoma stem cells to temozolomide","volume":"14","author":"Tentori","year":"2014","journal-title":"BMC Cancer"},{"issue":"4","key":"10.1016\/j.phrs.2026.108380_bib424","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/S0921-8777(01)00076-3","article-title":"Methoxyamine potentiates DNA single strand breaks and double strand breaks induced by temozolomide in colon cancer cells","volume":"485","author":"Taverna","year":"2001","journal-title":"Mutat. Res."},{"key":"10.1016\/j.phrs.2026.108380_bib425","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2024.216622","article-title":"Triptolide induces apoptosis and cytoprotective autophagy by ROS accumulation via directly targeting peroxiredoxin 2 in gastric cancer cells","volume":"587","author":"Chen","year":"2024","journal-title":"Cancer Lett"},{"issue":"9","key":"10.1016\/j.phrs.2026.108380_bib426","doi-asserted-by":"crossref","first-page":"3747","DOI":"10.7150\/ijbs.70679","article-title":"Repurposing Oxiconazole against Colorectal Cancer via PRDX2-mediated Autophagy Arrest","volume":"18","author":"Shi","year":"2022","journal-title":"Int. J. Biol. Sci."},{"issue":"6","key":"10.1016\/j.phrs.2026.108380_bib427","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1007\/s10517-022-05626-9","article-title":"Suppression of the Antioxidant System and PI3K\/Akt\/mTOR Signaling Pathway in Cisplatin-Resistant Cancer Cells by Quercetin","volume":"173","author":"Hasan","year":"2022","journal-title":"Bull. Exp. Biol. Med."},{"key":"10.1016\/j.phrs.2026.108380_bib428","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.bbrc.2021.02.077","article-title":"miR-324-3p reverses cisplatin resistance by inducing GPX4-mediated ferroptosis in lung adenocarcinoma cell line A549","volume":"549","author":"Deng","year":"2021","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"19","key":"10.1016\/j.phrs.2026.108380_bib429","doi-asserted-by":"crossref","DOI":"10.1002\/adhm.202100770","article-title":"Versatile Nanodrugs Containing Glutathione and Heme Oxygenase 1 Inhibitors Enable Suppression of Antioxidant Defense System in a Two-Pronged Manner for Enhanced Photodynamic Therapy","volume":"10","author":"Zhong","year":"2021","journal-title":"Adv. Healthc. Mater."},{"issue":"1","key":"10.1016\/j.phrs.2026.108380_bib430","doi-asserted-by":"crossref","first-page":"4205","DOI":"10.1038\/s41467-020-18020-8","article-title":"GLUT1 inhibition blocks growth of RB1-positive triple negative breast cancer","volume":"11","author":"Wu","year":"2020","journal-title":"Nat. Commun."},{"issue":"16","key":"10.1016\/j.phrs.2026.108380_bib431","doi-asserted-by":"crossref","first-page":"4830","DOI":"10.7150\/jca.58494","article-title":"Shikonin Inhibits Tumor Growth of ESCC by suppressing PKM2 mediated Aerobic Glycolysis and STAT3 Phosphorylation","volume":"12","author":"Zhang","year":"2021","journal-title":"J. Cancer"},{"issue":"4","key":"10.1016\/j.phrs.2026.108380_bib432","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1208\/s12248-020-00466-9","article-title":"Vitro and In Vivo Efficacy of AZD3965 and Alpha-Cyano-4-Hydroxycinnamic Acid in the Murine 4T1 Breast Tumor Model","volume":"22","author":"Guan","year":"2020","journal-title":"AAPS J"},{"key":"10.1016\/j.phrs.2026.108380_bib433","article-title":"B-9-8, a Novel Harman Dimer, Reverses ABCG2-mediated Chemotherapeutic Drug Resistance","author":"Zhao","year":"2025","journal-title":"Recent Pat. Anticancer Drug Discov."},{"key":"10.1016\/j.phrs.2026.108380_bib434","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.actbio.2021.03.055","article-title":"Liposome technologies towards colorectal cancer therapeutics","volume":"127","author":"Sang","year":"2021","journal-title":"Acta Biomater"},{"issue":"3","key":"10.1016\/j.phrs.2026.108380_bib435","first-page":"288","article-title":"RN486, a Bruton's Tyrosine Kinase inhibitor, antagonizes multidrug resistance in ABCG2-overexpressing cancer cells","volume":"12","author":"Dong","year":"2024","journal-title":"J. Transl. Int. Med."},{"key":"10.1016\/j.phrs.2026.108380_bib436","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.msec.2017.08.075","article-title":"Overcoming STC2 mediated drug resistance through drug and gene co-delivery by PHB-PDMAEMA cationic polyester in liver cancer cells","volume":"83","author":"Cheng","year":"2018","journal-title":"Mater. Sci. Eng. C Mater. Biol. Appl."},{"issue":"47","key":"10.1016\/j.phrs.2026.108380_bib437","doi-asserted-by":"crossref","first-page":"27294","DOI":"10.1039\/C9RA04961D","article-title":"Synthesis and discovery of 18\u03b2-glycyrrhetinic acid derivatives inhibiting cancer stem cell properties in ovarian cancer cells","volume":"9","author":"Li","year":"2019","journal-title":"RSC Adv"},{"issue":"50","key":"10.1016\/j.phrs.2026.108380_bib438","doi-asserted-by":"crossref","first-page":"15892","DOI":"10.1021\/jacs.5b09970","article-title":"Facilitated Anion Transport Induces Hyperpolarization of the Cell Membrane That Triggers Differentiation and Cell Death in Cancer Stem Cells","volume":"137","author":"Soto-Cerrato","year":"2015","journal-title":"J. Am. Chem. Soc."},{"issue":"5","key":"10.1016\/j.phrs.2026.108380_bib439","first-page":"6611","article-title":"The enhanced delivery of salinomycin to CD133(+) ovarian cancer stem cells through CD133 antibody conjugation with poly(lactic-co-glycolic acid)-poly(ethylene glycol) nanoparticles,","volume":"15","author":"Mi","year":"2018","journal-title":"Oncol. Lett."},{"issue":"9","key":"10.1016\/j.phrs.2026.108380_bib440","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1016\/j.ymthe.2019.06.013","article-title":"The Delivery of a Wnt Pathway Inhibitor Toward CSCs Requires Stable Liposome Encapsulation and Delayed Drug Release in Tumor Tissues","volume":"27","author":"Li","year":"2019","journal-title":"Mol. Ther."},{"issue":"6","key":"10.1016\/j.phrs.2026.108380_bib441","doi-asserted-by":"crossref","first-page":"5725","DOI":"10.1021\/nn506928p","article-title":"Chitosan-Decorated Doxorubicin-Encapsulated Nanoparticle Targets and Eliminates Tumor Reinitiating Cancer Stem-like Cells","volume":"9","author":"Rao","year":"2015","journal-title":"ACS Nano"},{"issue":"8","key":"10.1016\/j.phrs.2026.108380_bib442","doi-asserted-by":"crossref","first-page":"7022","DOI":"10.1021\/acsami.8b01633","article-title":"Cerasomal Lovastatin Nanohybrids for Efficient Inhibition of Triple-Negative Breast Cancer Stem Cells To Improve Therapeutic Efficacy","volume":"10","author":"Song","year":"2018","journal-title":"ACS Appl. Mater. Interfaces"},{"issue":"30","key":"10.1016\/j.phrs.2026.108380_bib443","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.1701911114","article-title":"Multiplexed RNAi therapy against brain tumor-initiating cells via lipopolymeric nanoparticle infusion delays glioblastoma progression","volume":"114","author":"Yu","year":"2017","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"12","key":"10.1016\/j.phrs.2026.108380_bib444","doi-asserted-by":"crossref","first-page":"2217","DOI":"10.1039\/C6MD00297H","article-title":"Histone deacetylase inhibitors for the treatment of cancer stem cells","volume":"7","author":"Dvorakova","year":"2016","journal-title":"MedChemComm"},{"key":"10.1016\/j.phrs.2026.108380_bib445","doi-asserted-by":"crossref","DOI":"10.1016\/j.tice.2022.101853","article-title":"Inhibition of the Wnt\/b-catenin pathway using PNU-74654 reduces tumor growth in in vitro and in vivo models of colorectal cancer","volume":"77","author":"Amerizadeh","year":"2022","journal-title":"Tissue Cell"},{"issue":"15","key":"10.1016\/j.phrs.2026.108380_bib446","doi-asserted-by":"crossref","first-page":"12868","DOI":"10.1021\/acs.jmedchem.4c00843","article-title":"Canadine Platinum(IV) Complexes Targeting Epithelial-Mesenchymal Transition as Antiproliferative and Antimetastatic Agents","volume":"67","author":"Chen","year":"2024","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.phrs.2026.108380_bib447","article-title":"Self-assembled genistein nanoparticles suppress the epithelial-mesenchymal transition in glioblastoma by targeting MMP9","volume":"31","author":"Zhao","year":"2025","journal-title":"Mater. Today Bio"},{"key":"10.1016\/j.phrs.2026.108380_bib448","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/j.actbio.2022.08.024","article-title":"Reversal of epithelial-mesenchymal transition and inhibition of tumor stemness of breast cancer cells through advanced combined chemotherapy","volume":"152","author":"Cui","year":"2022","journal-title":"Acta Biomater"},{"issue":"8029","key":"10.1016\/j.phrs.2026.108380_bib449","first-page":"101","article-title":"Radiotherapy and hyperbaric oxygen in head and neck cancer","volume":"2","author":"Henk","year":"1977","journal-title":"Final report of first controlled clinical trial, Lancet"},{"issue":"4","key":"10.1016\/j.phrs.2026.108380_bib450","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1667\/0033-7587(2001)155[0515:IOTOBM]2.0.CO;2","article-title":"Improvement of tumor oxygenation by mild hyperthermia","volume":"155","author":"Song","year":"2001","journal-title":"Radiat. Res."},{"key":"10.1016\/j.phrs.2026.108380_bib451","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms12308","article-title":"The anti-malarial atovaquone increases radiosensitivity by alleviating tumour hypoxia","volume":"7","author":"Ashton","year":"2016","journal-title":"Nat. Commun."},{"issue":"9","key":"10.1016\/j.phrs.2026.108380_bib452","doi-asserted-by":"crossref","first-page":"2459","DOI":"10.1158\/1078-0432.CCR-20-4128","article-title":"Mitochondrial Inhibitor Atovaquone Increases Tumor Oxygenation and Inhibits Hypoxic Gene Expression in Patients with Non-Small Cell Lung Cancer","volume":"27","author":"Skwarski","year":"2021","journal-title":"Clin. Cancer Res."},{"issue":"42","key":"10.1016\/j.phrs.2026.108380_bib453","doi-asserted-by":"crossref","first-page":"10756","DOI":"10.1073\/pnas.1808945115","article-title":"Papaverine and its derivatives radiosensitize solid tumors by inhibiting mitochondrial metabolism","volume":"115","author":"Benej","year":"2018","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"3","key":"10.1016\/j.phrs.2026.108380_bib454","doi-asserted-by":"crossref","first-page":"149","DOI":"10.5306\/wjco.v10.i3.149","article-title":"Evaluation of a locked nucleic acid form of antisense oligo targeting HIF-1\u03b1 in advanced hepatocellular carcinoma","volume":"10","author":"Wu","year":"2019","journal-title":"World J. Clin. Oncol."},{"issue":"5","key":"10.1016\/j.phrs.2026.108380_bib455","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1038\/s41591-021-01324-7","article-title":"Inhibition of hypoxia-inducible factor-2\u03b1 in renal cell carcinoma with belzutifan: a phase 1 trial and biomarker analysis","volume":"27","author":"Choueiri","year":"2021","journal-title":"Nat. Med."},{"issue":"8","key":"10.1016\/j.phrs.2026.108380_bib456","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1016\/j.ajpath.2020.04.003","article-title":"Understanding the Oxygen-Sensing Pathway and Its Therapeutic Implications in Diseases","volume":"190","author":"Liao","year":"2020","journal-title":"Am. J. Pathol."},{"issue":"3","key":"10.1016\/j.phrs.2026.108380_bib457","doi-asserted-by":"crossref","DOI":"10.3390\/cells10030678","article-title":"Hypoxia-Driven Effects in Cancer: Characterization, Mechanisms, and Therapeutic Implications","volume":"10","author":"Shi","year":"2021","journal-title":"Cells"},{"issue":"1","key":"10.1016\/j.phrs.2026.108380_bib458","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S1470-2045(00)00006-1","article-title":"The role of hypoxia-activated prodrugs in cancer therapy","volume":"1","author":"Denny","year":"2000","journal-title":"Lancet Oncol"},{"issue":"11","key":"10.1016\/j.phrs.2026.108380_bib459","doi-asserted-by":"crossref","first-page":"5137","DOI":"10.1172\/JCI96268","article-title":"Targeted hypoxia reduction restores T cell infiltration and sensitizes prostate cancer to immunotherapy","volume":"128","author":"Jayaprakash","year":"2018","journal-title":"J. Clin. Invest."},{"issue":"11","key":"10.1016\/j.phrs.2026.108380_bib460","doi-asserted-by":"crossref","first-page":"3050","DOI":"10.1158\/1078-0432.CCR-20-4118","article-title":"A Phase I Dose-Escalation Study to Evaluate the Safety and Tolerability of Evofosfamide in Combination with Ipilimumab in Advanced Solid Malignancies","volume":"27","author":"Hegde","year":"2021","journal-title":"Clin. Cancer Res."},{"issue":"4","key":"10.1016\/j.phrs.2026.108380_bib461","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1016\/j.juro.2011.11.101","article-title":"Phase 2 study of adjuvant intravesical instillations of apaziquone for high risk nonmuscle invasive bladder cancer","volume":"187","author":"Hendricksen","year":"2012","journal-title":"J. Urol."},{"key":"10.1016\/j.phrs.2026.108380_bib462","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.semcancer.2022.12.011","article-title":"Tumor hypoxia: From basic knowledge to therapeutic implications","volume":"88","author":"Liao","year":"2023","journal-title":"Semin. Cancer Biol."},{"issue":"3","key":"10.1016\/j.phrs.2026.108380_bib463","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1124\/mol.116.108084","article-title":"Tumor Microenvironment Targeting and Responsive Peptide-Based Nanoformulations for Improved Tumor Therapy","volume":"92","author":"Qin","year":"2017","journal-title":"Mol. Pharmacol."},{"issue":"7732","key":"10.1016\/j.phrs.2026.108380_bib464","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1038\/s41586-018-0670-5","article-title":"DYNLL1 binds to MRE11 to limit DNA end resection in BRCA1-deficient cells","volume":"563","author":"He","year":"2018","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.phrs.2026.108380_bib465","doi-asserted-by":"crossref","first-page":"5406","DOI":"10.1038\/s41467-018-07855-x","article-title":"The ASCIZ-DYNLL1 axis promotes 53BP1-dependent non-homologous end joining and PARP inhibitor sensitivity","volume":"9","author":"Becker","year":"2018","journal-title":"Nat. Commun."},{"issue":"12","key":"10.1016\/j.phrs.2026.108380_bib466","doi-asserted-by":"crossref","first-page":"1868","DOI":"10.1038\/s41417-024-00841-0","article-title":"BAIAP2L2 promotes the malignancy of hepatocellular carcinoma via GABPB1-mediated reactive oxygen species imbalance","volume":"31","author":"Jia","year":"2024","journal-title":"Cancer Gene Ther"},{"key":"10.1016\/j.phrs.2026.108380_bib467","doi-asserted-by":"crossref","DOI":"10.1016\/j.drup.2023.100976","article-title":"Targeting ACYP1-mediated glycolysis reverses lenvatinib resistance and restricts hepatocellular carcinoma progression","volume":"69","author":"Wang","year":"2023","journal-title":"Drug Resist. Updat."},{"issue":"3","key":"10.1016\/j.phrs.2026.108380_bib468","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1038\/clpt.2013.208","article-title":"Interaction of the efflux transporters ABCB1 and ABCG2 with imatinib, nilotinib, and dasatinib","volume":"95","author":"Eadie","year":"2014","journal-title":"Clin. Pharmacol. Ther."},{"issue":"6","key":"10.1016\/j.phrs.2026.108380_bib469","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1053\/j.gastro.2023.01.041","article-title":"N6-Methyladenosine-Mediated Up-Regulation of FZD10 Regulates Liver Cancer Stem Cells' Properties and Lenvatinib Resistance Through WNT\/\u03b2-Catenin and Hippo Signaling Pathways","volume":"164","author":"Wang","year":"2023","journal-title":"Gastroenterology"},{"issue":"5","key":"10.1016\/j.phrs.2026.108380_bib470","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1016\/j.cell.2012.10.035","article-title":"MED12 controls the response to multiple cancer drugs through regulation of TGF-\u03b2 receptor signaling","volume":"151","author":"Huang","year":"2012","journal-title":"Cell"},{"issue":"7","key":"10.1016\/j.phrs.2026.108380_bib471","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1053\/j.gastro.2016.02.040","article-title":"Tumor-Associated Neutrophils Recruit Macrophages and T-Regulatory Cells to Promote Progression of Hepatocellular Carcinoma and Resistance to Sorafenib","volume":"150","author":"Zhou","year":"2016","journal-title":"Gastroenterology"},{"issue":"5","key":"10.1016\/j.phrs.2026.108380_bib472","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1158\/1078-0432.CCR-12-1630","article-title":"BRAF inhibition is associated with enhanced melanoma antigen expression and a more favorable tumor microenvironment in patients with metastatic melanoma","volume":"19","author":"Frederick","year":"2013","journal-title":"Clin. Cancer Res."},{"issue":"6","key":"10.1016\/j.phrs.2026.108380_bib473","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/S1470-2045(00)00391-0","article-title":"Radiotherapy and cellular signalling","volume":"2","author":"Lewanski","year":"2001","journal-title":"Lancet Oncol"},{"issue":"5","key":"10.1016\/j.phrs.2026.108380_bib474","doi-asserted-by":"crossref","DOI":"10.3390\/cancers9050052","article-title":"Epidermal Growth Factor Receptor Cell Proliferation Signaling Pathways","volume":"9","author":"Wee","year":"2017","journal-title":"Cancers (Basel)"},{"issue":"5","key":"10.1016\/j.phrs.2026.108380_bib475","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1158\/2159-8290.CD-12-0531","article-title":"Relief of feedback inhibition of HER3 transcription by RAF and MEK inhibitors attenuates their antitumor effects in BRAF-mutant thyroid carcinomas","volume":"3","author":"Montero-Conde","year":"2013","journal-title":"Cancer Discov"},{"issue":"3","key":"10.1016\/j.phrs.2026.108380_bib476","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1158\/2159-8290.CD-11-0341","article-title":"EGFR-mediated re-activation of MAPK signaling contributes to insensitivity of BRAF mutant colorectal cancers to RAF inhibition with vemurafenib","volume":"2","author":"Corcoran","year":"2012","journal-title":"Cancer Discov"},{"issue":"7387","key":"10.1016\/j.phrs.2026.108380_bib477","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1038\/nature10868","article-title":"Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR","volume":"483","author":"Prahallad","year":"2012","journal-title":"Nature"},{"issue":"5","key":"10.1016\/j.phrs.2026.108380_bib478","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.semcancer.2009.05.003","article-title":"The angiogenic switch in carcinogenesis","volume":"19","author":"Baeriswyl","year":"2009","journal-title":"Semin. Cancer Biol."},{"issue":"4","key":"10.1016\/j.phrs.2026.108380_bib479","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1038\/74651","article-title":"Mechanisms of angiogenesis and arteriogenesis","volume":"6","author":"Carmeliet","year":"2000","journal-title":"Nat. Med."},{"issue":"4","key":"10.1016\/j.phrs.2026.108380_bib480","doi-asserted-by":"crossref","first-page":"1732","DOI":"10.1172\/JCI65385","article-title":"Tumor VEGF:VEGFR2 autocrine feed-forward loop triggers angiogenesis in lung cancer","volume":"123","author":"Chatterjee","year":"2013","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.phrs.2026.108380_bib481","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.drup.2015.12.001","article-title":"The ERK cascade inhibitors: Towards overcoming resistance","volume":"25","author":"Maik-Rachline","year":"2016","journal-title":"Drug Resist. Updat."},{"issue":"10","key":"10.1016\/j.phrs.2026.108380_bib482","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1158\/2159-8290.CD-12-0103","article-title":"Reactivation of ERK signaling causes resistance to EGFR kinase inhibitors","volume":"2","author":"Ercan","year":"2012","journal-title":"Cancer Discov"},{"issue":"2","key":"10.1016\/j.phrs.2026.108380_bib483","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1158\/2159-8290.CD-19-0209","article-title":"Resistance Mechanisms to SYK Inhibition in Acute Myeloid Leukemia","volume":"10","author":"Cremer","year":"2020","journal-title":"Cancer Discov"},{"issue":"4","key":"10.1016\/j.phrs.2026.108380_bib484","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.ccr.2007.08.030","article-title":"A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer","volume":"12","author":"Berns","year":"2007","journal-title":"Cancer Cell"},{"issue":"12","key":"10.1016\/j.phrs.2026.108380_bib485","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1200\/JCO.2014.55.2158","article-title":"PIK3CA mutations are associated with decreased benefit to neoadjuvant human epidermal growth factor receptor 2-targeted therapies in breast cancer","volume":"33","author":"Majewski","year":"2015","journal-title":"J. Clin. Oncol."},{"issue":"10","key":"10.1016\/j.phrs.2026.108380_bib486","doi-asserted-by":"crossref","first-page":"4286","DOI":"10.1158\/0008-5472.CAN-08-4765","article-title":"PI3K pathway activation mediates resistance to MEK inhibitors in KRAS mutant cancers","volume":"69","author":"Wee","year":"2009","journal-title":"Cancer Res"},{"issue":"1","key":"10.1016\/j.phrs.2026.108380_bib487","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1158\/2159-8290.CD-13-0642","article-title":"Acquired resistance and clonal evolution in melanoma during BRAF inhibitor therapy","volume":"4","author":"Shi","year":"2014","journal-title":"Cancer Discov"},{"issue":"2","key":"10.1016\/j.phrs.2026.108380_bib488","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.semradonc.2025.02.008","article-title":"Predictors of Radiation Resistance and Novel Radiation Sensitizers in Head and Neck Cancers: Advancing Radiotherapy Efficacy","volume":"35","author":"Sobti","year":"2025","journal-title":"Semin. Radiat. Oncol."},{"key":"10.1016\/j.phrs.2026.108380_bib489","doi-asserted-by":"crossref","DOI":"10.1016\/j.drup.2024.101114","article-title":"Cancer plasticity in therapy resistance: Mechanisms and novel strategies","volume":"76","author":"Niu","year":"2024","journal-title":"Drug Resist. Updat."},{"issue":"33","key":"10.1016\/j.phrs.2026.108380_bib490","doi-asserted-by":"crossref","first-page":"4725","DOI":"10.1038\/onc.2010.223","article-title":"Global analysis of CpG methylation reveals epigenetic control of the radiosensitivity in lung cancer cell lines","volume":"29","author":"Kim","year":"2010","journal-title":"Oncogene"},{"issue":"9","key":"10.1016\/j.phrs.2026.108380_bib491","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2021.109202","article-title":"Therapy-induced DNA methylation inactivates MCT1 and renders tumor cells vulnerable to MCT4 inhibition","volume":"35","author":"Vander Linden","year":"2021","journal-title":"Cell Rep"},{"key":"10.1016\/j.phrs.2026.108380_bib492","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.ejphar.2018.08.021","article-title":"Epigenetic tools (The Writers, The Readers and The Erasers) and their implications in cancer therapy","volume":"837","author":"Biswas","year":"2018","journal-title":"Eur. J. Pharmacol."},{"issue":"11","key":"10.1016\/j.phrs.2026.108380_bib493","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.add3243","article-title":"HDAC3 is critical in tumor development and therapeutic resistance in Kras-mutant non-small cell lung cancer","volume":"9","author":"Eichner","year":"2023","journal-title":"Sci. Adv."},{"issue":"9","key":"10.1016\/j.phrs.2026.108380_bib494","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1080\/15384101.2022.2035915","article-title":"Effects of noncoding RNAs in radiotherapy response in breast cancer: a systematic review","volume":"21","author":"Oghabi Bakhshaiesh","year":"2022","journal-title":"Cell Cycle"},{"issue":"1","key":"10.1016\/j.phrs.2026.108380_bib495","doi-asserted-by":"crossref","first-page":"4718","DOI":"10.1038\/s41467-018-07264-0","article-title":"Targeting 17q23 amplicon to overcome the resistance to anti-HER2 therapy in HER2+ breast cancer","volume":"9","author":"Liu","year":"2018","journal-title":"Nat. Commun."},{"issue":"12","key":"10.1016\/j.phrs.2026.108380_bib496","doi-asserted-by":"crossref","first-page":"3350","DOI":"10.1158\/0008-5472.CAN-17-3146","article-title":"Enhancer Remodeling and MicroRNA Alterations Are Associated with Acquired Resistance to ALK Inhibitors","volume":"78","author":"Yun","year":"2018","journal-title":"Cancer Res"},{"issue":"1","key":"10.1016\/j.phrs.2026.108380_bib497","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1038\/s41420-024-02220-y","article-title":"Xanthohumol overcomes osimertinib resistance via governing ubiquitination-modulated Ets-1 turnover","volume":"10","author":"Ma","year":"2024","journal-title":"Cell Death Discov"},{"issue":"7869","key":"10.1016\/j.phrs.2026.108380_bib498","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1038\/s41586-021-03741-7","article-title":"EGFR activation limits the response of liver cancer to lenvatinib","volume":"595","author":"Jin","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.phrs.2026.108380_bib499","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2023.216181","article-title":"A multi-functional nano-system combining PI3K-110\u03b1\/\u03b2 inhibitor overcomes P-glycoprotein mediated MDR and improves anti-cancer efficiency","volume":"563","author":"Lin","year":"2023","journal-title":"Cancer Lett"},{"issue":"7899","key":"10.1016\/j.phrs.2026.108380_bib500","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1038\/s41586-022-04437-2","article-title":"Effective drug combinations in breast, colon and pancreatic cancer cells","volume":"603","author":"Jaaks","year":"2022","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.phrs.2026.108380_bib501","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1158\/1078-0432.CCR-17-1807","article-title":"A Multicenter Phase I Study Evaluating Dual PI3K and BRAF Inhibition with PX-866 and Vemurafenib in Patients with Advanced BRAF V600-Mutant Solid Tumors","volume":"24","author":"Yam","year":"2018","journal-title":"Clin. Cancer Res."},{"issue":"17","key":"10.1016\/j.phrs.2026.108380_bib502","doi-asserted-by":"crossref","first-page":"1632","DOI":"10.1056\/NEJMoa1908075","article-title":"Encorafenib, Binimetinib, and Cetuximab in BRAF V600E-Mutated Colorectal Cancer","volume":"381","author":"Kopetz","year":"2019","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.phrs.2026.108380_bib503","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1038\/s41591-022-02181-8","article-title":"Combined PD-1, BRAF and MEK inhibition in BRAF(V600E) colorectal cancer: a phase 2 trial","volume":"29","author":"Tian","year":"2023","journal-title":"Nat. Med."},{"issue":"4","key":"10.1016\/j.phrs.2026.108380_bib504","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1158\/1078-0432.CCR-14-1814","article-title":"A phase Ib dose-escalation study of the oral pan-PI3K inhibitor buparlisib (BKM120) in combination with the oral MEK1\/2 inhibitor trametinib (GSK1120212) in patients with selected advanced solid tumors","volume":"21","author":"Bedard","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.phrs.2026.108380_bib505","doi-asserted-by":"crossref","first-page":"992","DOI":"10.3389\/fonc.2020.00992","article-title":"Understanding the Mechanisms by Which Epigenetic Modifiers Avert Therapy Resistance in Cancer","volume":"10","author":"Quagliano","year":"2020","journal-title":"Front. Oncol."},{"key":"10.1016\/j.phrs.2026.108380_bib506","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/j.semcancer.2021.03.013","article-title":"Current paradigms in epigenetic anticancer therapeutics and future challenges","volume":"83","author":"Singh","year":"2022","journal-title":"Semin. Cancer Biol."},{"issue":"6","key":"10.1016\/j.phrs.2026.108380_bib507","doi-asserted-by":"crossref","DOI":"10.3390\/nu10060731","article-title":"Targeting Histone Deacetylases with Natural and Synthetic Agents: An Emerging Anticancer Strategy","volume":"10","author":"Singh","year":"2018","journal-title":"Nutrients"},{"issue":"4","key":"10.1016\/j.phrs.2026.108380_bib508","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1038\/s41591-024-02813-1","article-title":"Combined anti-PD-1, HDAC inhibitor and anti-VEGF for MSS\/pMMR colorectal cancer: a randomized phase 2 trial","volume":"30","author":"Wang","year":"2024","journal-title":"Nat. Med."},{"issue":"4","key":"10.1016\/j.phrs.2026.108380_bib509","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13040634","article-title":"Anticancer Therapy with HDAC Inhibitors: Mechanism-Based Combination Strategies and Future Perspectives","volume":"13","author":"Jenke","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.phrs.2026.108380_bib510","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2021.113825","article-title":"Combining histone deacetylase inhibitors (HDACis) with other therapies for cancer therapy","volume":"226","author":"Zhou","year":"2021","journal-title":"Eur. J. Med. Chem."},{"issue":"3","key":"10.1016\/j.phrs.2026.108380_bib511","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1038\/s41576-023-00662-1","article-title":"Non-coding RNAs in disease: from mechanisms to therapeutics","volume":"25","author":"Nemeth","year":"2024","journal-title":"Nat. Rev. Genet."},{"issue":"4","key":"10.1016\/j.phrs.2026.108380_bib512","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1158\/1535-7163.MCT-23-0747","article-title":"PROTACs: Current and Future Potential as a Precision Medicine Strategy to Combat Cancer","volume":"23","author":"Rutherford","year":"2024","journal-title":"Mol. Cancer Ther."},{"issue":"1","key":"10.1016\/j.phrs.2026.108380_bib513","doi-asserted-by":"crossref","DOI":"10.1002\/mog2.69","article-title":"Insight into Janus kinases specificity: From molecular architecture to cancer therapeutics","volume":"3","author":"Wei","year":"2024","journal-title":"MedComm - Oncology"},{"issue":"6659","key":"10.1016\/j.phrs.2026.108380_bib514","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1126\/science.adg9652","article-title":"Chemical remodeling of a cellular chaperone to target the active state of mutant KRAS","volume":"381","author":"Schulze","year":"2023","journal-title":"Science"},{"issue":"14","key":"10.1016\/j.phrs.2026.108380_bib515","doi-asserted-by":"crossref","first-page":"5740","DOI":"10.1039\/D2CS00200K","article-title":"Target and tissue selectivity of PROTAC degraders","volume":"51","author":"Guenette","year":"2022","journal-title":"Chem. Soc. Rev."},{"issue":"1","key":"10.1016\/j.phrs.2026.108380_bib516","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1186\/s13045-020-00924-z","article-title":"Proteolysis targeting chimeras (PROTACs) are emerging therapeutics for hematologic malignancies","volume":"13","author":"He","year":"2020","journal-title":"J. Hematol. Oncol."},{"issue":"11","key":"10.1016\/j.phrs.2026.108380_bib517","doi-asserted-by":"crossref","first-page":"7415","DOI":"10.1021\/acs.jmedchem.2c00030","article-title":"Medicinal Chemistry Strategies for the Development of Bruton's Tyrosine Kinase Inhibitors against Resistance","volume":"65","author":"Sun","year":"2022","journal-title":"J. Med. Chem."},{"issue":"3","key":"10.1016\/j.phrs.2026.108380_bib518","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1021\/acs.jmedchem.9b01566","article-title":"Discovery of Potent and Selective Epidermal Growth Factor Receptor (EGFR) Bifunctional Small-Molecule Degraders","volume":"63","author":"Cheng","year":"2020","journal-title":"J. Med. Chem."},{"issue":"8","key":"10.1016\/j.phrs.2026.108380_bib519","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1021\/acsmedchemlett.8b00314","article-title":"C797S Resistance: The Undruggable EGFR Mutation in Non-Small Cell Lung Cancer?","volume":"9","author":"Grabe","year":"2018","journal-title":"ACS Med. Chem. Lett."},{"issue":"24","key":"10.1016\/j.phrs.2026.108380_bib520","doi-asserted-by":"crossref","first-page":"15883","DOI":"10.1021\/acs.jmedchem.0c01609","article-title":"Potent and Selective Mitogen-Activated Protein Kinase Kinase 1\/2 (MEK1\/2) Heterobifunctional Small-molecule Degraders","volume":"63","author":"Hu","year":"2020","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.phrs.2026.108380_bib521","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.canlet.2019.05.008","article-title":"Targeting the Shc-EGFR interaction with indomethacin inhibits MAP kinase pathway signalling","volume":"457","author":"Lin","year":"2019","journal-title":"Cancer Lett"},{"issue":"12","key":"10.1016\/j.phrs.2026.108380_bib522","doi-asserted-by":"crossref","first-page":"5214","DOI":"10.1039\/D2CS00193D","article-title":"PROTACs: past, present and future","volume":"51","author":"Li","year":"2022","journal-title":"Chem. Soc. Rev."},{"key":"10.1016\/j.phrs.2026.108380_bib523","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2024.107984","article-title":"Design and optimization strategies of PROTACs and its Application, Comparisons to other targeted protein degradation for multiple oncology therapies","volume":"154","author":"Malarvannan","year":"2025","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.phrs.2026.108380_bib524","doi-asserted-by":"crossref","first-page":"325","DOI":"10.3390\/biom16020325","article-title":"Targeted Protein Degradation in Cancer: PROTACs, New Targets, and Clinical Mechanisms","volume":"16","author":"Faryal","year":"2026","journal-title":"Biomolecules"},{"key":"10.1016\/j.phrs.2026.108380_bib525","doi-asserted-by":"crossref","first-page":"2019","DOI":"10.3389\/fgene.2019.00478","article-title":"The Potential for microRNA Therapeutics and Clinical Research","volume":"10","author":"Hanna","year":"2019","journal-title":"Frontiers in Genetics"},{"issue":"3","key":"10.1016\/j.phrs.2026.108380_bib526","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1038\/nrd.2016.246","article-title":"MicroRNA therapeutics: towards a new era for the management of cancer and other diseases","volume":"16","author":"Rupaimoole","year":"2017","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.phrs.2026.108380_bib527","doi-asserted-by":"crossref","first-page":"501","DOI":"10.3390\/pharmaceutics17040501","article-title":"PROTAC Delivery Strategies for Overcoming Physicochemical Properties and Physiological Barriers in Targeted Protein Degradation","volume":"17","author":"Syahputra","year":"2025","journal-title":"Pharmaceutics"},{"issue":"8","key":"10.1016\/j.phrs.2026.108380_bib528","doi-asserted-by":"crossref","first-page":"e434","DOI":"10.1016\/S1470-2045(19)30157-3","article-title":"Integration of radiotherapy and immunotherapy for treatment of oligometastases","volume":"20","author":"Pitroda","year":"2019","journal-title":"Lancet Oncol"},{"issue":"2","key":"10.1016\/j.phrs.2026.108380_bib529","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1172\/JCI67313","article-title":"Irradiation and anti-PD-L1 treatment synergistically promote antitumor immunity in mice","volume":"124","author":"Deng","year":"2014","journal-title":"J. Clin. Invest."},{"issue":"38","key":"10.1016\/j.phrs.2026.108380_bib530","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abd2712","article-title":"Revisiting the PD-1 pathway","volume":"6","author":"Patsoukis","year":"2020","journal-title":"Sci. Adv."},{"issue":"5","key":"10.1016\/j.phrs.2026.108380_bib531","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1016\/j.immuni.2014.10.019","article-title":"STING-Dependent Cytosolic DNA Sensing Promotes Radiation-Induced Type I Interferon-Dependent Antitumor Immunity in Immunogenic Tumors","volume":"41","author":"Deng","year":"2014","journal-title":"Immunity"},{"issue":"11","key":"10.1016\/j.phrs.2026.108380_bib532","doi-asserted-by":"crossref","first-page":"3015","DOI":"10.1158\/1078-0432.CCR-11-3225","article-title":"Molecular pathways: interferon\/stat1 pathway: role in the tumor resistance to genotoxic stress and aggressive growth","volume":"18","author":"Khodarev","year":"2012","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.phrs.2026.108380_bib533","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms15618","article-title":"DNA exonuclease Trex1 regulates radiotherapy-induced tumour immunogenicity","volume":"8","author":"Vanpouille-Box","year":"2017","journal-title":"Nat. Commun."},{"issue":"2","key":"10.1016\/j.phrs.2026.108380_bib534","first-page":"119","article-title":"The multiple roles of amphiregulin in human cancer","volume":"1816","author":"Busser","year":"2011","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.phrs.2026.108380_bib535","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.semcdb.2014.01.005","article-title":"Amphiregulin","volume":"28","author":"Berasain","year":"2014","journal-title":"Semin. Cell Dev. Biol."},{"issue":"8","key":"10.1016\/j.phrs.2026.108380_bib536","doi-asserted-by":"crossref","first-page":"3728","DOI":"10.1210\/en.2010-0319","article-title":"Amphiregulin promotes intestinal epithelial regeneration: roles of intestinal subepithelial myofibroblasts","volume":"151","author":"Shao","year":"2010","journal-title":"Endocrinology"},{"issue":"16","key":"10.1016\/j.phrs.2026.108380_bib537","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1200\/JCO.2017.76.2229","article-title":"Safety and Clinical Activity of Pembrolizumab and Multisite Stereotactic Body Radiotherapy in Patients With Advanced Solid Tumors","volume":"36","author":"Luke","year":"2018","journal-title":"J. Clin. Oncol."},{"issue":"4894 Pt 1","key":"10.1016\/j.phrs.2026.108380_bib538","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1126\/science.2466334","article-title":"Structure and function of human amphiregulin: a member of the epidermal growth factor family","volume":"243","author":"Shoyab","year":"1989","journal-title":"Science"},{"issue":"17","key":"10.1016\/j.phrs.2026.108380_bib539","doi-asserted-by":"crossref","first-page":"6528","DOI":"10.1073\/pnas.85.17.6528","article-title":"Amphiregulin: a bifunctional growth-modulating glycoprotein produced by the phorbol 12-myristate 13-acetate-treated human breast adenocarcinoma cell line MCF-7","volume":"85","author":"Shoyab","year":"1988","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"2","key":"10.1016\/j.phrs.2026.108380_bib540","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.immuni.2012.09.023","article-title":"Amphiregulin enhances regulatory T cell-suppressive function via the epidermal growth factor receptor","volume":"38","author":"Zaiss","year":"2013","journal-title":"Immunity"},{"issue":"2","key":"10.1016\/j.phrs.2026.108380_bib541","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.immuni.2015.01.020","article-title":"Emerging functions of amphiregulin in orchestrating immunity, inflammation, and tissue repair","volume":"42","author":"Zaiss","year":"2015","journal-title":"Immunity"},{"issue":"4","key":"10.1016\/j.phrs.2026.108380_bib542","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1016\/j.immuni.2017.09.013","article-title":"Epidermal Growth Factor Receptor Expression Licenses Type-2 Helper T Cells to Function in a T Cell Receptor-Independent Fashion","volume":"47","author":"Minutti","year":"2017","journal-title":"Immunity"},{"key":"10.1016\/j.phrs.2026.108380_bib543","doi-asserted-by":"crossref","DOI":"10.1038\/s41586-025-08994-0","article-title":"Radiation-induced amphiregulin drives tumour metastasis","author":"Piffk\u00f3","year":"2025","journal-title":"Nature"},{"issue":"7","key":"10.1016\/j.phrs.2026.108380_bib544","doi-asserted-by":"crossref","first-page":"3101","DOI":"10.4049\/jimmunol.1302736","article-title":"Enhancement of T cell responses as a result of synergy between lower doses of radiation and T cell stimulation","volume":"192","author":"Spary","year":"2014","journal-title":"J. Immunol."},{"issue":"9","key":"10.1016\/j.phrs.2026.108380_bib545","doi-asserted-by":"crossref","first-page":"2162","DOI":"10.1158\/0008-5472.CAN-11-3687","article-title":"T-regulatory cells: key players in tumor immune escape and angiogenesis","volume":"72","author":"Facciabene","year":"2012","journal-title":"Cancer Res"},{"issue":"4","key":"10.1016\/j.phrs.2026.108380_bib546","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/j.cell.2017.01.017","article-title":"Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy","volume":"168","author":"Sharma","year":"2017","journal-title":"Cell"},{"issue":"4","key":"10.1016\/j.phrs.2026.108380_bib547","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1158\/2326-6066.CIR-14-0196","article-title":"Stereotactic Radiation Therapy Augments Antigen-Specific PD-1-Mediated Antitumor Immune Responses via Cross-Presentation of Tumor Antigen","volume":"3","author":"Sharabi","year":"2015","journal-title":"Cancer Immunol. Res."},{"issue":"4","key":"10.1016\/j.phrs.2026.108380_bib548","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1016\/j.ijrobp.2010.09.034","article-title":"Radiation enhances regulatory T cell representation","volume":"81","author":"Kachikwu","year":"2011","journal-title":"Int. J. Radiat. Oncol. Biol. Phys"},{"issue":"9","key":"10.1016\/j.phrs.2026.108380_bib549","doi-asserted-by":"crossref","first-page":"2782","DOI":"10.1158\/0008-5472.CAN-12-3981","article-title":"CSF1R signaling blockade stanches tumor-infiltrating myeloid cells and improves the efficacy of radiotherapy in prostate cancer","volume":"73","author":"Xu","year":"2013","journal-title":"Cancer Res"},{"key":"10.1016\/j.phrs.2026.108380_bib550","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1146\/annurev-med-051013-052304","article-title":"Regulation of tumor metastasis by myeloid-derived suppressor cells","volume":"66","author":"Condamine","year":"2015","journal-title":"Annu. Rev. Med."},{"issue":"7","key":"10.1016\/j.phrs.2026.108380_bib551","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1053\/j.gastro.2016.02.070","article-title":"Radiation Therapy Induces Macrophages to Suppress T-Cell Responses Against Pancreatic Tumors in Mice","volume":"150","author":"Seifert","year":"2016","journal-title":"Gastroenterology"},{"issue":"48","key":"10.1016\/j.phrs.2026.108380_bib552","doi-asserted-by":"crossref","first-page":"78653","DOI":"10.18632\/oncotarget.11823","article-title":"Mertk on tumor macrophages is a therapeutic target to prevent tumor recurrence following radiation therapy","volume":"7","author":"Crittenden","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.phrs.2026.108380_bib553","doi-asserted-by":"crossref","first-page":"157","DOI":"10.3389\/fphys.2013.00157","article-title":"The irradiated tumor microenvironment: role of tumor-associated macrophages in vascular recovery","volume":"4","author":"Russell","year":"2013","journal-title":"Front. Physiol."},{"issue":"1","key":"10.1016\/j.phrs.2026.108380_bib554","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ccr.2011.01.005","article-title":"Polarization of tumor-associated macrophages: a novel strategy for vascular normalization and antitumor immunity","volume":"19","author":"Huang","year":"2011","journal-title":"Cancer Cell"},{"issue":"1","key":"10.1016\/j.phrs.2026.108380_bib555","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1186\/s12967-020-02618-z","article-title":"Tumor-associated macrophage, angiogenesis and lymphangiogenesis markers predict prognosis of non-small cell lung cancer patients","volume":"18","author":"Hwang","year":"2020","journal-title":"J. Transl. Med."},{"issue":"1","key":"10.1016\/j.phrs.2026.108380_bib556","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.it.2016.10.002","article-title":"TIGIT: A Key Inhibitor of the Cancer Immunity Cycle","volume":"38","author":"Manieri","year":"2017","journal-title":"Trends Immunol"},{"issue":"1","key":"10.1016\/j.phrs.2026.108380_bib557","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1007\/s00262-022-03227-z","article-title":"TIGIT blockade enhances tumor response to radiotherapy via a CD103\u2009+\u2009dendritic cell-dependent mechanism","volume":"72","author":"Zhao","year":"2023","journal-title":"Cancer Immunol. Immunother."},{"issue":"21","key":"10.1016\/j.phrs.2026.108380_bib558","doi-asserted-by":"crossref","first-page":"5368","DOI":"10.1158\/1078-0432.CCR-18-1038","article-title":"Resistance to Radiotherapy and PD-L1 Blockade Is Mediated by TIM-3 Upregulation and Regulatory T-Cell Infiltration","volume":"24","author":"Oweida","year":"2018","journal-title":"Clin. Cancer Res."},{"issue":"11","key":"10.1016\/j.phrs.2026.108380_bib559","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1158\/2326-6066.CIR-17-0040","article-title":"Stereotactic Radiotherapy Increases Functionally Suppressive Regulatory T Cells in the Tumor Microenvironment","volume":"5","author":"Muroyama","year":"2017","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.phrs.2026.108380_bib560","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2020.104745","article-title":"TGF-\u03b2 in radiotherapy: Mechanisms of tumor resistance and normal tissues injury","volume":"155","author":"Farhood","year":"2020","journal-title":"Pharmacol. Res."},{"issue":"5","key":"10.1016\/j.phrs.2026.108380_bib561","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/1074-7613(94)90071-X","article-title":"CTLA-4 can function as a negative regulator of T cell activation","volume":"1","author":"Walunas","year":"1994","journal-title":"Immunity"},{"issue":"2","key":"10.1016\/j.phrs.2026.108380_bib562","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-000867","article-title":"Tumor-draining lymph node is important for a robust abscopal effect stimulated by radiotherapy","volume":"8","author":"Buchwald","year":"2020","journal-title":"J. Immunother. Cancer"},{"issue":"1","key":"10.1016\/j.phrs.2026.108380_bib563","doi-asserted-by":"crossref","first-page":"5500","DOI":"10.1038\/s41467-024-49873-y","article-title":"Delayed tumor-draining lymph node irradiation preserves the efficacy of combined radiotherapy and immune checkpoint blockade in models of metastatic disease","volume":"15","author":"Telarovic","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.phrs.2026.108380_bib564","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2022.102499","article-title":"Mechanisms of resistance to immune checkpoint inhibitors in melanoma: What we have to overcome?","volume":"113","author":"Ziogas","year":"2023","journal-title":"Cancer Treat. Rev."},{"issue":"8","key":"10.1016\/j.phrs.2026.108380_bib565","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1093\/intimm\/dxy038","article-title":"Oxygen-dependent regulation of immune checkpoint mechanisms","volume":"30","author":"Ohta","year":"2018","journal-title":"Int. Immunol."},{"issue":"9","key":"10.1016\/j.phrs.2026.108380_bib566","doi-asserted-by":"crossref","DOI":"10.1172\/JCI150846","article-title":"Targeting HIF-1\u03b1 abrogates PD-L1-mediated immune evasion in tumor microenvironment but promotes tolerance in normal tissues,","volume":"132","author":"Bailey","year":"2022","journal-title":"J. Clin. Invest."},{"issue":"1","key":"10.1016\/j.phrs.2026.108380_bib567","doi-asserted-by":"crossref","first-page":"4118","DOI":"10.1038\/s41467-022-31764-9","article-title":"Hypoxia induces HIF1\u03b1-dependent epigenetic vulnerability in triple negative breast cancer to confer immune effector dysfunction and resistance to anti-PD-1 immunotherapy","volume":"13","author":"Ma","year":"2022","journal-title":"Nat. Commun."},{"issue":"7355","key":"10.1016\/j.phrs.2026.108380_bib568","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1038\/nature10169","article-title":"Tumour hypoxia promotes tolerance and angiogenesis via CCL28 and T(reg) cells,","volume":"475","author":"Facciabene","year":"2011","journal-title":"Nature"},{"issue":"6398","key":"10.1016\/j.phrs.2026.108380_bib569","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1038\/359843a0","article-title":"Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis","volume":"359","author":"Shweiki","year":"1992","journal-title":"Nature"},{"issue":"4","key":"10.1016\/j.phrs.2026.108380_bib570","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1158\/0008-5472.CAN-08-3030","article-title":"Host-derived angiopoietin-2 affects early stages of tumor development and vessel maturation but is dispensable for later stages of tumor growth","volume":"69","author":"Nasarre","year":"2009","journal-title":"Cancer Res"},{"issue":"6","key":"10.1016\/j.phrs.2026.108380_bib571","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1158\/0008-5472.CAN-12-4697","article-title":"Angiopoietin-2: an attractive target for improved antiangiogenic tumor therapy","volume":"73","author":"Gerald","year":"2013","journal-title":"Cancer Res"},{"issue":"3","key":"10.1016\/j.phrs.2026.108380_bib572","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.4049\/jimmunol.160.3.1224","article-title":"Vascular endothelial growth factor affects dendritic cell maturation through the inhibition of nuclear factor-kappa B activation in hemopoietic progenitor cells","volume":"160","author":"Oyama","year":"1998","journal-title":"J. Immunol."},{"issue":"12","key":"10.1016\/j.phrs.2026.108380_bib573","doi-asserted-by":"crossref","first-page":"4878","DOI":"10.1182\/blood-2002-07-1956","article-title":"VEGF inhibits T-cell development and may contribute to tumor-induced immune suppression","volume":"101","author":"Ohm","year":"2003","journal-title":"Blood"},{"issue":"2-3","key":"10.1016\/j.phrs.2026.108380_bib574","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1385\/IR:23:2-3:263","article-title":"VEGF as a mediator of tumor-associated immunodeficiency","volume":"23","author":"Ohm","year":"2001","journal-title":"Immunol. Res."},{"issue":"2","key":"10.1016\/j.phrs.2026.108380_bib575","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1084\/jem.20140559","article-title":"VEGF-A modulates expression of inhibitory checkpoints on CD8+ T cells in tumors","volume":"212","author":"Voron","year":"2015","journal-title":"J. Exp. Med."},{"issue":"5","key":"10.1016\/j.phrs.2026.108380_bib576","first-page":"1111","article-title":"Endothelial intercellular adhesion molecule-1 expression is suppressed in human malignancies: the role of angiogenic factors","volume":"56","author":"Griffioen","year":"1996","journal-title":"Cancer Res"},{"issue":"3","key":"10.1016\/j.phrs.2026.108380_bib577","first-page":"881","article-title":"The contribution of vascular endothelial growth factor to the induction of regulatory T-cells in malignant effusions","volume":"29","author":"Wada","year":"2009","journal-title":"Anticancer Res"},{"issue":"2","key":"10.1016\/j.phrs.2026.108380_bib578","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1182\/blood-2007-01-065714","article-title":"Distinct roles of VEGFR-1 and VEGFR-2 in the aberrant hematopoiesis associated with elevated levels of VEGF","volume":"110","author":"Huang","year":"2007","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.phrs.2026.108380_bib579","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1097\/00008390-200510000-00010","article-title":"Tumour-associated macrophage infiltration, neovascularization and aggressiveness in malignant melanoma: role of monocyte chemotactic protein-1 and vascular endothelial growth factor-A","volume":"15","author":"Varney","year":"2005","journal-title":"Melanoma Res"},{"issue":"7","key":"10.1016\/j.phrs.2026.108380_bib580","doi-asserted-by":"crossref","first-page":"4183","DOI":"10.4049\/jimmunol.1002802","article-title":"Angiopoietin 2 stimulates TIE2-expressing monocytes to suppress T cell activation and to promote regulatory T cell expansion","volume":"186","author":"Coffelt","year":"2011","journal-title":"J. Immunol."},{"issue":"13","key":"10.1016\/j.phrs.2026.108380_bib581","doi-asserted-by":"crossref","first-page":"5270","DOI":"10.1158\/0008-5472.CAN-10-0012","article-title":"Angiopoietin-2 regulates gene expression in TIE2-expressing monocytes and augments their inherent proangiogenic functions","volume":"70","author":"Coffelt","year":"2010","journal-title":"Cancer Res"},{"issue":"1","key":"10.1016\/j.phrs.2026.108380_bib582","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/bjc.2017.434","article-title":"Mechanisms of resistance to immune checkpoint inhibitors","volume":"118","author":"Jenkins","year":"2018","journal-title":"Br. J. Cancer"},{"issue":"1","key":"10.1016\/j.phrs.2026.108380_bib583","doi-asserted-by":"crossref","first-page":"5120","DOI":"10.1038\/s41467-020-18794-x","article-title":"Concepts of extracellular matrix remodelling in tumour progression and metastasis","volume":"11","author":"Winkler","year":"2020","journal-title":"Nat. Commun."},{"issue":"5","key":"10.1016\/j.phrs.2026.108380_bib584","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1038\/s41419-024-06697-4","article-title":"Modulating extracellular matrix stiffness: a strategic approach to boost cancer immunotherapy","volume":"15","author":"Mai","year":"2024","journal-title":"Cell Death Dis"},{"issue":"9","key":"10.1016\/j.phrs.2026.108380_bib585","doi-asserted-by":"crossref","DOI":"10.1016\/j.xcrm.2025.102322","article-title":"Modulation of fibronectin extracellular matrix enhances anti-tumor efficacy of immune checkpoint blockade","volume":"6","author":"Khan","year":"2025","journal-title":"Cell Reports Medicine"},{"key":"10.1016\/j.phrs.2026.108380_bib586","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1016\/j.jconrel.2024.07.076","article-title":"Engineered bacteria breach tumor physical barriers to enhance radio-immunotherapy","volume":"373","author":"Zhang","year":"2024","journal-title":"J. Control. Release"},{"issue":"1","key":"10.1016\/j.phrs.2026.108380_bib587","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1038\/s41467-020-15726-7","article-title":"Transcriptional downregulation of MHC class I and melanoma de- differentiation in resistance to PD-1 inhibition","volume":"11","author":"Lee","year":"2020","journal-title":"Nat. Commun."},{"issue":"10","key":"10.1016\/j.phrs.2026.108380_bib588","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12102870","article-title":"Tumor Microenvironment: Implications in Melanoma Resistance to Targeted Therapy and Immunotherapy","volume":"12","author":"Falcone","year":"2020","journal-title":"Cancers (Basel)"},{"issue":"9","key":"10.1016\/j.phrs.2026.108380_bib589","doi-asserted-by":"crossref","first-page":"1846","DOI":"10.1158\/0008-5472.CAN-19-3158","article-title":"NOX4 Inhibition Potentiates Immunotherapy by Overcoming Cancer-Associated Fibroblast-Mediated CD8 T-cell Exclusion from Tumors","volume":"80","author":"Ford","year":"2020","journal-title":"Cancer Res"},{"issue":"9","key":"10.1016\/j.phrs.2026.108380_bib590","doi-asserted-by":"crossref","first-page":"2636","DOI":"10.1158\/1078-0432.CCR-20-4226","article-title":"Molecular Features of Cancer-associated Fibroblast Subtypes and their Implication on Cancer Pathogenesis, Prognosis, and Immunotherapy Resistance","volume":"27","author":"Galbo","year":"2021","journal-title":"Clin. Cancer Res."},{"issue":"12","key":"10.1016\/j.phrs.2026.108380_bib591","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1158\/2326-6066.CIR-18-0086","article-title":"Stromal Fibroblasts Mediate Anti-PD-1 Resistance via MMP-9 and Dictate TGF\u03b2 Inhibitor Sequencing in Melanoma","volume":"6","author":"Zhao","year":"2018","journal-title":"Cancer Immunol. Res."},{"issue":"5","key":"10.1016\/j.phrs.2026.108380_bib592","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1016\/j.ccell.2017.10.005","article-title":"Cancer-Associated Fibroblasts Neutralize the Anti-tumor Effect of CSF1 Receptor Blockade by Inducing PMN-MDSC Infiltration of Tumors","volume":"32","author":"Kumar","year":"2017","journal-title":"Cancer Cell"},{"issue":"21","key":"10.1016\/j.phrs.2026.108380_bib593","doi-asserted-by":"crossref","first-page":"5407","DOI":"10.1158\/1078-0432.CCR-18-0125","article-title":"Cancer-Stimulated CAFs Enhance Monocyte Differentiation and Protumoral TAM Activation via IL6 and GM-CSF Secretion","volume":"24","author":"Cho","year":"2018","journal-title":"Clin. Cancer Res."},{"issue":"6","key":"10.1016\/j.phrs.2026.108380_bib594","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1016\/j.ccell.2022.04.011","article-title":"Mesothelial cell-derived antigen-presenting cancer-associated fibroblasts induce expansion of regulatory T cells in pancreatic cancer","volume":"40","author":"Huang","year":"2022","journal-title":"Cancer Cell"},{"issue":"SEP","key":"10.1016\/j.phrs.2026.108380_bib595","article-title":"NK cell metabolism and tumor microenvironment","volume":"10","author":"Terr\u00e9n","year":"2019","journal-title":"Front. Immunol."},{"issue":"3191","key":"10.1016\/j.phrs.2026.108380_bib596","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1126\/science.123.3191.309","article-title":"On the origin of cancer cells","volume":"123","author":"Warburg","year":"1956","journal-title":"Science"},{"issue":"7779","key":"10.1016\/j.phrs.2026.108380_bib597","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1038\/s41586-019-1678-1","article-title":"Metabolic regulation of gene expression by histone lactylation","volume":"574","author":"Zhang","year":"2019","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.phrs.2026.108380_bib598","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.cmet.2019.06.001","article-title":"Macrophages and Metabolism in the Tumor Microenvironment","volume":"30","author":"Vitale","year":"2019","journal-title":"Cell Metab"},{"issue":"2","key":"10.1016\/j.phrs.2026.108380_bib599","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1038\/s41577-019-0259-8","article-title":"The hypoxia\u2013lactate axis tempers inflammation","volume":"20","author":"Ivashkiv","year":"2020","journal-title":"Nat. Rev. Immunol."},{"issue":"4","key":"10.1016\/j.phrs.2026.108380_bib600","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1038\/s41419-020-2434-z","article-title":"Reprogramming of lipid metabolism in cancer-associated fibroblasts potentiates migration of colorectal cancer cells","volume":"11","author":"Gong","year":"2020","journal-title":"Cell Death Dis"},{"issue":"17","key":"10.1016\/j.phrs.2026.108380_bib601","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.aan4631","article-title":"Suppression of FIP200 and autophagy by tumor-derived lactate promotes na\u00efve T cell apoptosis and affects tumor immunity","volume":"2","author":"Xia","year":"2017","journal-title":"Sci. Immunol."},{"issue":"19","key":"10.1016\/j.phrs.2026.108380_bib602","doi-asserted-by":"crossref","first-page":"3681","DOI":"10.1038\/s41388-019-0688-7","article-title":"Lactate modulates CD4(+) T-cell polarization and induces an immunosuppressive environment, which sustains prostate carcinoma progression via TLR8\/miR21 axis,","volume":"38","author":"Comito","year":"2019","journal-title":"Oncogene"},{"issue":"3","key":"10.1016\/j.phrs.2026.108380_bib603","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.4049\/jimmunol.1202702","article-title":"Tumor-derived lactate modifies antitumor immune response: Effect on myeloid-derived suppressor cells and NK cells","volume":"191","author":"Husain","year":"2013","journal-title":"J. Immunol."},{"issue":"1","key":"10.1016\/j.phrs.2026.108380_bib604","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1186\/s13046-024-03025-8","article-title":"GPR65 sensing tumor-derived lactate induces HMGB1 release from TAM via the cAMP\/PKA\/CREB pathway to promote glioma progression","volume":"43","author":"Yan","year":"2024","journal-title":"J. Exp. Clin. Cancer Res."},{"issue":"14","key":"10.1016\/j.phrs.2026.108380_bib605","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14143505","article-title":"A 'Hybrid' Radiotherapy Regimen Designed for Immunomodulation: Combining High-Dose Radiotherapy with Low-Dose Radiotherapy","volume":"14","author":"Ji","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"1","key":"10.1016\/j.phrs.2026.108380_bib606","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.semradonc.2014.07.005","article-title":"Radiotherapy and immunogenic cell death","volume":"25","author":"Golden","year":"2015","journal-title":"Semin. Radiat. Oncol."},{"key":"10.1016\/j.phrs.2026.108380_bib607","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2025.1546875","article-title":"Potential immunogenic modulation of hypo-fractionated radiotherapy at optimal schedules and the subsequent vaccine-like effect of local irradiation - a systematic review","volume":"15","author":"Singh","year":"2025","journal-title":"Front. Oncol."},{"issue":"4","key":"10.1016\/j.phrs.2026.108380_bib608","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1016\/j.ijrobp.2012.06.020","article-title":"Radiation therapy to convert the tumor into an in situ vaccine","volume":"84","author":"Formenti","year":"2012","journal-title":"Int. J. Radiat. Oncol. Biol. Phys"},{"issue":"9","key":"10.1016\/j.phrs.2026.108380_bib609","doi-asserted-by":"crossref","DOI":"10.1002\/cti2.1169","article-title":"Enhancing the efficacy of immunotherapy using radiotherapy","volume":"9","author":"Keam","year":"2020","journal-title":"Clin Transl Immunology"},{"issue":"1","key":"10.1016\/j.phrs.2026.108380_bib610","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.ijrobp.2006.11.045","article-title":"Low-dose radiotherapy as a chemopotentiator of gemcitabine in tumors of the pancreas or small bowel: a phase I study exploring a new treatment paradigm","volume":"68","author":"Regine","year":"2007","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"issue":"2","key":"10.1016\/j.phrs.2026.108380_bib611","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1158\/1535-7163.MCT-10-0630","article-title":"Low-dose fractionated radiation potentiates the effects of cisplatin independent of the hyper-radiation sensitivity in human lung cancer cells","volume":"10","author":"Gupta","year":"2011","journal-title":"Mol. Cancer Ther."},{"issue":"2","key":"10.1016\/j.phrs.2026.108380_bib612","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.ygyno.2010.10.018","article-title":"Low-dose abdominal radiation as a docetaxel chemosensitizer for recurrent epithelial ovarian cancer: a phase I study of the Gynecologic Oncology Group","volume":"120","author":"Kunos","year":"2011","journal-title":"Gynecol. Oncol."},{"issue":"6","key":"10.1016\/j.phrs.2026.108380_bib613","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1179\/1973947813Y.0000000163","article-title":"FOLFIRI-bevacizumab and concurrent low-dose radiotherapy in metastatic colorectal cancer: preliminary results of a phase I-II study","volume":"26","author":"Morganti","year":"2014","journal-title":"J. Chemother."},{"issue":"8","key":"10.1016\/j.phrs.2026.108380_bib614","doi-asserted-by":"crossref","first-page":"e417","DOI":"10.1016\/S1470-2045(19)30401-2","article-title":"Rational combinations of immunotherapy with radiotherapy in ovarian cancer","volume":"20","author":"Herrera","year":"2019","journal-title":"Lancet Oncol"},{"issue":"5","key":"10.1016\/j.phrs.2026.108380_bib615","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1016\/0360-3016(92)90778-G","article-title":"Analysis of complications in patients treated with abdomino-pelvic radiation therapy for ovarian carcinoma,","volume":"22","author":"Fyles","year":"1992","journal-title":"Int. J. Radiat. Oncol. Biol. Phys"},{"issue":"10405","key":"10.1016\/j.phrs.2026.108380_bib616","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1016\/S0140-6736(23)01384-3","article-title":"Stereotactic ablative radiotherapy with or without immunotherapy for early-stage or isolated lung parenchymal recurrent node-negative non-small-cell lung cancer: an open-label, randomised, phase 2 trial","volume":"402","author":"Chang","year":"2023","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.phrs.2026.108380_bib617","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1016\/j.eururo.2020.07.032","article-title":"Final Analysis of the Ipilimumab Versus Placebo Following Radiotherapy Phase III Trial in Postdocetaxel Metastatic Castration-resistant Prostate Cancer Identifies an Excess of Long-term Survivors","volume":"78","author":"Fizazi","year":"2020","journal-title":"Eur. Urol."},{"issue":"5","key":"10.1016\/j.phrs.2026.108380_bib618","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/S2213-2600(20)30391-X","article-title":"Pembrolizumab with or without radiotherapy for metastatic non-small-cell lung cancer: a pooled analysis of two randomised trials","volume":"9","author":"Theelen","year":"2021","journal-title":"Lancet Respir. Med."},{"issue":"7","key":"10.1016\/j.phrs.2026.108380_bib619","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1016\/S1470-2045(14)70189-5","article-title":"Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial","volume":"15","author":"Kwon","year":"2014","journal-title":"Lancet Oncol"},{"issue":"9","key":"10.1016\/j.phrs.2026.108380_bib620","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1001\/jamaoncol.2019.1478","article-title":"Effect of Pembrolizumab After Stereotactic Body Radiotherapy vs Pembrolizumab Alone on Tumor Response in Patients With Advanced Non-Small Cell Lung Cancer: Results of the PEMBRO-RT Phase 2 Randomized Clinical Trial","volume":"5","author":"Theelen","year":"2019","journal-title":"JAMA Oncol"},{"issue":"20","key":"10.1016\/j.phrs.2026.108380_bib621","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1056\/NEJMoa1709937","article-title":"Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer","volume":"377","author":"Antonia","year":"2017","journal-title":"N. Engl. J. Med."},{"issue":"10434","key":"10.1016\/j.phrs.2026.108380_bib622","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1016\/S0140-6736(24)00317-9","article-title":"Pembrolizumab or placebo with chemoradiotherapy followed by pembrolizumab or placebo for newly diagnosed, high-risk, locally advanced cervical cancer (ENGOT-cx11\/GOG-3047\/KEYNOTE-A18): a randomised, double-blind, phase 3 clinical trial","volume":"403","author":"Lorusso","year":"2024","journal-title":"Lancet"},{"issue":"552","key":"10.1016\/j.phrs.2026.108380_bib623","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaw7843","article-title":"Dynamic changes in glioma macrophage populations after radiotherapy reveal CSF-1R inhibition as a strategy to overcome resistance","volume":"12","author":"Akkari","year":"2020","journal-title":"Sci. Transl. Med."},{"issue":"1","key":"10.1016\/j.phrs.2026.108380_bib624","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1186\/s40425-019-0634-9","article-title":"Optimized fractionated radiotherapy with anti-PD-L1 and anti-TIGIT: a promising new combination","volume":"7","author":"Grapin","year":"2019","journal-title":"J. Immunother. Cancer"},{"issue":"8","key":"10.1016\/j.phrs.2026.108380_bib625","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1021\/acs.accounts.4c00843","article-title":"Inorganic Nanobiomaterials Boost Tumor Immunotherapy: Strategies and Applications","volume":"58","author":"Meng","year":"2025","journal-title":"Acc. Chem. Res."},{"issue":"9","key":"10.1016\/j.phrs.2026.108380_bib626","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1038\/s41568-024-00723-5","article-title":"Enhancing cellular immunotherapies in cancer by engineering selective therapeutic resistance","volume":"24","author":"Wellhausen","year":"2024","journal-title":"Nat. Rev. Cancer"},{"issue":"4","key":"10.1016\/j.phrs.2026.108380_bib627","doi-asserted-by":"crossref","first-page":"3990","DOI":"10.1021\/acsnano.7b00476","article-title":"Ultrasmall Semimetal Nanoparticles of Bismuth for Dual-Modal Computed Tomography\/Photoacoustic Imaging and Synergistic Thermoradiotherapy","volume":"11","author":"Yu","year":"2017","journal-title":"ACS Nano"},{"issue":"37","key":"10.1016\/j.phrs.2026.108380_bib628","doi-asserted-by":"crossref","first-page":"24331","DOI":"10.1021\/acsami.6b08391","article-title":"MoS2 Quantum Dot@Polyaniline Inorganic-Organic Nanohybrids for in Vivo Dual-Modal Imaging Guided Synergistic Photothermal\/Radiation Therapy","volume":"8","author":"Wang","year":"2016","journal-title":"ACS Appl. Mater. Interfaces"},{"issue":"1","key":"10.1016\/j.phrs.2026.108380_bib629","first-page":"267","article-title":"MicroRNA-381 increases radiosensitivity in esophageal squamous cell carcinoma","volume":"5","author":"Zhou","year":"2015","journal-title":"Am. J. Cancer Res."},{"issue":"11","key":"10.1016\/j.phrs.2026.108380_bib630","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1038\/onc.2015.212","article-title":"Targeting of \u03b21 integrins impairs DNA repair for radiosensitization of head and neck cancer cells","volume":"35","author":"Dickreuter","year":"2016","journal-title":"Oncogene"},{"issue":"9","key":"10.1016\/j.phrs.2026.108380_bib631","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1038\/s41556-024-01361-7","article-title":"Ironing out the details of ferroptosis","volume":"26","author":"Zhang","year":"2024","journal-title":"Nat. Cell Biol."},{"issue":"5","key":"10.1016\/j.phrs.2026.108380_bib632","doi-asserted-by":"crossref","first-page":"2458","DOI":"10.1007\/s12011-024-04356-5","article-title":"Review Article on Molecular Basis of Zinc and Copper Interactions in Cancer Physiology","volume":"203","author":"Joshi","year":"2025","journal-title":"Biol. Trace Elem. Res."},{"key":"10.1016\/j.phrs.2026.108380_bib633","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.jconrel.2016.07.049","article-title":"Increase of intracellular cisplatin levels and radiosensitization by ultrasound in combination with microbubbles","volume":"238","author":"Lammertink","year":"2016","journal-title":"J. Control. Release"},{"key":"10.1016\/j.phrs.2026.108380_bib634","article-title":"Spatially fractionated radiotherapy and immunotherapy: a synergistic strategy for systemic anti-tumor immunity","author":"Li","year":"2026","journal-title":"J. Transl. Med."},{"issue":"765","key":"10.1016\/j.phrs.2026.108380_bib635","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.adk0642","article-title":"Intratumoral radiation dose heterogeneity augments antitumor immunity in mice and primes responses to checkpoint blockade","volume":"16","author":"Jagodinsky","year":"2024","journal-title":"Sci. Transl. Med."},{"issue":"1","key":"10.1016\/j.phrs.2026.108380_bib636","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1186\/s13014-026-02860-7","article-title":"Spatially fractionated radiation therapy for bulky tumors: a systematic review of clinical outcomes and dosimetric challenges","volume":"21","author":"Franco","year":"2026","journal-title":"Radiation Oncology"},{"issue":"17","key":"10.1016\/j.phrs.2026.108380_bib637","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14174123","article-title":"Recent Trends in Nanomedicine-Based Strategies to Overcome Multidrug Resistance in Tumors","volume":"14","author":"Khan","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.phrs.2026.108380_bib638","article-title":"Multifunctional nanoplatforms for tumor microenvironment remodeling: Toward precision and intelligent cancer therapy","volume":"35","author":"Deng","year":"2025","journal-title":"Mater. Today Bio"},{"issue":"11","key":"10.1016\/j.phrs.2026.108380_bib639","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1038\/nrm3212","article-title":"Imaging the coordination of multiple signalling activities in living cells","volume":"12","author":"Welch","year":"2011","journal-title":"Nat. Rev. Mol. Cell Biol."},{"issue":"4","key":"10.1016\/j.phrs.2026.108380_bib640","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1038\/nrclinonc.2010.194","article-title":"Preclinical development of molecular-targeted agents for cancer","volume":"8","author":"Ocana","year":"2010","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"2-3","key":"10.1016\/j.phrs.2026.108380_bib641","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.biosystems.2005.05.014","article-title":"Cancer: a Systems Biology disease","volume":"83","author":"Hornberg","year":"2006","journal-title":"Biosystems"},{"issue":"6","key":"10.1016\/j.phrs.2026.108380_bib642","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1515\/jtim-2024-0033","article-title":"Computational analyses to reveal the key determinants of the high malignancy level of cholangiocarcinoma","volume":"12","author":"Li","year":"2024","journal-title":"J. Transl. Int. Med."},{"issue":"1","key":"10.1016\/j.phrs.2026.108380_bib643","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1038\/s41392-026-02631-6","article-title":"Multi-omics and artificial intelligence for precision drug discovery and potential clinical applications","volume":"11","author":"Liu","year":"2026","journal-title":"Signal Transduct. Target. Ther."},{"issue":"7","key":"10.1016\/j.phrs.2026.108380_bib644","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1038\/s41568-026-00922-2","article-title":"Advancing AI for multi-omics and clinical data integration in basic and translational cancer research","volume":"26","author":"Liu","year":"2026","journal-title":"Nature Reviews Cancer"},{"issue":"15","key":"10.1016\/j.phrs.2026.108380_bib645","doi-asserted-by":"crossref","first-page":"2011","DOI":"10.1200\/JCO.2010.33.5091","article-title":"Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status","volume":"29","author":"Van Cutsem","year":"2011","journal-title":"J. Clin. Oncol"},{"issue":"11","key":"10.1016\/j.phrs.2026.108380_bib646","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1093\/annonc\/mdn401","article-title":"A phase II randomized multicenter trial of gefitinib plus FOLFIRI and FOLFIRI alone in patients with metastatic colorectal cancer","volume":"19","author":"Santoro","year":"2008","journal-title":"Ann. Oncol."},{"issue":"1","key":"10.1016\/j.phrs.2026.108380_bib647","doi-asserted-by":"crossref","first-page":"5146","DOI":"10.1038\/s41467-023-40844-3","article-title":"Immunotherapy targeting different immune compartments in combination with radiation therapy induces regression of resistant tumors","volume":"14","author":"Rudqvist","year":"2023","journal-title":"Nat. Commun."},{"issue":"18","key":"10.1016\/j.phrs.2026.108380_bib648","doi-asserted-by":"crossref","first-page":"5514","DOI":"10.1158\/1078-0432.CCR-16-1673","article-title":"Fractionated Radiation Therapy Stimulates Antitumor Immunity Mediated by Both Resident and Infiltrating Polyclonal T-cell Populations when Combined with PD-1 Blockade","volume":"23","author":"Dovedi","year":"2017","journal-title":"Clin. Cancer Res."},{"issue":"19","key":"10.1016\/j.phrs.2026.108380_bib649","doi-asserted-by":"crossref","first-page":"5458","DOI":"10.1158\/0008-5472.CAN-14-1258","article-title":"Acquired resistance to fractionated radiotherapy can be overcome by concurrent PD-L1 blockade","volume":"74","author":"Dovedi","year":"2014","journal-title":"Cancer Res"},{"issue":"12","key":"10.1016\/j.phrs.2026.108380_bib650","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1038\/s43018-022-00467-x","article-title":"Highly aneuploid non-small cell lung cancer shows enhanced responsiveness to concurrent radiation and immune checkpoint blockade","volume":"3","author":"Spurr","year":"2022","journal-title":"Nat. Cancer"},{"issue":"13","key":"10.1016\/j.phrs.2026.108380_bib651","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13133290","article-title":"Lattice or Oxygen-Guided Radiotherapy: What If They Converge? Possible Future Directions in the Era of Immunotherapy","volume":"13","author":"Ferini","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"16","key":"10.1016\/j.phrs.2026.108380_bib652","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14163909","article-title":"Impressive Results after \"Metabolism-Guided\" Lattice Irradiation in Patients Submitted to Palliative Radiation Therapy: Preliminary Results of LATTICE_01 Multicenter Study","volume":"14","author":"Ferini","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.phrs.2026.108380_bib653","article-title":"Salvage LATTICE radiotherapy for a growing tumour despite conventional radio chemotherapy treatment of lung cancer","volume":"39","author":"Kinj","year":"2023","journal-title":"Clin. Transl. Radiat. Oncol."},{"key":"10.1016\/j.phrs.2026.108380_bib654","article-title":"Lattice Radiation Therapy in clinical practice: A systematic review","volume":"39","author":"Iori","year":"2023","journal-title":"Clin. Transl. Radiat. Oncol."},{"issue":"2","key":"10.1016\/j.phrs.2026.108380_bib655","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1667\/RR3819.1","article-title":"vivo effects of lattice radiation therapy on local and distant lung cancer: potential role of immunomodulation","volume":"182","author":"Kanagavelu","year":"2014","journal-title":"Radiat. Res."},{"issue":"3","key":"10.1016\/j.phrs.2026.108380_bib656","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1016\/j.ijrobp.2018.10.009","article-title":"An Antitumor Immune Response Is Evoked by Partial-Volume Single-Dose Radiation in 2 Murine Models","volume":"103","author":"Markovsky","year":"2019","journal-title":"Int. J. Radiat. Oncol. Biol. Phys"},{"issue":"21","key":"10.1016\/j.phrs.2026.108380_bib657","doi-asserted-by":"crossref","DOI":"10.3390\/ijms262110640","article-title":"Biomarkers in Stereotactic Ablative Radiotherapy: Current Evidence and Future Directions","volume":"26","author":"Metawe","year":"2025","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.phrs.2026.108380_bib658","article-title":"Liquid biopsy in cancer drug resistance: real-time monitoring, mechanistic insights, and translational applications","volume":"17","author":"Li","year":"2026","journal-title":"Front. Immunol."},{"issue":"9","key":"10.1016\/j.phrs.2026.108380_bib659","doi-asserted-by":"crossref","DOI":"10.1200\/CCI-24-00160","article-title":"Early Circulating Tumor DNA Kinetics as a Dynamic Biomarker of Cancer Treatment Response","author":"Li","year":"2025","journal-title":"JCO Clin Cancer Inform"},{"issue":"48","key":"10.1016\/j.phrs.2026.108380_bib660","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000046239","article-title":"Exosomal miRNAs versus circulating tumor DNA: diagnostic accuracy for early detection of recurrence post-radical prostatectomy: A narrative review","volume":"104","author":"Bashir","year":"2025","journal-title":"Medicine (Baltimore)"},{"issue":"7","key":"10.1016\/j.phrs.2026.108380_bib661","first-page":"1601","article-title":"Early diagnostic and prognostic value of serum exosomal miR-1246 in non-small cell lung cancer","volume":"13","author":"Huang","year":"2020","journal-title":"Int. J. Clin. Exp. Pathol."},{"issue":"1","key":"10.1016\/j.phrs.2026.108380_bib662","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1186\/s12967-022-03392-w","article-title":"Mechanism and clinical value of exosomes and exosomal contents in regulating solid tumor radiosensitivity","volume":"20","author":"Sun","year":"2022","journal-title":"J. Transl. Med."},{"issue":"12","key":"10.1016\/j.phrs.2026.108380_bib663","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1038\/nrclinonc.2017.141","article-title":"Radiomics: the bridge between medical imaging and personalized medicine","volume":"14","author":"Lambin","year":"2017","journal-title":"Nature Reviews Clinical Oncology"},{"issue":"6","key":"10.1016\/j.phrs.2026.108380_bib664","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1007\/s13244-018-0657-7","article-title":"Radiomics and liquid biopsy in oncology: the holons of systems medicine","volume":"9","author":"Neri","year":"2018","journal-title":"Insights into Imaging"}],"container-title":["Pharmacological Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661826002951?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661826002951?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T15:01:47Z","timestamp":1789398107000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1043661826002951"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":664,"alternative-id":["S1043661826002951"],"URL":"https:\/\/doi.org\/10.1016\/j.phrs.2026.108380","relation":{},"ISSN":["1043-6618"],"issn-type":[{"value":"1043-6618","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Drug resistance in cancer radiotherapy: From mechanisms to overcoming strategies","name":"articletitle","label":"Article Title"},{"value":"Pharmacological Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.phrs.2026.108380","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"108380"}}